An Evaluation of Psychosocial and Socio-demographic Factors Associated with Metabolic Syndrome and Cardiovascular Risk in Polycystic Ovary Syndrome Cases and Controls by Cipkala-Gaffiin, Janet A.
  
 
 
AN EVALUATION OF PSYCHOLOGICAL AND SOCIO- 
DEMOGRAPHIC FACTORS ASSOCIATED WITH METABOLIC SYNDROME 
AND CARDIOVASCULAR RISK IN POLYCYSTIC OVARY SYNDROME 
CASES AND CONTROLS 
 
 
 
 
 
by 
Janet A. Cipkala-Gaffin 
BSN, University of Cincinnati, 1982 
MN, University of California, Los Angeles, 1985 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
Graduate School of Public Health in partial fulfillment  
of the requirements for the degree of 
Doctor of Public Health 
 
 
 
 
 
University of Pittsburgh 
 
 
2009 
 
 UNIVERSITY OF PITTSBURGH 
Graduate School of Public Health 
This dissertation was presented 
by 
Janet A. Cipkala-Gaffin  
 
It was defended on 
March 24, 2009 
and approved by 
Dissertation Advisor: 
Evelyn O. Talbott Dr.PH  
Professor 
Department of Epidemiology 
Graduate School of Public Health 
University of Pittsburgh 
 
Emma Barinas-Mitchell PhD 
Assistant Professor 
Department of Epidemiology 
Graduate School of Public Health 
University of Pittsburgh 
 
Charlotte Brown PhD 
Associate Professor 
Department of Psychiatry 
School of Medicine, University of Pittsburgh
 
Mi-Kyung Song PhD 
Assistant Professor 
                      School of Nursing 
                         University of North Carolina at Chapel Hill 
 
         John Wilson PhD 
          Associate Professor 
           Department of Biostatistics 
          Graduate School of Public Health 
         University of Pittsburgh 
 ii 
Copyright © by Janet A. Cipkala-Gaffin 
2009 
 iii 
 iv 
 
                                                                                                        Evelyn O. Talbott, DrPH 
 
 
AN EVALUATION OF PSYCHOLOGICAL AND SOCIO-DEMOGRAPHIC 
FACTORS ASSOCIATED WITH METABOLIC SYNDROME AND 
CARDIOVASCULAR RISK IN POLYCYSTIC OVARY SYNDROME 
CASES AND CONTROLS 
 
Janet A. Cipkala-Gaffin, Dr.PH 
 
University of Pittsburgh, 2009 
 
Background:  Major aims of the psychological research in PCOS were: (1) to compare the 
prevalence of depressive symptoms in women with PCOS to controls; (2) to determine 
whether depression and psychological traits (anger, anxiety, hostility/cynicism) and 
satisfaction with life are associated with PCOS  (3) to determine the prevalence of Metabolic 
Syndrome (MS) in PCOS cases and controls (4) to determine if psychological factors are risk 
factors for Metabolic Syndrome independent of age, marital status, education, and parity (5) 
to determine if psychological factors, independent of baseline cardiovascular risk factors, are 
a risk factor for IMT in women with PCOS. 
Design:  Prospective and cross sectional. 
Methods:  Cases (n=161) and controls (n=161) matched on age, race, and neighborhood  a 
subset of the Cardiovascular Health and Risk Measurement study (CHARM) investigating 
coronary heart disease risk factors in women with PCOS.  Psychological measures were  
Beck Depression Inventory I (BDI I),  Speilberger Trait Anger and Anxiety Scales, Cook-
Medley Scale,  Diener Satisfaction with Life Scale.  
Results:  PCOS women had a higher prevalence of depression (BDI scores > 9; 
predominately a mild level of depression): 31% vs. 17% in controls (P=.016; OR 1.9; CI 
1.55-2.16). Within cases, BMI, education, and parity were statistically significant predictors 
of depression, p<.05.  The odds of being depressed (at least mild severity) increased by 6% 
 v 
 
for each unit increase of BMI, the odds of being depressed decreased by 20% for each year of 
education, and the odds of being depressed increased by 44% for parity (per live birth). The 
odds of having PCOS increased with each unit of BDI score by 1.06 times, adjusting for 
marital status, BMI, smoking, and education (entire sample). 
 Results from MS, 27% (n=40) of the cases and 9.9% (n=15) of the controls had MS 
(p<.05; OR 3.4; CI 1.726-6.400.  The odds of having MS increased by 10% for each year of 
age and threefold for PCOS cases. 
 There were no effects from the psychological factors independent baseline 
cardiovascular risk factors on IMT.  
Conclusions:  Depression is a major psychological concern in PCOS.   
Public Health Significance:  Women with PCOS should be screened on diagnosis and 
monitored closely for depression.      
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1.0  DISSERTATION OVERVIEW AND OBJECTIVE 
  Polycystic Ovary Syndrome (PCOS) is the most common reproductive endocrine condition 
with a prevalence rate between 6-10%.  Features of PCOS, a heterogeneous disorder, include 
chronic anovulation, hyperandrogenism, and insulin resistance.  Metabolic abnormalities often 
occur in women with PCOS and have been identified as Metabolic Syndrome or Metabolic 
Cardiovascular Syndrome.  The abnormalities include central adiposity, increased triglycerides, 
low levels of high density lipoproteins (HDLc), hypertension, impaired glucose tolerance and 
Diabetes.  Subclinical cardiovascular disease has been identified as a major concern.  PCOS 
affects not only the physical functioning of women with the disorder, but also has multiple 
emotional consequences. Although limited, some studies have investigated the relationship of 
mental health disorders in women with PCOS.  
The purpose of this dissertation is to evaluate the psychological factors associated with 
PCOS.  Specifically, the following aims are the foci in a series of three papers. 
 
     1.  Associations among Depressive Symptoms, Anxiety, Anger, Hostility, and 
     Satisfaction with Life in Women with Polycystic Ovary Disease (PCOS) 
 
          1.  Women with PCOS have been identified as individuals that are at risk for depression 
    due to the physiological and body image changes that occur from this syndrome.  Studies 
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   primarily utilizing small samples have supported the finding that depressive symptoms are 
    more prevalent in PCOS women. This paper focuses on the following research questions: 
a. What is the relationship between PCOS and depressive symptoms?  
b. What is the point prevalence of clinically significant self-reported depressive 
symptoms in PCOS women when compared to controls? 
c. What is the relationship between satisfaction with life and other psychological 
characteristics (personality traits), anxiety, anger, and hostility, in women with 
PCOS?  
d. Are age, BMI, education, parity, testosterone levels, and marital and smoking 
status potential covariates in this relationship? 
 
2.  PCOS, Psychological Manifestations, and the Metabolic Syndrome.  What is the 
     relationship?    
   
     1.  Metabolic Syndrome (MS) and its components are often found in women with 
PCOS.  An association between depression and insulin resistance, a characteristic of MS, 
has been reported.  The literature describing MS in women with PCOS and its 
relationship with psychological variables are limited. 
 
      This paper focuses on the following research questions: 
    a.  What is the point prevalence of Metabolic Syndrome (MS) in PCOS 
   cases and controls? 
     b.  Are psychological factors (depressive symptoms, anger, anxiety, 
          hostility/cynicism, and satisfaction with life) risk factors for Metabolic  
          Syndrome independent of age, marital status, education, and parity? 
  2
 3.  PCOS, Psychological Factors, and IMT   
     1. Earlier work has shown that women with PCOS have increased subclinical 
atherosclerosis as measured by IMT.  Thus far, there has been little attention paid to the 
investigation of psychological risk factors as predictors of cardiovascular disease 
(measuring carotid intima-media thickness [IMT]) in women with PCOS. 
 
      This paper focuses on the question: 
        a.  Are psychological factors (independent of baseline cardiovascular risk factors) 
             predictors for IMT in women with PCOS? 
      
Research questions for all three papers were evaluated from the CHARM Study, a large 
matched-pair study of 161 PCOS cases and controls.  Paper one was the foundation for the 
subsequent papers, at is was a descriptive study determining the prevalence of psychological 
factors in women with PCOS as compared to controls. 
Paper two explored the relationship between psychological factors and Metabolic 
Syndrome, a common medical condition in women with PCOS. 
Finally, paper three investigated the relationship between PCOS, psychological 
factors, and IMT. 
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2.0  INTRODUCTION 
 
Polycystic ovary syndrome (PCOS) is a heterogeneous reproductive disorder that has a 
known prevalence of up to 20% in women. Beyond the physiological sequela of PCOS, 
psychological consequences coexist and need further study.  The purpose of this dissertation is to 
evaluate the psychological characteristics (i.e. depression, anxiety, anger, hostility, and 
satisfaction with life) in individuals with PCOS compared to controls. In doing so, it is also 
intended to determine the point prevalence of depression in this population by utilizing a self-
report screening questionnaire to assess depressive symptoms. Because the physiological and 
psychological features of PCOS are complex and interrelated, health correlates (i.e. 
cardiovascular disease, obesity, type II diabetes, and insulin resistance) and their relationship to 
the psychological characteristics will be explored. Finally, it will be determined whether in 
women with PCOS, the psychological characteristics of depression or satisfaction with life are 
independent risk factors for subclinical atherosclerosis (measured by intima-media wall thickness 
and the prevalence of plaque) over and above the traditional cardiovascular risk factors. 
The basis for this secondary analysis of the data from the Cardiovascular Health and Risk 
Measurement Study (CHARM) originated in 1992-1994 with the goal of comparing 
cardiovascular heart disease risk factors in women with and without PCOS. From this case 
control study, results published in 1995 revealed that after controlling for age, body mass index 
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(BMI), and other confounding variables, differences in cardiovascular risk factors  were  
elevated in PCOS women who were largely premenopausal (age 15-55) compared to similar 
aged controls. In CHARM I, the psychological data was presented at several meetings and 
univariate analyses of data were completed, (American Heart Association, AHA, 1998), but 
these data were not examined within the context of the full cardiovascular profile. 
In 1998 Talbott and colleagues reported when compared to controls, PCOS women  had 
substantially higher low density lipoprotein (LDL-C) and total cholesterol levels at each age 
group under 45 years of age after adjustment for BMI, hormone use and insulin levels and other 
health correlates of PCOS (1).  Further research continued in the same population, with a follow-
up phase to CHARM II from1996-1999, but no longer in a matched-pair format. This case 
control study found evidence for an association between PCOS and premature carotid 
atherosclerosis in middle-aged women through measurements of carotid plaque distribution and 
intima media thickness. More recently, published findings in 2004 and 2007 highlighted the 
association between metabolic cardiovascular syndrome (2) in PCOS and incidence and 
prevalence of Type II diabetes in PCOS, respectively. To add to advances in clinical treatment of 
PCOS, further knowledge of the psychological effects of this syndrome is essential. The mind–
body connection is paramount in the understanding of PCOS in order to ultimately provide 
comprehensive treatment (emotional and medical) to women with PCOS. The findings from the 
secondary analyses of the baseline data focusing on the psychological aspects of PCOS may be 
useful to the future psychological treatment of PCOS women, a much needed aspect of their 
care. 
 For this dissertation the following series of three research papers will take advantage of 
data from CHARM I and CHARM II: 
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1.  Associations among Depressive Symptoms, Anxiety, Anger, Hostility, and Satisfaction      
     with Life in Women with Polycystic Ovary Disease (PCOS). 
    Women with PCOS have been identified as individuals that are at risk for depression due     
    to the physiological and body image changes that occur from this syndrome. Studies   
    primarily utilizing small samples have supported the finding that depressive symptoms are  
    more prevalent in PCOS women. This paper focuses on the following research questions: 
a.  What is the relationship between PCOS and depressive symptoms?  
b. What is the point prevalence of clinically significant self-reported depressive 
symptoms in PCOS women when compared to controls? 
c.  What is the relationship between satisfaction with life and other psychological 
characteristics (personality traits): anxiety, anger, hostility in women with PCOS?  
d.  Are age, BMI, education, parity, testosterone levels, marital and smoking status 
potential covariates in this relationship? 
2. PCOS, Psychological Manifestations and the Metabolic Syndrome. What is the 
relationship?    
      Metabolic Syndrome (MS) and its components are often found in women with PCOS.          
      An association between depression and insulin resistance, a characteristic of MS, has 
       been reported.  The literature describing the MS in women with PCOS and the 
       relationship between psychological effects are limited.  This paper focuses on the 
       following research questions: 
a. What is the point prevalence of Metabolic Syndrome (MS) in PCOS 
             cases and controls? 
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b.  Are psychological factors (depressive symptoms, anger, anxiety, 
hostility/cynicism, and satisfaction with life) risk factors for Metabolic  
Syndrome independent of age, marital status, education and parity? 
3.  PCOS, Psychological Factors and IMT   
     Earlier work has shown that women with PCOS have increased subclinical  
     atherosclerosis as measured by IMT.  Thus far there has been little attention in the 
     investigation to the psychological risk factors as predictors of cardiovascular diseas 
     (measuring carotid intima-media thickness [IMT]) in women with PCOS.  This paper 
     focuses on the question: 
      a.  Are psychological factors (independent of baseline cardiovascular risk factors)     
predictors for IMT in women with PCOS? 
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3.0  LITERATURE REVIEW 
Polycystic ovary syndrome (PCOS) is a common heterogeneous reproductive disorder 
with a known prevalence of 5% to 10% in women (3-7). PCOS manifests in puberty, typically 
with chronic anovulation, hirsutism, acne and obesity (5, 7-12). Other features include infertility, 
male-pattern balding, ovarian enlargement, and signs of insulin resistance, ie. central obesity and 
acanthosis nigricans (7, 9-11, 13).  As this is a lifetime disorder, other medical problems may 
surface such as cardiovascular disease, dyslipidemia and Type II Diabetes (8, 9, 14-16).  There is 
no known cure for PCOS and the goal of treatment is to reduce the symptoms and risk factors for 
other health problems(17). 
The etiology of PCOS is unclear and the natural history of the disease is unpredictable. 
PCOS has been known as one of the most confusing and complicated diseases.  This is probably 
due to the multiple manifestations of the syndrome, the various definitions given it, as well as the 
differing diagnostic criteria (18). Early on, PCOS was referred to as the Stein-Leventhal 
syndrome (10).  
In 1990, the National Institute of Health met to investigate PCOS.   However, there was 
no consensus regarding the definition of the disorder (19). For research purposes, though, PCOS 
has been defined by using the recommendations from the conference (16, 20). These 
recommendations suggested that PCOS be defined, in order of importance, as:  1.) 
hyperandrogenism (increased levels of male sexual hormones) and or hyperandrogenemia (an 
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excess of androgens, which is identified by external changes, i.e. acne, hirsutism), 2.) ovulatory 
dysfunction, and 3.) the exclusion of related disorders such as hyperprolactinemia (19). 
Later in 2003, an expert panel developed diagnostic criteria for PCOS, called the 
Rotterdam criteria (20). They concluded that the presence of 2 of the 3 criteria, 
oligo/anovulation, hyperandrogenism, and polycystic ovaries, in the absence of secondary causes 
is sufficient for diagnosis (6, 20).  Talbott et al. in 1995 (4) utilized the definition of PCOS to 
include a history of chronic anovulation in association with either clinical evidence of androgen 
excess (hirsutism) or if total testosterone level was >2 nm/L or the luteinizing hormone/follicle-
stimulating hormone ratio was greater then 2. As of today, the exact definition of PCOS is still 
controversial.  
3.1 HORMONE IMBALANCE 
Hormone dysregulation of PCOS (hyperandrogenism and menstrual irregularities) 
represents the major medical complaint in young women and in cases of infertility in adults with 
PCOS (6, 20).  Initially, there are outward physical changes that begin to occur early in 
adolescence (onset approximately age 14) progressing to more severe insults such as infertility, 
insulin resistance, and cardiovascular health problems. In a recent study,  Matar, (21) reported 
that women with  PCOS experience infertility (mean incidence of 74%), hyperandrogenism 
(69%), amenorrhea (29%), dysfunctional bleeding (29%), and sterilization (21%).  In  PCOS, 
there is a chronic presence of increased  testosterone levels concurrent with low levels of 
progesterone and estradiol (22, 23).  Further, it has been found that the sex-hormone binding 
globulin (SHBG) can be significantly lowered which then  results in increased levels of free 
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testosterone (FT) (24).   Along with FT, others have reported  increased androstenedione (free 
androgen index) which occurs in 70-90% of women (24). Serum leutenizing hormone levels are 
also raised (24).  
A multitude of gynecological problems can result from hormonal dysfunction in women 
of all ages with PCOS, as noted earlier by Matar (21).  Probably the most serious repercussion is 
infertility.  Reports reveal that pregnant PCOS women have a miscarriage rate of approximately 
30%, twice the rate of early miscarriages in non-PCOS women (25).   
Menstrual irregularities and its association with cardiovascular disease are also 
considered a serious complication of PCOS.  Solomon et al. in 2002, (26) reported on menstrual 
cycle irregularity and the risk for future cardiac disease. He highlighted the results of the Nurses’ 
Health Study (n = 82,439) (27). It was found that women with a history of menstrual irregularity, 
or chronic anovulation, had increased relative risk of fatal and nonfatal coronary heart disease of 
1.25 and 1.67, respectively, after a 14 year follow up. After adjusting for BMI, the increased risk 
for coronary heart disease was slightly attenuated, but still remained statistically significant.  
3.2 CARDIOVASCULAR EFFECTS   
In addition to a diagnosis of PCOS, women are now being monitored for cardiovascular 
disease as the research has shown that there is an association between PCOS and  cardiovascular 
disease (4, 14, 16, 28).  PCOS is often associated with several cardiovascular risk factors such as 
decreased HDL cholesterol (HDLc), increased levels of  LDL cholesterol (LDLc), increased 
triglycerides, increased obesity, increased waist-hip ratio, increased hypertension, increased 
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insulin resistance and abnormalities of coagulation (4, 14, 29).  Further, PCOS has been 
associated with endothelial dysfunction and subclinical cardiovascular disease (30). 
Dyslipidemia is a term utilized to describe abnormal levels in HDLc, triglycerides, LDLc, 
and LDL to HDL ratios (4). Both obese and lean women with PCOS have dyslipidemia.(31) 
Lean women tend to present with reduced levels of HDLc and the HDL subfraction known as 
HDL-2 (31). A low HDLc level has been identified as a strong predictor of  cardiovascular 
disease in women (30).  Many researchers have contended that prolonged exposure to 
dyslipidemia can result in increased cardiovascular risk (1, 4, 14, 15, 29).  
Hypertension is one of the major cardiovascular risk factors for cardiovascular disease.  
In 1992, Zimmerman et al.(32) reported that most of the premenopausal women with PCOS have 
blood pressure readings in the normal range. Of concern, when PCOS women were compared 
with controls, Holte et al., (33) found that PCOS subjects had higher ambulatory daytime systolic 
and mean arterial pressures. In the same study, they reported that PCOS subjects compared to 
controls had a higher prevalence of labile blood pressure independent of insulin sensitivity.  
Talbott et al., 1995, (4) reported that mean systolic and diastolic blood pressures were greater in 
women with PCOS than control subjects. Further, in this study, they found that mean systolic 
blood pressure among case subjects was 113 ± 14.3 mm Hg and among control subjects, 110.3 ± 
14.3 mm Hg (p=.025). Mean diastolic pressure was not significantly different. The prevalence of 
mean diastolic readings ≥ 90mmHg was 5.9% in women with PCOS and only 3.3% of controls. 
Abnormalities in coagulation also contribute to the risk of cardiovascular disease in 
women with PCOS (1, 29).  Talbott et al. (15) measured a panel of  coagulation and fibrinolytic 
factors in the Pittsburgh cohort in the CHARM II study.  Included markers were: tissue 
plasminogen activator (TPA), Factor VII, D-Dimer, C-reactive protein and Fragment 1.2 in 
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addition to PAI-1 levels.  When adjusting for BMI and age, only PAI-1  remained significantly 
different between PCOS cases and controls. Further, the addition of log insulin to a PCOS-BMI 
regression model, the difference between cases and controls remained significant. This suggests 
that the higher PAI-1 levels were not completely explained by increased BMI and insulin levels. 
Vascular dysfunction is seen an early occurrence in the process of atherosclerosis and 
therefore its assessment serves as a useful prognostic tool prior to the development of 
cardiovascular risk factors (34).  Endothelial function of flow and resistance (i.e. impaired 
arterial vasodilatation, increased arterial stiffness, and increased hemostasis) are often identified 
as cardiovascular endpoints studied in PCOS (28).  Arterial endothelial dysfunction is one of the 
earliest markers of arterial damage and plaque formation in atherosclerosis (35).  The endothelial 
layer of the artery has many homeostatic functions, one being control over thrombosis (36).  
Abnormalities in the endothelium have been identified as a precursor of atherosclerosis. Mather 
et al.(37), conducted a cross-sectional study of endothelium-dependent and independent vascular 
function using brachial ultrasound on women with PCOS and matched controls. In the sample of 
18 PCOS women and 19 age-matched controls they reported no evidence of impaired endothelial 
function in women with PCOS as compared to controls. On the other hand, more recent studies 
have reported abnormal arterial stiffness and abnormal endothelial function in PCOS case control 
studies (38-42). 
The research has identified two major anatomical markers for subclinical cardiovascular 
disease dealing with endothelial flow. They are coronary artery calcification and carotid intima 
thickness (14, 43). Coronary artery calcification is associated with atherosclerotic plaque (44) 
and also predicts an increased risk of cardiac events.      
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Epidemiological studies in the 1990’s focused on cardiovascular disease in PCOS (29, 
45, 46).  These studies investigated lipid abnormalities in hirsute women (29), the role of 
hyperinsulinemia in the development of lipid disturbances in non-obese and obese women with 
PCOS (45), and the risk of myocardial infarction in PCOS women (46). Wild and colleagues 
(47) investigated coronary artery disease (CAD) in relationship to hyperandrogenism in 102 
women through case series. He utilized cardiac catheterization to measure cardiac status. In this 
cross-sectional study, he found that the CAD cases had twice the amount of excess hair (OR; 3.7; 
95% CI, 1.5-9.1). Although this study did not diagnose PCOS it alluded to the possible 
relationship between PCOS features and cardiovascular disease. 
More refined epidemiological studies continued, as Talbott et al.(4) conducted a large 
scale epidemiological study, (244 PCOS cases and 244 controls), matched on age, race, and 
neighborhood. They investigated the coronary heart disease (CHD) risk factors in women with 
PCOS and demonstrated that women with PCOS have adverse lipid profiles, (i.e. increased 
LDLc and triglycerides) and decreased HDLc in comparison to controls. It was found that the 
cardiovascular risk profiles were worse among PCOS cases than controls. HDL cholesterol was 
lower, and total cholesterol and LDL cholesterol were higher among cases than controls (P < 
.05). Triglycerides were also significantly higher in cases than controls (P < 0.001)(4).  Mean 
systolic and diastolic blood pressures were greater in PCOS cases than controls (P = .009, P = 
.04). Diastolic readings were ≥ 90mmHg in 6.1% of cases and 2.6% of controls (P = .03). 
Additionally, fasting insulin and were greater in cases than controls (P < .001). Women with 
PCOS had significantly higher lipid levels than controls when adjusting for potentially 
confounding variables (48).  When adjusting for BMI, fasting insulin independently contributed 
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to the variation in HDLc, LDLc and triglycerides. In PCOS cases, decreased estradiol levels 
were independently associated with increased LDLc (4). 
Using this same population, Talbott et al.(1998) also evaluated the age-specific coronary 
heart disease risk profiles in women with PCOS compared with matched controls in four specific 
age groups (19-24 years; 25-34 years; 35-44 years and 45+ years). The average age of cases and 
controls was 35.3 ± 7.4 and 36.7 ± 7.7, respectively.  Women with PCOS compared to controls 
had substantially higher LDLc and total cholesterol levels at each age group under 45 years after 
adjusting for BMI, hormone use and insulin levels. These findings suggest that women with 
PCOS exhibit significantly adverse lipid profiles and CHD at a young age. Such findings raise 
the concern that when compared with normally menstruating women, women with PCOS could 
be more vulnerable to premature coronary heart disease because of their exposure to excess 
LDLc and HDLc. 
Further research by Talbott et al.(2002)(14) continued, and they investigated the  
association between PCOS and premature carotid atherosclerosis in middle-aged women. The 
purpose of this study was to evaluate subclinical atherosclerosis among women with PCOS and 
controls matched by age. One hundred and twenty five white women with PCOS and 142 
controls ≥ 30 years of age were recruited.  In this follow-up study (approximately 5 years after 
the initial study reported in 1995), subjects underwent B-mode ultrasonography of the carotid 
arteries for the evaluation of carotid intima-media wall thickness (IMT) and the prevalence of 
plaque. A significant difference was observed in the distribution of carotid plaque among women 
with PCOS when compared with controls (7.2% (9/125) had a plaque index of ≥ 3 compared to  
0.7% (1/ 142) in age-matched controls (P = .05).  No difference was noted in mean carotid IMT 
between PCOS cases and controls overall and in the group aged 30-44 years. On the other hand, 
  14
in women in the age group ≥ 45 years PCOS cases had significantly greater mean IMT than did 
controls (P= 0.05). This difference remained significant after adjustment for age and BMI. These 
results suggest that women with PCOS who are exposed to adverse cardiovascular profiles 
develop premature cardiovascular disease. The PCOS relationship to IMT can be explained to 
some degree by weight and fat distribution and other related risk factors.  
Others continued to investigate the cardiovascular risk associated with PCOS. Christian 
et al. (43) examined the prevalence of coronary artery calcification (CAC) in a cohort of  36 
women with PCOS. They found that the women aged 30-45 years of age had a higher rate of 
CAC than the control group of 71 women who were matched for body mass index (BMI) and 
age (39% vs. 21%, respectively; odds ratio (OR) = 2.4; confidence interval (CI) 0.99-5.73; P = 
0.05). Women with PCOS had a greater mean CAC score when compared to controls (P = 0.04). 
When adjusting for BMI, PCOS was no longer a significant predictor of CAC (OR = 1.99; P = 
0.21). 
More recently, the cardiovascular risk attributed to metabolic cardiovascular syndrome 
(MCS) has been of great concern (15, 49). The prevalence of metabolic syndrome has been 
reported from 33.4% to 46% in women with PCOS (50, 51).  In 2004, Talbott et al.(15) studied 
the association between MCS and coronary and aortic calcification among women with PCOS. 
In this study, MCS was characterized as the clustering within an individual of 3 or more of the 
following risk factors: abnormal central adiposity (waist circumference > 88cm), increased 
triglycerides (>150mg/dl), low levels of high-density lipoprotein cholesterol (<50 mg/dl), 
hypertension (130/85 mm Hg or more or treated for hypertension), or increased fasting glucose 
(≥110mg/dl) or diagnosed with type 2 diabetes (52-54) . In this prospective study by Talbott et 
al. (2004)(15), 61 PCOS cases and 85 similarly aged controls were screened for risk factors and 
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were reevaluated 5 years later. The purpose of the study was to determine the prevalence of 
coronary artery (CAC) and aortic (AC) calcification among middle aged women with PCOS and 
controls. They also explored the relationship among calcification and MCS, and other 
cardiovascular risk factors assessed 9 years earlier. CAC and AC were measured by electron 
beam tomography. They found that when compared to controls, women with PCOS had a higher 
prevalence of CAC (45.9% vs. 30.6%, respectively) and AC (68.9%vs 55.3%, respectively). 
When adjusting for age and body mass index, PCOS was a significant predictor of CAC (odds 
ratio = 2.31; 95% confidence interval (CI) = 1.00, 5.33; P = 0.049). Total testosterone was an 
independent risk factor for AC in subjects after controlling for PCOS, age and body mass index 
(P= 0.034). High-density lipoprotein cholesterol and insulin appeared to mediate the influence of 
PCOS on CAC. 
Since 2004, several studies have reported an increased prevalence of metabolic syndrome 
in women with PCOS when compared to controls (16, 55-57). In these studies, the term 
metabolic syndrome was used versus the metabolic cardiac syndrome (MCS). Results may differ 
in studies based on differences in definitions. Nevertheless, it is important to address the role 
obesity plays in the relationship with metabolic syndrome and or MCS.  Faloia et al.(56) 
evaluated the effects of metabolic characteristics of PCOS and found no lean subjects exhibiting 
the metabolic syndrome compared with the 37% of overweight/obese PCOS subjects and 33% of 
the overweight/obese controls. Consistent with these findings, Dokras et al.(55) found that the 
prevalence of metabolic syndrome did not differ when comparing women with PCOS and age-
matched controls did not differ significantly after controlling for BMI. Disputing the findings of 
the two previous studies mentioned, Azziz et al (2006) (57), found a higher prevalence of  
metabolic syndrome in obese women with PCOS independent of age and BMI. One of the most 
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striking findings with BMI and MCS was by Talbott et al.(16) in 2004.  MCS was evaluated at 
baseline between relatively young women with PCOS and controls (mean age 38.7 and 40.4 
years respectively) with similar BMI (<35kg/m²). They found that women with PCOS were 
approximately 4.4 times more likely to exhibit MCS than controls. 
Studies linking PCOS to primary cardiovascular events such as stroke and myocardial 
infarction are speculative (58).  Wild et al.(54) studied cardiovascular mortality and morbidity in 
middle aged women previously diagnosed with PCOS and age-matched controls. In this 
retrospective cohort study of women diagnosed with PCOS in the United Kingdom, they 
collected data on 319 women with PCOS and 1060 age-matched controls. Data was collected by 
death certificates, general practitioners’ records and questionnaires with measurement of 
cardiovascular risk factors in a sub-sample of questionnaire respondents. Results indicated that 
all-cause and cardiovascular mortality in the cohort were similar to the women in the general 
population (standardized mortality ratios (95% CI): 93 (72-117) and 78 (45-124), respectively. 
They reported that women with PCOS had higher levels of diabetes (P = 0.002); hypertension (P 
= 0.04); hypercholesterolemia (P < 0.001); hypertriglyceridemia (P =0.02) and increased waist: 
hip ratio (P =  0.004). When adjusting for BMI, odds ratios (OR) were 2.2 (CI: 0.9-5.2) for 
diabetes, 1.4 (CI: 0.9-2.0) for hypertension and 3.2 (CI: 1.7-6.0) for hypercholesterolemia. A 
history of cerebrovascular disease was significantly more common in women with PCOS with a 
crude OR (95% CI) of 2.8 (CI: 1.1-7.1) as opposed to the history of CHD which was not 
significantly more common in women with PCOS; OR (95% CI) 1.5 (0.07- 2.9). 
Pierpoint et al.(59) in 1998 studied cardiovascular mortality in PCOS over long-term 
follow-up. There were 786 women with a history of PCOS identified through hospital records 
and the investigated through the National Health Service Registry over a 42 year period. In this 
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study the ratio of observed-to-expected deaths as a result of all circulatory disease was not 
increased (standard mortality ratio of SMR, 0.83; (95% CI); (0.46-1.37). In this study it was 
questioned whether unopposed estrogen in PCOS might be protective against cardiovascular 
disease. 
In the second follow-up period of the Cardiovascular Health and Risk Measurement 
Study (CHARM II) by Talbott et al.(14) (1997-99), a medical history of cardiovascular events 
including myocardial infarction, doctor diagnosed angina pectoris, coronary insufficiency, 
bypass angioplasty as well as stroke was obtained. This cohort was comprised of 127 PCOS 
cases and 142 Caucasian controls. The population represented 75% of the original cohort. In this 
sample, there were a total of 5 cardiovascular events representing one myocardial infarction with 
bypass surgery, one angina pectoris with bypass surgery and three doctor-diagnosed angina 
pectoris (medically treated). When compared to controls of similar age, no events were observed. 
The result yielded an odds ratio (OR) 5.86: P< .05. 
More recently, in 2007, Cussons et al. (34) critiqued the literature on the epidemiology of 
cardiovascular disease in PCOS and noted that definitive evidence of an increased incidence is 
unproven due to the short periods of follow-up, the use of highly selected clinic populations, 
small sample size, and confounding factors such as treatment effects at baseline. 
 
3.3  INSULIN RESISTANCE AND TYPE II DIABETES  
Another major health problem in women with  PCOS is insulin resistance, which is often 
associated with Type II Diabetes (60).  While it is difficult to find a universal definition for 
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Insulin Resistance (IR), some (61) have defined IR as the failure of target cells to respond to 
ordinary levels of circulating insulin. In 2004, Legro (62) reported a 50-75% prevalence rate for 
insulin resistance in women with PCOS. When IR occurs in women, it puts them at a greater risk 
not only for developing PCOS, but also for Type II Diabetes, essential hypertension, 
nonalcoholic steatohepatitis, dyslipidemia, and certain cancers (62, 63).  Research has also linked 
insulin resistance with cardiovascular disease in women with PCOS (62). Although insulin 
resistance is not recognized as an independent risk factor for cardiovascular disease, it is 
associated with known cardiovascular risk factors (64).  Insulin resistance is also associated with 
the metabolic syndrome in women with PCOS (30). 
Type II Diabetes is a heterogeneous metabolic disorder characterized by hyperglycemia 
which is due to a combination of resistance to insulin and an inadequate compensatory insulin 
secretory response (65). The prevalence of Type II Diabetes in the general population according 
to the U.S. Third National Health and Nutrition Examination Survey (NHANES III) (66) is 7.8% 
in adults ≥ 20 years of age. Rates increase with age to 18.8% in individuals ≥ 60 years old.(66). 
Type 2 diabetes, associated with insulin resistance, affects a large proportion of the female 
population, although generally at an older mean age than in PCOS women (65).  Among women 
with PCOS, 7.5% to 10% have type Type II  Diabetes by their fourth decade (52, 67).  
Menopausal status has also been researched in relationship to the prevalence of Type II 
Diabetes in women with PCOS. A retrospective study (68) found an increased prevalence of 
Type II Diabetes in both premenopausal and postmenopausal women with PCOS. Two studies 
have reported a higher prevalence of PCOS among women with Type II  Diabetes (69, 70).  
Others(52, 60, 71-73) have found that women with PCOS appeared to develop Type II Diabetes 
at a younger age than women without PCOS.  In 2007, Talbott (8) reported that 15% to 35.6% of 
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all incident cases of Diabetes Type II in Caucasian women may be attributable to PCOS.  The 
prevalence and incidence of Type II Diabetes is reportedly on the increase in young women 
between the ages of 20-35 (4, 59, 74).   Research on Type II Diabetes Type 2 in women with 
PCOS continues to be of interest as diabetes itself is becoming a major epidemic world wide. 
Even though many of the prospective or retrospective studies investigating the relationship 
women with PCOS were performed with matched controls and adequate sample sizes, (8, 58, 67, 
74), longitudinal studies should be considered in order to address the lifetime incidence of 
Diabetes Type 2 in women with PCOS, particularly across the wide age range in PCOS women. 
3.4 OBESITY 
Yet another physiological implication of PCOS is obesity.  Obesity is a comorbid     
occurrence with the previously described clinical features such as MCS, infertility, insulin 
resistance and Diabetes II.  Obesity has not been included in the definition or the diagnoses of 
PCOS, but is a major contributor to body dissatisfaction in women with PCOS.  In a large 
sample of women, Carmina (58) reported that 70% of women with PCOS had increased body 
weight (body mass index) BMI > 25kg/m².  Categories of obesity are seen below in Table 1.  
Obesity is known to worsen insulin resistance, which can ultimately lead to cardiovascular 
disease (58). 
Early studies have substantiated that women with PCOS have a higher prevalence of 
obesity (2, 50). Depending on ethnicity, genetics, other medical problems, lifestyle and 
geography, the presence of obesity varies.  Carmina (75) noted that overall obesity is present in 
approximately 44% of PCOS women.  More recently, the prevalence of obesity in women with 
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PCOS has ranged between 38% and 88%(76, 77). As one might expect, obesity worsens the 
manifestations of PCOS. Some features of PCOS that worsen are insulin resistance and androgen 
levels. Insulin resistance increases and there is a further elevation of ovarian and adrenal 
androgens and unbound testosterone (78).  When obesity is present, it is usually of the android 
type, with increased waist-to-hip ratio (1).  The mechanism of weight gain in PCOS is attributed 
to both genetic predisposition and environment (i.e., poor diet and reduced exercise)(79).  
In 1995, Talbott et al.(4) highlighted the differences in BMI between women with PCOS 
and controls. They reported that cases weighed more than controls (176.9 ± 49 versus 153.76 ± 
35.7 pounds, respectively, P< .001).  Almost 50% of the cases and 27.8% of the controls 
weighed 170 pounds or more (P < .01).  Mean BMI for cases was 30.5 ± 8.3 versus 26.3 ± 6.5 
for controls; (P< .001).  In the Pittsburgh study cohort by Talbott et al.(14) approximately  40% 
of the PCOS Caucasian women were not overweight/obese by the criterion of a BMI of 
27.3kg/m² proposed by the national standards.  In 2005, a compelling finding was reported from 
a study by Glueck et al.(80) on women with PCOS from the ages of 20-41.  Utilizing a sample of 
401 PCOS women matched with population controls, they found that major weight gain 
manifested by the age of 20-24 and continued through 32-41 years. Moreover, 91%, were 
overweight, obese, or extremely obese. As women age,  obesity continues to be a major concern 
and struggle for women with PCOS. 
Most early and more recent research studies (4, 12, 75, 81) have examined obesity along 
with the major features of PCOS and in some studies have found obesity to be a confounding 
variable. Many studies have reported controlling for BMI to determine independent associations 
with PCOS physiological determinants (1, 4, 14, 16).  Talbott et al.(4, 15), after controlling for 
BMI, found that cardiovascular risk factors differed significantly between PCOS cases and 
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controls. Women with PCOS were more than twice as likely as controls to exhibit coronary 
artery calcification(4).  In a later study by Talbott and colleagues (14) women with PCOS ≥ 45 
years of age compared to controls of similar age had significantly greater IMT readings. In a 
later study that investigated the association between MCS and CAC in women with PCOS, 
Talbott and colleagues (15)  found that components of MCS mediate the association between 
PCOS and CAC, independent of obesity. On the other hand, in prior work examining premature 
cardiovascular disease in middle aged women, Talbott et al.(14) found BMI to be a powerful 
predictor of IMT, particularly in women with PCOS.  Similarly, in a 1998 study investigating the 
adverse lipid and CHD risk profiles in young women with PCOS, Talbott et al.(1) reported that 
BMI predicted both systolic and diastolic blood pressure in younger PCOS women. In addition 
to BMI, fasting insulin level has been found to be a significant predictor of blood pressure levels 
in older PCOS women (1).  
The parameters for BMI measurement have been fairly consistent with the categories for 
BMI as listed below in Table 3-1.  However, it is important to consider the definitions of BMI 
by categories before interpreting the results of research studies.  Additionally, the link between 
obesity and PCOS is a complex interplay between many organ and endocrine systems. Research 
studies have moved toward trying to understand this phenomena through stratification of samples 
by age (82).  As the obesity epidemic continues world-wide, this clinical correlate will likely 
remain a central issue for future studies of PCOS.  
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Table 3-1 Categories of excessive body mass index, BMI * 
BMI 18.5-24.9 kg/mg²                    Normal weight    
BMI 25-29.9 kg/mg²                      Overweight  
BMI 30-34.9 kg/mg²                     Obesity Class 1 
BMI 35-39.9 kg/mg²                      Obesity Class 2 
BMI  >40 kg/mg²                           Obesity Class 3 
*BMI categories based on criteria from the National Heart, Lung, and Blood Institute (83) 
3.5 PSYCHOLOGICAL/MENTAL HEALTH PERSPECTIVE OF PCOS 
In addition to the medical ramifications of PCOS, mental health consequences may also 
manifest as a result of this condition. Most research has been primarily focused on the 
biophysiological characteristics without sufficient attention to the psychological outcomes.  As 
described by many researchers (84-89), the medical features of PCOS make them particularly 
susceptible to the psychological effects that result from changes in body image related to insulin 
resistance and hyperandrogenism. These psychological effects may consist of symptoms of 
depression, reduction in life satisfaction, as well as increased anxiety, anger and hostility in 
everyday life. These changes are depicted in Figure 3-1.  Clinical Significance of PCOS with 
Physiological changes and Psychological consequences. 
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Figure 3-1 Clinical Significance of PCOS with Physiological changes and Psychological consequences 
3.6 PSYCHOLOGICAL CONSEQUENCES OF PCOS:  DEPRESSION 
One psychological consequence of the physical changes associated with is depression. 
The term ‘depression’ has varied definitions when used in both clinical and research contexts. 
Some research studies use the term ‘depression’ to refer to depressive symptoms that are 
measured by a self-report of interviewer-administered questionnaire.  These studies often use a 
pre-determined score or cutpoint on the scale to identify persons with symptoms that are above 
the ‘normal range.’ It is important to differentiate between the assessment of depressive 
symptoms and the diagnosis of a clinical illness. Symptom scales cannot be used to diagnose 
clinical depression. One common form of clinical depression is Major Depressive Disorder 
(MDD).  MDD consists of a sad mood or loss of interest or pleasure in one’s life combined in 
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addition to other symptoms such as sleep disturbance, low energy, decreased appetite, poor 
concentration, feelings of worthlessness, and guilt that are persistent over a two week period 
(90).  In addition to the presence of at least five of these symptoms, a key aspect of the diagnosis 
of this clinical illness is that these symptoms impair the person’s ability to function. Although 
major depression can occur only once in an individual’s lifetime, it also an illness that can recur 
repeatedly. Other forms of clinical depression include dysthymia, which is a milder but more 
chronic form of clinical depression that last at least two years, and bipolar disorder, in which an 
individual experiences  periods of major depression as well as periods of mania.  
Currently, the Diagnostic and Statistical Manual of Mental Disorders (DSM IV-TR) (90)  
is the accepted standard resource which provides guidelines in determining psychiatric 
diagnoses.  It includes the criteria for the diagnosis of Major Depressive Disorder (MDD) (Single 
Episode and Recurrent); Dysthymia, and Bipolar Disorder. i.e. depression. 
It is well documented that women are at a greater risk for depression as reported in a 
community epidemiological study, the National Comorbidity Survey (NCS) (91, 92). Women 
were found to be approximately (21.3% in women and 12.7% in men) 1.7 times as likely as men 
to report a Major Depressive Episode (MDE) in their lifetime (91). Even though this study is 
criticized for only sampling subjects less than 55 years of age, it is precisely that age group that 
is most affected with PCOS.  In another well known community study by  (93),  The 
Epidemiologic Catchment Area Study, (ECA) it was also found that when compared to men, 
women women were more than twice as likely to experience major depression (2.7: 1) in their 
lifetime (93).   
Other studies have also identified women as being more vulnerable to depression than 
men (94, 95).  Internationally, others have posited that women suffer from higher rates of 
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depression due to biological determinants(95).   From this large community study, Bebbington et 
al. (1998) (95) reported that there was a clear reversal of the sex difference in the prevalence of 
depression in women over the age of 55 as compared to men.  The prevalence of depression in 
women decreased from an OR (2.07 to 0.78). 
There are numerous screening tools that are utilized to identify individuals who may be at 
risk for depression.  In 2003,  Nease and Malouin (96) evaluated depression screening  
instruments for primary care settings . They  recommended  4 screening instruments for 
assessing depression, the Primary Care Evaluation of Mental Disorders (PRIME- MD) the 
PRIME-MD Patient Health Questionnaire (PHQ), Symptom-Driven Diagnostic System for 
Primary Care (SDDS-PC), and the PRIME_MD Patient Health Questionnaire (PHQ-9) (96).   
The BDI is a self-report inventory, which measures characteristic attitudes and symptoms 
of depression.  It contains 21 questions with a cutoff of >9 (total score) to identify potential 
clinically significant symptoms of depression.  The psychometric properties of the BDI have 
been reported as high with internal consistency estimates that range from .73 to .92 with a mean 
of .86.  The split-half reliability coefficient reported was .93.  Concurrent validity, determined by 
correlations with clinician ratings of depression using the revised BDI ranged from .62 to .66 
(97).   The BDI has been used in prior research studies on the PCOS population (87, 89), as well 
as research studies on women with obesity.   
As one would expect, it is well known that there are higher rates of depression in the 
medical population (those with medical illnesses) ranging from 21-47 %  (98-100). Others have 
reported point prevalence rates of major depression in primary care outpatients to range from 2-
16% and from 9-20% for all depressive disorders (101-106).  The incidence and prevalence of 
depression in the PCOS population is still debatable. 
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The prevalence of depression in women with PCOS is unknown because there are few 
studies that have investigated the psychological sequela of PCOS as well as the lack of 
appropriate methods to obtain psychiatric diagnoses.   More importantly have used symptoms 
inventories, rather than DSM criteria to determine diagnoses of depression.  Therefore, related 
studies that have investigated the prevalence of depression in women may provide the 
framework and insights into understanding the association between PCOS and depression.   
Early on, research on the psychiatric morbidity associated with PCOS was reported using 
case studies.  One of the first investigations of psychological morbidity in women with PCOS 
was done in London in 1993 by Bruce-Jones et al.(84).  This was a modest case series in which 
Bruce-Jones and colleagues noted that a significant proportion of their sample exhibited 
“psychological problems”. It is flawed in that it is a small sample within a psychiatric practice. A 
case series of 10 patients with both significant psychological problems and PCOS were 
discussed. The patients were referred to a hospital liaison psychiatry service. Psychiatric 
diagnoses were defined according to the DSM III-R  (107).  The diagnosis of PCOS was made 
by endocrinologists or gynecologists based on the clinical presentations and endocrine profile. 
Seven cases of PCOS were actually diagnosed after their psychiatric disorder Of these case 
reports, 70% had a diagnosis of a depressive syndrome (5 had Major Depression, 1 had 
Dysthymia, and 1 had Bipolar Depression), while most of the others were anxiety disorders 
(general anxiety disorder, obsessive compulsive disorder and panic disorder). 
Rasgon et al. (86) in 2003, also investigated the prevalence of depression in women with 
PCOS. This pilot study done in Los Angeles, California in 2003 evaluated  32 women with 
PCOS in a Reproductive Endocrinology Clinic. Similar to the previous study, there was no 
control group. The subjects completed the Center for Epidemiological Studies Rating Scale 
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(CES-D) during the initial visit and had subsequent diagnostic work-ups to establish a correlation 
between clinical and biochemical markers of PCOS and the CES-D scores.  It was found that 16 
women had clinically significant CES-D scores (CES-D scores ≥16).  They reported that 
depression was associated with greater insulin resistance (p=0.02), and with a higher body mass 
index (p=0.05).  Limitations of this study were small sample size, sample selection bias, the use 
of a screening tool versus diagnostic measures to identify depression, and lack of a comparison 
group. This was the first reported pilot study to examine the rate of depression among women 
with documented PCOS (with clinical and biochemical markers) and to correlate them with 
scores from a screening tool for depression (CES-D). 
In a recent cross-sectional study done in Iowa by Hollinrake et al.(87) 2007, 103 women 
with PCOS (Rotterdam Criteria)(20) and 103 controls without PCOS seen during the same time 
period for an annual exam were studied to estimate the prevalence of depressive disorders in 
women with PCOS. This study also investigated the role of androgens and other metabolic 
markers associated with PCOS in the development of depression. It was the first case control 
study to examine the risk of depressive disorders in women with PCOS based on the DSM IV 
diagnostic criteria.  Depression was screened for using the Primary Care Evaluations of Mental 
Disorders Patient Health Questionnaire (Prime-MD PHQ) and the Beck Depression Inventory 
(BDI).  The Prime-MD PHQ is a self-report screening measure which provides a simple way to 
assess both diagnostic criteria and severity.(108)  This scale demonstrates a  sensitivity of 73% 
and specificity of 93(108).  Subjects were women 18-50 years of age.  Women with PCOS were 
at an increased risk of depression (new cases) compared with controls (21% versus 3%, OR 5.11; 
(95%; (CI: 1.26-20.69); p<.03).  The overall risk of depressive disorders in this sample was OR; 
4.23; (95% CI 1.49-11.98; p<.01), independent of obesity and infertility. When compared with 
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the non-depressed PCOS subjects, the depressed PCOS subjects had a higher body mass index 
(BMI) and evidence of insulin resistance (p<.02).  Although  the Prime-MD PHQ .(108)  was 
used to screen for depression, it is not fully recognized as a diagnostic measure for depression, 
which may affect the interpretation of the results of this study. 
3.7 DEPRESSION AND BODY IMAGE IN PCOS 
Body image is a salient variable that can affect mood negatively in PCOS. Two-thirds of 
the women with PCOS are overweight and over three-fourths exhibit significant  hirsutism(6).  
Acne and male balding are also common physical disturbances seen in women with PCOS 
women(4, 6, 85, 89).   In 2002, Mc Cook et al. in (109) found that body satisfaction (defined as 
satisfaction with the size and shape of one’s body) was lower in women with PCOS than in a 
nationally representative sample of college women. 
A qualitative study, “The thief of womanhood: a women’s experience of polycystic 
ovarian syndrome”,  reported by Kitzinger and Willmott in 2002,(85) reported findings from 
interviews of women with PCOS. Thirty women were recruited through a self-help organization 
in London. In depth, semi-structured, tape-recorded interviews were conducted. Twenty-four 
white and 6 non-white heterosexual subjects (age 21-42) with a mean age of 29 participated. The 
thematic analysis of the interviews revealed the women  felt “freakish”, “abnormal” and not 
“proper” women. These feelings were related to excess hair growth, irregular or absent periods, 
and infertility.  In this study, one area of focus was hirsutism (an overproduction of hair), a 
feature women with PCOS experience, and which psychologically can induce profound feelings 
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of despair and alienation. Kitzinger and Willmott (85) found that women with hirsutism also 
referred to themselves as unfeminine. 
The research on hirsutism and psychological disturbances is limited.  Some studies have 
reported on women with depression and idiopathic hirsutism(110) and found that  7 of the 20 
women studied had clinically significant levels of depressive symptoms. Others dating back to 
1993 (111) report psychological morbidity for hirsute women at no greater degree than other 
hospital outpatients. 
Androgens play a part in distorting the body image of women with PCOS because  
hyperandrogenism can exacerbate an increased amount of superficial and facial hair as well as 
male patterned baldness. In PCOS, hyperandrogenism and hyperinsulinemia are comorbid 
features. Hyperinsulinemia is linked to acanthosis nigracans as well as central adiposity. In 
addition it has been theorized that abnormal gonadal hormones (androgens) can contribute to the 
manifestation of dysfunctional mood states in women through activational effects on the 
brain(112).   PCOS is a hormonal disorder that begins in puberty and  is characterized by 
chronically augmented free testosterone (113).   Increased free testosterone (FT) has been 
associated with depression in women.(114) and testosterone has correlated with anger and 
depression in women during both the pre and post partum period (115). 
Recently, Weiner et al. in 2004 (113), examined androgens and mood dysfunction in 
women with PCOS. Weiner and colleagues compared studied 27 women with PCOS with 27 
normally menstruating women, all of whom were matched on BMI.  The PCOS cases were 
referred from the Department of Endocrinology at the University of Chicago. PCOS was 
diagnosed by (1)oligo/amenorrhea, (2) hyperandrogenemia (increased free testosterone level), 
(3) hyperandrogenism (infertility, hirsutism, acne and or alopecia), and (4) exclusion of non-
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classic congenital adrenal hyperplasia, Cushing’s syndrome, hypothyroidism, or significant 
elevations in serum prolactin. Controls were obtained through advertisements and also matched 
on age, education, and race. Subjects with PCOS had a mean age of 28.19 ± 4.84 and controls 
had a mean age of 30.07 ± 6.48. Mean BMI for women with PCOS was 37.70 ± 8.46 and 36.89 
± 7.24 for controls.  Serum levels of FT, total testosterone, and other labs were taken. Self-
reported depression, anger, anxiety and aggression were analyzed and compared across hormonal 
values. A curvilinear relationship between FT and negative affect across groups was suggested. 
The most elevated negative mood-scale scores were associated with FT values just beyond the 
upper limits of normal, while lower negative mood levels corresponded to the normal and 
extremely high values of FT. These findings support the activational influences of testosterone. 
Self reported depression, anger, anxiety and aggression were analyzed and compared 
across hormonal values. The State-Trait Depression Adjective Check List (116); the State-Trait 
Anger Expression Inventory  (STAXI)(117); the State-Trait Anxiety Inventory (STAI)(118); and 
the Aggression Questionnaire (AQ) (119) were administered. Depression was significantly 
increased in the PCOS group P< .01; and was significantly greater in the PCOS group for both 
state and trait univariate analyses. Results from the STAXI, STAI and the AQ did not show any 
significant differences between groups.  Limitations of this study included self report measures 
and small sample size. These findings suggest that a relationship exists between androgen levels 
and negative mood states, particularly depression.    
Others continued to study the psychological consequences of PCOS. In 2006, Himelein 
and Thatcher (120) compared 40 women with PCOS with controls without PCOS who were 
infertile, and to a third group who had neither PCOS or infertility problems. PCOS was defined 
in this study as women having at least 2 of the following clinical symptoms (ovulatory 
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dysfunction, hyperandrogenism, biochemical markers such as elevated androgen). The groups 
did not differ in age, race, education, income, or religious affiliation. The majority (98%) were 
white with a mean age of 32.1 ± 5.5 years. They were well educated with a mean of 15.6 ± 2.2 
years of education, and represented a variety of income levels. The groups differed in marital 
status as the PCOS and infertility groups were more likely to be married (88% and 95% 
respectively) than the women in the convenience control group. Subjects with PCOS had 
typically known about their diagnosis for a considerable length of time (mean of 36.7 ± 54.7 
months) which may have affected potential depressive symptoms. Individuals may have adjusted 
to PCOS and thus depressive symptoms may have decreased. Subjects were recruited from 2 
separate offices of south-eastern clinics in the United States that specialized in treating women 
with reproductive and endocrine disorders. All participants were administered 3 questionnaires, 
the 13-item short form of the Beck Depression Inventory, BDI,  (121) the Multidimensional 
Body-Self Relations Questionnaire-Appearance Scales, (MBSRQ-AS)(122) and the Body 
Feature Satisfaction, adapted from the Body Satisfaction Questionnaire.(123) In the PCOS 
group, 78% reported receiving some type of treatment for PCOS. Fifteen percent of the PCOS 
group was considered to be normal weight. The PCOS women reported higher depression scores 
and greater body dissatisfaction (p<.001) than comparison group women. Post-hoc comparisons 
revealed that women with PCOS reported significantly more depressive symptoms than women 
in either the infertility or convenience control groups. The mean depression score for the PCOS 
group fell within the mildly depressed range of the short form of the Beck Depression Inventory, 
compared with mean scores in the normal range for both comparison groups. Furthermore, 
scores in the moderate to severe level of depression (totals of 12 or greater) were reported by 
28% of women with PCOS, compared to 10% in women with infertility and 2 % in the 
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convenience control group. When controlling for body mass (BMI), body image (defined as 
overall looks and discrete physical characteristics and measured by the MBSRQ-AS) was 
strongly associated with depression scores on the BDI. They also found that women with PCOS 
expressed more dissatisfaction than comparison group women with four additional body 
characteristics: skin complexion; visible facial hair; general hair features; and overall 
appearance. Limitations of this study included the cross-sectional design and bias due to the 
sampling bias.  As well, a convenience sample was used and 98% were Caucasian.  Furthermore, 
another limitation that may have affected the findings was that the PCOS subjects knew about 
their disorder for approximately 3 years prior to the study and thus may have developed 
strategies to cope with or adapt to the emotional repercussions associated with PCOS. 
The research studies on PCOS and depression are limited to 6 investigations from 1993 to 
2007.  See Table 3-2 for the studies investigating PCOS and depression. 
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Table 3-2 Studies Investigating PCOS and Depression 
Study Year N Design Findings Comments 
Bruce Jones et 
al.  (84) 
1993  
PCOS 
Cases 
n=10 
Case series 
referred for  medical 
in-patient consultation 
Majority 50% had 
Major Depression 
Small sample; no 
standardized tools 
Kitzinger & 
Wilmott (85)   
2002  
PCOS 
Cases 
n=30 
Semi-structured tape 
recorded interviews 
Analyses revealed 
women saw 
themselves as 
different and less 
feminine. 
qualitative 
Rasgon et al. 
 (86) 
2003  
PCOS 
Cases 
n=32 
Descriptive 50% had scores 
indicative de- 
pression (not on 
OCP*) p=.03;De-
pression was 
associated with > 
insulin-resistance 
and BMI 
Pilot study 
No control group 
CES-D used 
Weiner et al. 
 (113) 
2004  
PCOS 
Cases 
n=27 
& 
controls 
n=27 
 
 
Case Control 
Matched on BMI, age, 
education, and race 
Depressive 
symptoms were 
significantly 
increased in 
PCOS group. 
State and trait 
depression = 
P<.01 
measured 
testosterone  & 
relationship to 
depression; used  
State-Trait 
Depression Adjective 
Checklist 
Himelein & 
Thatcher (89) 
2006  
PCOS 
Cases 
n=40 
& 2 
control 
groups 
n=120 
 
Case control 
Did not identify 
matching; but stated 
no difference in age, 
race, education, 
income, or religion in 
results 
PCOS women  
reported higher 
depression scores 
and body dis- 
satisfaction p<.05. 
Case control 
Compared PCOS 
women to: 2 groups 
infertile/no PCOS; 
and to normal women 
BDI 13 item used 
Hollinrake et 
al. (124) 
2007 
 
 
PCOS 
Cases 
n=103 
& 
controls 
n= 103 
 
Case Control 
No matching 
  
Multivariate analysis 
Was performed on 
BMI and fasting 
glucose 
OR 5.11 (CI-1.26-
20.69), p<.03 
risk of depression 
for PCOS cases 
compared to 
controls; 
OR 4.23 (CI-1.49-
11.98)p<.01 
independent of 
obesity and 
infertility 
Prime-MD PHQ used 
for diagnostic 
measure of 
depression 
BDI also used. 
*OCP= oral contraceptives 
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3.8 DEPRESSION AND SUBCLINICAL CARDIOVASCULAR DISEASE 
Subclinical cardiovascular disease, also known as cardiovascular disease that has not 
reached a clinical presentation, has been identified by the presence of  underlying disease such as 
atherosclerosis(125).  B-mode ultrasonography, a measurement of carotid wall intima-media 
thickness (IMT) is utilized as a diagnostic tool to measure atherosclerosis(126).   IMT correlates 
substantially with atherosclerosis in the coronary arteries and can predict clinical coronary 
events(125).  
Epidemiological studies dating back to 1993 have demonstrated that there is a link 
between depression and the risk of developing cardiovascular disease (127, 128).  Patients with 
depression have a twofold to fourfold increased risk of developing cardiovascular disease (127, 
129). In a review article by Musselman et al.(1998)(130) they reported that symptoms of 
depression predict future coronary events for initially health individuals. Although there are a 
multitude of studies reporting on depression and different aspects of cardiovascular disease,(127-
131) there are none known that have described the possible independent relationship between 
depression and subclinical cardiovascular disease in PCOS. Since cardiovascular disease is an 
important concern in PCOS, (e.g., sub-clinical disease noted by Talbott et al.(2000)(14) and 
Christian et al. (2003)(43), it is important to examine the studies linking depression and 
cardiovascular disease, specifically those sub-clinical in nature. 
There are few studies reporting on the relationship between depression and sub-clinical 
cardiovascular disease (131-133).  In 2003, Jones et al.(134) studied the lifetime history of 
depression and carotid atherosclerosis in middle-aged women in the Study of Women’s Health 
Around the Nation, (SWAN), a 7 site, prospective, longitudinal study of the perimenopausal 
transition.  Age of subjects ranged from 42-52 upon study entry.  A cohort of 463 healthy 
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middle-aged women, predominately white (one-third African Americans) from the parent study 
of 463 participants, was assessed for depression and subclinical atherosclerosis as measured by 
B-mode carotid ultrasound scanning of the right and left common carotid arteries, carotid bulb, 
and the first 1.5 cm of the internal and external carotid arteries were obtained. The 
ultrasonographer imaged the vessel in several planes for each location and then focused on the 
interfaces required to measure IMT and on the largest are of focal plaque. The IMT and plaque 
scores were computed by trained readers at the Pittsburgh site. Both the ultrasonographers and 
readers were blind to the participant’s Structured Clinical Interview (SCID-IV) diagnoses, and 
the SCID-IV interviewers were blind to the plaque and IMT results. Psychiatric diagnoses were 
assessed using the Structured Clinical Interview (SCID) for the DSM-IV Axis I disorders-Non-
Patient Edition. Subjects were also administered the Center for Epidemiological Studies 
Depression Scale (CES-D)(135) to ascertain depressive symptoms during the past 7 days.  More 
than one third of the sample met the criteria for a major depressive episode during their lifetime 
and approximately 23% of the subjects reported clinically significant depressive symptoms 
during the past week on the CES-D (score ≥ 16 ) (132).   Women with a lifetime history of 
recurrent major depressive episodes demonstrated a twofold risk of plaque relative to women 
with no history of depression (odds ratio = 2.30; 95% confidence interval, 1.10-4.82). The 
lifetime history of a single major depression episode was not associated with plaque (OR = 0.63; 
95% CI, 0.20-1.98).  Current depressive symptoms (CES-D scores ≥ 16) were not significantly 
associated with plaque (P =.70) or IMT (P =.50). The findings remained the same when the 
current depressive symptoms were used as a continuous variable rather than a dichotomous one. 
Covariates included systolic BP, insulin and race.  A lifetime history of recurrent major 
depressive episodes remained significantly associated with plaque after controlling for age, 
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diastolic blood pressure, smoking history, and race. Lastly, the covariate, tricyclic 
antidepressants, was analyzed to determine if the tricyclic antidepressants mediated the 
association between recurrent major depression and plaque. This association remained 
statistically significant after controlling for the use of tricyclic antidepressants (OR = 2.56; CI, 
1.18-5.57). 
In another study, Agatisa et al. (2005)(132) (using the women in the SWAN study site in 
Pittsburgh) investigated coronary and aortic calcification in women with a history of major 
depression.  Fifty-eight African American women and 152 Caucasian women participated in the 
study.  A history of major depression was diagnosed using the SCID, administered at baseline 
and annually to assess participant’s mental health. The Center for Epidemiological Studies 
Depression Scale, (CESD) (135) was used to identify potential clinically significant symptoms of 
depression. At the beginning of the third year of the annual visits, electron beam tomography 
(EBT) measures of calcification of the coronary arteries and aorta were obtained. Of the 210 
women in the study, 53 (25%) met criteria for a history of recurrent major depression. Most of 
the subjects were Caucasian. Coronary calcification was identified in 103 women (49%) and 
aortic calcification in 144 women (54%); high calcification scores were classified at 
approximately 75% of the sample distribution (i.e. ≥10 for coronary calcium score (n = 49) and 
>100 for the aorta calcium score (n = 53).  Women with a history of recurrent major depression 
(n = 53) were more likely to have any coronary calcification or calcification in the high category 
at either site compared with women with a history of a single episode of depression or no 
depression. When adjusting for cardiovascular risk factors (age, race, education, BMI, 
triglycerides, smoking status) and sociodemographic characteristics, a history of recurrent major 
depression, compared with a single episode or no history was associated with increased risk (OR  
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2.46; 95% CI: 1.06–5.67) for any coronary calcification; with high coronary calcification (OR  
2.71; 95% CI: 1.08-6.81) and with high aortic calcification (OR 3.39; 95% CI :1.34-8.63).  
Adjusting for waist-hip ratio reduced the association (was no longer statistically significant) 
between history of recurrent depression and any calcification or with high calcification. 
In a recent study by Stewart et al. (2007)(133) from the Pittsburgh Healthy Heart Project, 
an ongoing prospective cohort study of healthy older men and women from the general 
community, negative emotions and a 3 year progression of subclinical atherosclerosis was 
studied. Three hundred and twenty-four subjects participated to determine a three year change in 
mean carotid intima-media thickness. This study was unique in that it simultaneously studied the 
effects of depressive symptoms, anxiety, and hostility/anger, on coronary artery disease (CAD).  
Participants were healthy adults with a mean age of 60.6 ± 4.7 years. Approximately 50% were 
women. The Beck Depression Inventory II, (BDI II) (97) was administered as one of the 
negative emotion scales along with the Cook-Medley Hostility Scale (136) and the State-Trait 
Anger Expression Inventory.(117) Carotid intima-media thickness (IMT) was measured by 
ultrasonography. Regression analyses indicated that higher depressive symptoms at baseline 
were associated with greater 3-year change in carotid intima-media thickness (ΔR²=0.026, 
P=.002) even when controlling for demographic factors, cardiovascular risk factors (blood 
pressure, BMI, total cholesterol, high-density lipoprotein cholesterol, triglycerides, low density 
lipoprotein cholesterol, fasting glucose, fasting insulin), medication use, medical conditions, and 
other correlated negative emotions. Additionally, mild to moderate depressive symptoms, as 
assessed by the BDI II, were associated with greater 3 year change in carotid IMT. Anxiety 
symptoms, hostility, anger experience and anger expression were each unrelated to IMT changes. 
Post hoc analyses showed that the somatic-vegetative symptoms (primarily included items 
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assessing the physical symptoms (i.e. anhedonia, fatigue, and sleep/appetite disturbance) of 
depression (ΔR²=0.027, P=.002) were positively associated with intima-media thickness change, 
while the cognitive-affective symptoms of depression were not.   Limitations to this study 
included asking participants to rate their symptoms on the BDI II during the past week instead of 
the past 2 weeks (recommended time frame for the BDI II) which may have underestimated the 
severity of depressive symptoms reported. In addition, the age range of the sample was older 
which limits generalizability. Despite the older population in this study, these findings evoke 
further questions regarding the relationship between depression and subclinical cardiovascular 
disease in women with PCOS. 
3.9 DEPRESSION AND CLINICAL CARDIOVASCULAR DISEASE 
Other large studies (137, 138) have examined depressive symptoms and their  association 
with heart disease and cardiac symptoms in women. Ferketich et al. (2000)(137) studied 
depressive symptoms as an antecedent to heart disease among women and men in the National 
Health and Nutrition Examination Survey (NHANES I) Study (139).   From the initial National 
Health and Nutrition Examination Follow-up Survey (NHEFS)(140) 5006 women were studied 
who were free of coronary heart disease (CHD).  Participants were evaluated from 1982 until 
1992 or until an occurrence of a CHD event.  Subjects were given the Center for Epidemiologic 
Studies Depression Scale (CES- D).  CHD incidence and CHD mortality were the outcome 
variables.  The mean age for women was 53.7 ± 13.9 and 55.9 ± 14.4 for men.  The mean scores 
for the CES-D were 8.79 ± 8.60 and 6.77 ± 7.13 for women and men, respectively.  The cut point 
for defining clinically significant depressive symptoms on the CES-D was 16, classifying 17.5% 
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of women and 9.7% of men as depressed.  Depressed women had a higher BMI than women who 
were not depressed.  Women experienced 187 nonfatal and 137 fatal events, compared with 187 
nonfatal and 129 fatal events among the men.  The adjusted RR of CHD incidence among 
depressed women was 1.73 (95% confidence interval (CI: 1.11-2.68) compared with 
nondepressed women.  One important limitation of this study is that it was not prospective.  
Because this was a prevalence study, it is difficult to discern if clinically significant depressive 
symptoms preceded the increased CHD risk or if the CHD risk preceded increased depressive 
symptoms. 
In another large multi-site study by Ruttledge et al. (2007)(138), Women’s Ischemia 
Syndrome Evaluation (WISE), sponsored by the National Heart, Lung, and Blood Institute 
(NHLBI),  750 women with a mean age of 53.4, were studied to determine the association 
between depressive symptoms and cardiac symptoms, mortality and hospitalization. Five-
hundred and five subjects completed the BDI at baseline. Approximately 18% of the women 
reported depression scores consistent with the presence of at least moderate depression at the 
time of baseline assessment. Depression symptom severity was linked to an increased mortality 
risk over follow-up. (RR = 1.05; 95% CI, 1.01-1.09).  Limitations of this study include not 
obtaining past depression history and severity, treatment or response to treatment.  Like the 
NHANES I study, the sample population of the WISE study enrolled women who were older 
women than those typically seen in the PCOS population.  However, these studies highlight the 
need to consider the effect of depression and depressive symptoms on the cardiovascular status 
of women at all ages with PCOS. 
In all, there is empirical evidence for depression as a risk factor for cardiovascular 
disease.  In Coronary Artery Disease (CAD), numerous cross-sectional studies have documented 
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a high prevalence of depressive symptoms in patients.  Depression confers a relative risk (RR of 
1.5-2.0) for the onset of CAD in healthy individuals (141).  In a review article by Rugulies (142) 
in 2002 cohort studies on depression and Coronary Heart Disease  were searched from 1997-
2000 to review and quantify the impact of depression on the development of CHD initially 
healthy subjects. The overall RR for the development of CHD in depressed subjects (of the 11 
studies evaluated) was 1.64 (95% confidence interval (CI) =1.29-2.08, P< 0.001).  The recently 
published results from a large study, Women’s Health Initiative (WHI) Observation Study (143),  
followed 93,676 postmenopausal women for an average of 4.1 years.  None of the subjects had 
cardiovascular disease.  When adjusting for other cardiac risk factors, results indicated that 
depression was an independent risk factor for developing and dying from CVD.  These findings 
give support to further investigate the effects of depression not only on cardiovascular disease in 
PCOS, but the silent precursor to CHD and CAD, subclinical cardiovascular disease. 
3.10 ANXIETY AND CARDIOVASCULAR DISEASE 
A meta-analysis of articles concerning anxiety and the pathogenesis leading to heart 
disease published between 1980 and 1998 concluded that anxiety plays a role in the onset of 
coronary heart disease (144).  Further, in this analysis, when investigating negative emotions and 
coronary heart disease, anxiety was the strongest predictor in comparison to anger and 
depression. Yet, in other studies (145, 146) there was a lack of association or correlation between 
anxiety and sub-clinical heart disease, which suggests that future research examine the role of 
anxiety and the temporal nature of its onset in predicting cardiovascular disease and associated 
mortality.   
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Although the relationship between anxiety and cardiovascular disease has been less 
frequently studied when compared to depression, there is evidence that anxiety has been 
associated with increased mortality in cardiac patients (147, 148)..  In one study looking at 
carotid atherosclerosis in postmenopausal women, (145) anxiety along with other psychological 
variables were evaluated for the prospective association with carotid atherosclerosis. A total of 
200 women underwent carotid ultrasound, intima media thickness (IMT), an indirect 
measurement for coronary risk.  Using the Spielberger Trait Anxiety Scale, anxiety scores were 
not associated with subsequent IMT in univariate and multivariate analyses.  The absence of a 
significant association between anxiety and IMT was due to the possibility that anxiety triggers 
clinical events (such as myocardial infarction) as opposed to contributing to atherosclerosis itself 
(145).   On the other hand, phobic anxiety, defined  as anxiety symptoms related to agoraphobia 
and simple phobias, (149)  has been associated with ventricular arrhythmias in patients with 
coronary heart disease. Although only 20% of the total sample (940) was female, women 
reported higher phobic anxiety than men and the correlation with female gender was r =.024, 
p<.0001).  To date, research findings are not precise in determining whether anxiety is a 
predictor of cardiovascular disease as the relationship with other psychosocial variables is 
complex. Moreover, in the past anxiety has been shown to predict depression in both men and 
women with heart disease (150) and may be an early prelude to sub-clinical cardiovascular 
disease. 
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3.11 ANGER, HOSTILITY, AND CARDIOVASCULAR DISEASE 
Anger and hostility are psychosocial traits that have often been studied simultaneously. 
Their relationship to cardiovascular disease has been studied predominately in men and both 
traits may be predictive of coronary artery disease in younger men(151).  In one of the earliest 
studies, the Framingham Heart Study (152) conducted between 1965 and 1967, psychosocial 
measures were administered to 1674 healthy men and women to investigate the development of 
coronary heart disease (CHD). Women between the ages of 45-64 who developed CHD scored 
significantly higher on the Framingham Type A behavior, suppressed hostility (holding in anger) 
than women who were free of CHD. In a multivariate analysis, Framingham Type A behavior 
and not discussing anger were independent predictors of CHD incidence when controlling for the 
standard coronary risk factors.   This study suggested that Type A behavior and suppressed 
hostility may be associated in the pathogenesis of CHD in women. 
In another study, The Women’s Ischemia Syndrome Evaluation Study (WISE)(153) the 
relationship between anger and hostility to angiographic coronary artery (CAD) was 
investigated. Women (636) with suspected CAD were assessed for hostility/anger by the Cook-
Medley Hostility Inventory and the Speilberger Anger Expression Scale.  Anger and hostility 
were higher in the women who reported increased cardiovascular symptoms. Logistic regression 
revealed that anger-out (aggressive behavior in response to angry feelings) was associated 
independently with the absence or presence of angiographic CAD (OR =1.09, CI 1.01-1.17).  
Further, the women who did not have angiographic CAD (women without cardiac symptoms) 
had the highest anger-out, anger expression, hostile affect, and aggressive responding scores.  
This study concluded that the relationship between the psychological factors, cardiac symptoms, 
and angiographic CAD are potentially important in providing care to those with suspected CAD. 
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Studies have also investigated the association between hostility and carotid 
atherosclerosis measured by ultrasound(154, 155).   In the study by Matthews and colleagues 
(154) 200 healthy middle-aged postmenopausal women were studied to determine the 
prospective association between measures of trait anger, hostility and anxiety.  Women with high 
Trait Anger and Anger-In had high IMT on average 10 years later.  The women with high Cook-
Medley scores reflective of hostility/cynicism had high IMT scores on an average of 1.5 years 
later.  Multivariate analyses that  adjusted for standard cardiovascular risk factors (that are highly 
recognized as predictors of IMT) indicated that holding anger in, being self-aware and having 
hostile attitudes were significant predictors of IMT. 
A similar study in 2006 (156) investigated the relationship between several positive and 
negative attributes (i.e. hostility and anger) and the risk for coronary and aortic calcification in 
healthy women.  Hostility was measured by the Cook-Medley Hostility Scale and anger was 
measured by the Anger-In Scale.  From the multivariate binary logistic regression analyses 
indicated that negative attributes were related to extent of aortic calcification.  For hostility the 
OR was 1.77 (95% CI, 1.15-2.74 ; p<.01) and for the Spielberger Anger-In: OR=1.49; (95% CI, 
0.98-2.26; p<.06).  These findings concluded that women’s overall psychosocial attributes were 
not related to coronary calcification, thereby suggesting that psychosocial attributes might be less 
important for early than late stages of coronary atherosclerosis.  This study was cross sectional 
which may have also affected the results. 
Lastly, numerous epidemiological studies have identified that there are psychosocial risk 
factors for CAD (153-155) , and that hostility/cynicism is one of the most consistent predictors 
of CAD (157). 
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3.12 RELATED AREAS OF DEPRESSION RELEVANT TO PCOS 
In 2006, Himelein and Thatcher (158)  reviewed 2100 PubMed citations on PCOS and  
Mental Health and reported that only 3% addressed psychological concerns.  Research studies on 
depression in women with PCOS have been varied; they’ve included the study of  risk and 
prevalence of depressive disorders (86, 124), investigation of depression secondary to the clinical 
features(84, 85),  and chronicity of PCOS(59) as it relates to  quality of life (159, 160). 
3.13 DEPRESSION AND CHRONIC ILLNESS 
Depression continues to be studied to determine if it is a predictor of chronic illness or 
whether it is a result of the chronicity of an illness. PCOS has been classified as a chronic illness, 
based on it’s diagnosis at an early age and the fact that there is no cure.  The Center for Disease 
Control (CDC) had addressed the link between chronic disease and depression (161) as well as 
others worldwide. Results from the World Health Surveys (2007) (162) addressed the important 
public-health problem of depression and chronic diseases. The World Health Survey (WHS) 
studied adults aged 18 years and older to obtain data for health, health-related outcomes and their 
determinants.  Prevalence of depression based on ICD-10 criteria was estimated.  Four chronic 
physical states were identified for the study and included: angina, arthritis, asthma, and diabetes.  
Observations on 245,404 participants from 60 countries in all regions of the world were reported.  
The 1 year prevalence for ICD-10 depressive episode alone was 3.2% (95%, CI, 3.0-3.5); for 
angina 4.5% (CI, 4.3-4.8); for arthritis 4.1% (CI, 3.8-4.3); for asthma 3.3% (CI, 2.9-3.6); and for 
diabetes 2.0% (CI,1.8-2.2). 
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There was an average between 9.3% and 23% of all participants with one or more chronic 
physical disease and comorbid depression. This result was found to be significantly higher than 
the likelihood of having depression in the absence of a chronic physical disease (p<.0001).  
When adjusting for socioeconomic factors and health conditions, depression had the greatest 
effect on worsening chronic health problems. The comorbid state of depression incrementally 
worsens health compared with depression alone, with any of the chronic diseases alone, and with 
any combination of chronic diseases without depression.   Another finding that was consistent 
across countries and varied demographic characteristics was that respondents with depression 
comorbid with one or more chronic diseases had the worst health scores of all the disease states. 
Depression has been linked prospectively to various chronic diseases such as known 
comorbidities of PCOS, cardiovascular disease, diabetes, and obesity.  The relationship between 
subclinical depression and cardiovascular disease was reported by the Women’s Health Initiative 
(143). The study found that depression increases cardiovascular disease independent of risk 
factors such as smoking or obesity. Other studies have reported that patients with depression 
have a 2-4 fold increased risk of developing cardiovascular disease (127, 129, 163-165).  . Early 
on, studies have reported that persons who are depressed are much more likely to develop 
coronary heart disease (166).  Meta analyses have revealed that the relative risk for developing 
heart disease in individuals with depression  or depressive symptoms is approximately 1.6 times 
greater than among non-depressed persons (142, 167)..  Further, Ruguilies (2002)(142) found a 
stronger effect for clinical depression on cardiovascular disease suggesting that the presence of a 
dose-response relationship. Kindler and colleagues(168) reported that depression has been 
positively associated with the metabolic syndrome among women younger than 40 years of age. 
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Diabetes is one of the many chronic diseases that appear to be adversely affected by 
comorbid depression  (169).   Studies have shown that patients with diabetes are 1.5 -2 times 
more likely to have depression compared with individuals who do not (170-173)..    In a study by 
Brown et al.(169) a population- based nested case-control study was done to explore the history 
of previous depression in people with incident diabetes compared to people without diabetes. 
Cases of type 2 diabetes based on diagnostic codes and prescription records for individuals were 
identified. Each case had 2 matched controls (matched on age, sex, and frequency of physician 
visits) randomly selected from the non-diabetic population during the same index year.  Results 
of the study revealed that individuals with newly diagnosed diabetes (1,622 of 33,257; 4%) were 
30% more likely to have had a previous history of depression compared with people without 
diabetes (2,279 of 59,420; 3.8%). This increased risk did not change after controlling for sex and 
number of physician visits but was limited to subjects 20-50 years of age (adjusted OR=1.23; 
95% CI; 1.10-1.37) and not in those aged ≥ 51 years.  In another recent study (a large multiethnic 
study of White, Black, Hispanic and Chinese men and women aged 45-84),  Golden et 
al.(2007)(174),  also noted  that depression was associated with a greater odds of treated diabetes 
(OR= 1.57; 95% CI, 1.27-1.96). 
Lastly, obesity is considered a chronic illness itself, but may also be comorbid with many 
other diseases, such as PCOS.  Recently, in 2007 researchers (175) reported that higher BMI’s 
are associated with depression which supports previous findings stating that the severely obese 
individuals may by more at risk for developing psychological problems (176, 177).  It has been 
reported that there may be a common pathophysiology that exits between obesity and depression 
(178) and researchers have studied neurotransmitters, serotonin and norepinephrine, which are 
often altered in depression.  Moreover, the relationship between obesity and depression appears 
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to be reciprocal (175).  This relationship can be devastating for PCOS patients as the dose effect 
(cumulative increase of symptoms over time) of either obesity or depression over the years could 
lead to clinical mental health disorders and affect one’s quality of life. 
3.14 PSYCHOLOGICAL OUTCOMES WITH PCOS:  QUALITY OF LIFE 
In line with investigating the relationship of depression with PCOS in women or other 
mental health problems, is the concern for one’s quality of life with PCOS.  Health related 
quality of life often encompasses a compilation of measurable constructs such as psychological 
or emotional functioning and physical, social and sexual satisfaction amongst others.  In a review 
article, Jones et al. (131) stated that gynecological conditions like PCOS were major causes of 
psychological dysfunction that can lead to a decrease in quality of life. 
Griffin-McCook (179) in 2005 studied health-related quality of life issues in women with 
PCOS in a cross-sectional correlational study of 128 women with PCOS. The Health-Related 
Quality of Life Questionnaire for women with PCOS (PCOSQ) was used in this study (180).  
The PCOSQ is the first instrument designed to measure specific PCOS-related psychological 
dysfunction. This instrument  identifies emotional, physical, and social problems that women 
with PCOS experienced as a result of having this condition and asks respondents to rate how the 
severity of the symptoms affects their daily lives (179) .  Validity reliability ratings are not 
reported, however the scales’ authors assert that there is construct and content validity. 
A convenience sample of 128 women from private reproductive practices in two 
southeast United States cities was obtained.  One half of the sample was attempting to conceive 
in addition to being treated for PCOS. Most were white (97%), and married (78%), with a mean 
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age of (30.4 ± 5.5 years). PCOS was determined by the Rotterdam Criteria (20), as previously 
defined on page 6.  They examined clinical measures such as BMI, waist-to-hip ratio and degree 
of hirsutism.  The main outcome measure was quality of life measured by the (PCOSQ).  Result 
indicated that the most common health-related quality of life concern was weight, followed by 
menstrual problems, infertility, emotions, and body hair.  BMI was significantly and negatively 
correlated with the weight subscale of the PCOSQ (r = -.33, p = .001). Limitations of this study 
include the absence of a control group and possible sample bias (i.e., the sample was a 
convenience sample, primarily comprised of Caucasian women, and biased geographically, 
representing 2 small cities in Appalachia).  It does, however, point to the need for assessment of 
the quality of life and evaluation of the comprehensive biological insults on the PCOS 
population, which can also lead to disturbances in mental/emotional functioning. 
One international study by Hahn et al. in 2005 (181) studied the extent of different PCOS 
symptoms on quality of life, psychosocial well-being and sexual satisfaction.  Metabolic, 
hormonal, clinical and psychosocial data were examined in 120 women with PCOS and were 
compared to 50 healthy women in order to quantify quality-of-life and emotional well-being. 
Patients were recruited from the Department of Medicine outpatient clinics at the University of 
Duisburg-Essen, Germany.  Diagnosis of PCOS was made by the 1990 NIH conference 
criteria(20).  Patients were compared to 50 healthy women recruited through a health screening 
program at the University of Duisburg-Essen, Germany and to normative data. Psychosocial 
variables and major clinical PCOS features, such as obesity (body mass index (BMI)), excessive 
hair (hirsutism), and others were analyzed. Quality-of- life was assessed with the German 
version of the SF-36 (182).. The SF-36 contains a total of 8 subscales, 3 of which are pertinent 
scales to PCOS; these are: Physical Function, Emotional Role Function, and Mental Health.  
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 Results indicated that PCOS subjects showed significant reductions in quality-of-life, 
increased psychological disturbances and decreased sexual satisfaction when compared to 
healthy controls.  Apart from other features of PCOS, only BMI and hirsutism scores showed 
significant reductions in quality-of-life, increased psychological disturbances, and decreased 
sexual satisfaction when compared with healthy controls.  PCOS patients reported significantly 
lower quality-of-life as measured by the SF-36 Health Survey in all dimensions except General 
Health when compared to normative data. Severity of depressive symptoms was significant at 
p<0.001 as measured by the SCL-90-R scale when compared to normative data. This study, 
however, did not reveal the demographics of the sample except for their mean age.  Therefore, 
caution must be considered in interpreting the results. 
In another prospective intervention study by Hahn et al.(183) (2006), the effects of 
metformin treatment on health related quality of life (HRQL), emotional distress and sexuality of 
women with PCOS was investigated.  Metformin improves biochemical, clinical and 
reproductive functions in women with PCOS.  In this prospective, observational study, they 
assessed the PCOS patient’s before, during, and 6 months after of treatment with Metformin.  A 
convenience sample of 85 patients was recruited from outpatient clinics in the Division of 
Endocrinology at the University of Duisburg-Essen and 64 patients with PCOS participated in 
the study.  The diagnosis of PCOS was made using the 1990 NIH conference criteria.  HRLQ 
was measured by the German version of the SF-36 (182).  The Symptom Check List-90-Revised 
(SCL-90-R)(184) was used to determine psychological symptoms. Subject results were 
compared with published German normative data. Prior to treatment, patients with PCOS 
demonstrated significantly higher SCL-90-R scale scores, indicating greater psychological 
disturbances in dimensions such as depression and aggression when compared to the German 
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normative data. During treatment with Metformin, the psychosocial aspects of health related 
quality of life, (i.e. Emotional Role Function, Mental Health, and the Psychological Sum scale 
from the SF-36 and the emotional well-being scale from the SCL-90-R) improved.  Limitations 
to this study included small sample size and the lack of a randomized placebo-controlled clinical 
trial. 
In a case control study by Elsenbruch, et al. (2003)(185) quality of life, psychosocial 
well-being, and sexual satisfaction in women with PCOS was also studied. This study used  
recruitment strategies and determination of diagnostic criteria for PCOS similar to the previously 
described study by Hahn et al. 2005 (181), with the exception that the controls were matched on 
age.  Fifty women and their controls were evaluated with standardized questionnaires (36-Item 
Short-Form Health Survey (SF-36), Symptom Checklist Revised (SCL-90-R), and Life 
Satisfaction Questionnaire (186). The features of PCOS, hirsutism, obesity, and infertility were 
assessed.  Patients showed increased psychological disturbances on the symptom checklist 
revised dimensions in areas such as depression, anxiety, interpersonal sensitivity and aggression.  
Patients with PCOS patients also had a lower level of life satisfaction on the life satisfaction 
questionnaire scales which were related to health, self, and sex.  Even though this study has its 
limitations in reference to generalizability due to selection bias, it has its merits in attempting to 
address the comprehensive aspects of one’s quality of life, inclusive of sexual satisfaction. 
Elsenbruch et al.(187) in 2006 further investigated the determinants of emotional distress 
in women with PCOS.  The goals of this study were to investigate the incidence of mental 
distress in women with untreated PCOS (had no medical treatment) using self-report measures, 
to identify PCOS cases who were at risk for psychiatric disorder and to assess the impact of 
emotional distress on quality of life in affected patients.  A sample of 143 women with untreated 
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PCOS were administered the SCL-90-R and the SF-36.  The SCL-90-R (184) is used to assess 
mental well-being.  It assesses symptomatology in 9 areas (Somatization, Obsessive Compulsive, 
Interpersonal Sensitivity, Depression, Anxiety, Aggression, Phobia, Paranoid Ideation, and 
Psychoticism).  The global severity index (GSI) represents the overall level of distress.(184) GSI 
t scores ≥ 63 identify cases with possible mental disorder (SCL cases).  Psychological disorder 
was based on the SCL-90-R.  Twenty-two patients (15.4%) had a possible psychological disorder 
with a global severity index of ≥ 63 (SCL cases).  Cases also had significantly elevated body 
mass index (BMI).  These findings support the hypothesis that subclinical levels of psychological 
disturbances may exist in patients with PCOS which often affects their quality of life.  
Limitations of this study included lack of a control group, self-report questionnaires, and the lack 
of diagnostic measurements to identify a psychiatric diagnosis. 
Quality of life and its relationship to Body Mass Index (BMI) has been an interest in 
PCOS as rapid weight gain is a common occurrence and a clinical manifestation of PCOS.  A 
cross-sectional study by Ching et al. in 2007(160) studied Australian women with PCOS.  A 
sample of 203 women between the ages of 15-65 were compared to the Australian population 
norms (women aged 18-44; (n= 173).  Subjects were ascertained through mailings of 
questionnaires.  Of these women, 64% were obese, 18% were overweight, and 18% were normal 
weight.  Diagnosis of PCOS was confirmed by an endocrinologist at a private practice or at a 
Diabetes Clinic.  Diagnostic criteria were used from the NIH  standards.(19).  Three standardized 
measures were used to assess quality of life.  The Short Form SF-36 (184), the General Health 
Questionnaire-28 (GHQ28)(188), and the Questionnaire for Women with Polycystic Ovary 
Syndrome (PCOSQ) (180).  The GHQ-28 is a measure of function or disturbance, comprising a 
global score and four scales for somatic symptoms, anxiety, insomnia, social dysfunction and 
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severe depression. The GHQ-28 identified psychological morbidity in 62.4%, compared to 
26.4% for the matched Australian population (p<0.001).  BMI was negatively correlated with 
quality of life (p<0.01). 
BMI and its relationship to quality of life in PCOS patients is controversial and somewhat 
inconclusive.  Trent (189) reported that when adjusting for BMI, no difference in quality of life 
was found between adolescent PCOS subjects and healthy controls .  Most importantly, however, 
it is clear that BMI is not the sole reason for determining quality of life in this population.(160)   
The research by Ching et al. (160), though, lacks a true representation of quality of life as it was 
cross-sectional.  On the other hand, it uses the most currently validated and reliable measures for 
assessing quality of life in the PCOS population. 
Another recent study, (2007) by Barnard et al.(159) addressed the quality of life and 
psychological well being in PCOS.  Aims of this study included determining the quality of life in 
PCOS women to determine an estimate of the prevalence of depression in a large community 
sample of women with PCOS.  Four groups of women were recruited: 192-224 with PCOS not 
taking anti-androgen medication (AA), 177-200 women with PCOS taking AA medication, 504-
548 healthy women not taking AAs , and 356-387 healthy women taking AAs. The subjects were 
contacted through the internet by e-mail. The Rotterdam diagnostic criteria (20) was utilized to 
determine PCOS women.  The study also required them to confirm diagnosis.  The Polycystic 
ovary syndrome health-related quality of life questionnaire (PCOSQ)(180) and the Zung 
depression scale(190) were used to measure quality of life and depression respectively.  Of  the 
PCOS women, 71% (taking AA medication) and  67% (not taking AA medication) were 
classified as depressed. Women with PCOS had lower quality of life on all seven factors of the 
modified PCOSQ. The PCOSQ was modified adding an additional factor, acne.  The 7 factors 
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were emotional disturbance, weight, infertility, acne, menstrual symptoms, menstrual 
predictability and hirsutism.  Weight was the greatest contributor to decreased quality of life for 
PCOS women taking or not taking AA medication.  Both PCOS groups were significantly more 
depressed than the control groups (all P-values <0.001). However, there were no significant 
differences between the 2 PCOS groups and the 2 control groups.  There was a significant 
association between the diagnosis of PCOS and severity of depression P < .001 with more cases 
of mild, moderate and extreme depression in the 2 PCOS groups.  Limitations of this study are 
the internet samples (selection-bias) and use of self-report measures. 
Quality of life in PCOS has been researched not only in those affected, but also in family 
members. A local study done in Pittsburgh by Malek, (191) in 2006, studied the quality of life 
and mental health status among family members with PCOS.  The aim of the study was to 
determine whether elevated BMI was associated with quality of life of family members with and 
without PCOS.  Additionally, she investigated whether mental health scores differ among female 
with PCOS and family members.  One hundred and one subjects, 20 PCOS cases, 52 non-PCOS 
cases and 29 males participated.  Quality of life was determined by the SF-36.(184)   Quality of 
life as determined by the SF-36 found that PCOS females did not differ significantly when 
compared to non-PCOS family members on the total scores of most domains.  Self- reported 
depression was rated as higher in PCOS females, although it was not a statistically significant 
difference.  BMI was a significant predictor for most domain scores among females with and 
without PCOS.   Limitations of this study included small sample size and under representation of 
the general population as the majority of the sample were white.  Table 3-3 summarizes the 
relevant PCOS studies on quality of life and depression. 
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Table 3-3 PCOS Studies and Quality of Life and Measurement of Depression 
Study Year N Design QUA PSYCH Comments 
Elsenbruch et al. 
(185) 
 
German 
2003 50 PCOS 
cases & 
controls 
Case 
Control 
PCOS causes major 
Reduction in QOL  
PCOS pts 
showed 
↑ depression 
Used 
SCL-90-R; 
SF-36 
Griffin et al. (179)  
 
U.S. 
2005 128 PCOS 
women; 
Convenience 
sample 
Cross-
sectional; 
Correla-
tional 
Most QOL concerns: 
obesity; menstrual 
problems; infertility; 
emotions; body hair 
 Used 
PCOSQ 
Hahn et al.(181) 
 
 
German 
2005 120 PCOS 
cases and 50 
controls 
 
Case 
Control 
BMI and hirsutism 
affected physical 
aspects of QOL & 
sexual functioning 
 
 
 
 
Used 
SCL-90-R; 
SF-36 
Elsenbruch et al.  
(187) 
 
 
 
German 
2006 143 untreated 
PCOS patients 
compared to 
normative data 
Cross- 
sectional  
compared 
to 
normative 
prevalence 
 15.4% had a 
possible 
Psychological 
disorder 
Used 
SCL-90-R; 
SF-36 
Hahn et al.(183) 
 
 
 
German 
 
 
 
2006 64 PCOS 
patients 
treated with 
Metformin 
Prospec-
tive 
Observa-
tional 
Metformin appeared to 
significantly improve 
psychosocial domains of  
SF-36 
 Used 
SCL-90-R; 
SF-36 
Ching et al. (160) 
 
 
 
 
Australia 
2007 443 PCOS 
women 
compared to 
population 
norms 
Cross-
sectional 
GHQ identified psycholog-
ical morbidity in 62.4% of 
PCOS women compared to 
26.4% matched norms 
 Used SF-36 
PCOSQ, 
GHQ-28, 
PIQ 
Malek (191) 
 
US 
2006 20 PCOS 
Cases 
52 Non-PCOS 
cases + 
29 males in 
family 
Cross-
Sectional 
BMI was a significant 
predictor for a majority of 
the SF-36 domains in 
PCOS females and non-
PCOS females. 
Highest was in physical  
Functioning p< 0.001 
Self report 
depression was 
higher in PCOS 
adults compared 
to non PCOS 
adults although 
not statistically 
significant 
Used SF-36 
 
 
Barnard et al. (159)  
 
London 
 
2007 
4 Groups of 
women Large 
community 
sample: 
approx 400 
PCOS 
compared to 
approx 800+ 
controls 
Cross-
sectional 
 
 
Internet 
PCOS women had lower 
qol on all seven factors  
 
Wt  most affected QOA 
Both PCOS 
group more 
depressed 
than controls  
P<.001 
Self-report  
PCOSQ 
 
Zung 
Depression  
Scale 
SF-36 used in study * 
PCOSQ = Polycystic Ovary Syndrome health related Questionnaire 
QUA = Quality of Life 
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As can be seen, the literature is limited in investigating psychological implications of 
PCOS.  To date, the studies investigating the impact of PCOS primarily on mental health i.e. 
(depression) are limited as there are 1 case report, 1 qualitative study, 1 descriptive study and 
only 3 case-control studies that have been reported.  Likewise, there are only 8 relevant studies 
that have measured quality of life in women with PCOS which began in 2003 until present.  
Until more recently, the focus of this incurable syndrome has been on the biophysiological 
ramifications of PCOS.  An explanation for this lack of psychological research on PCOS may be 
in part because the syndrome is extremely complex in its presentation, inclusive of body image 
disturbances, i.e.hirsutism and obesity, infertility, insulin resistance, and hyperandrogenism (85). 
From the available literature it would appear that there are few large well characterized 
case control studies of women with PCOS and controls on whom data was collected 
prospectively on both cardiovascular risk factors and psychological characteristics.  The present 
study will seek to determine if women with PCOS compared to controls exhibit increased 
psychological sequela and cardiovascular risk factors in addition to a reduction in life 
satisfaction related to the syndrome.  Moreover, the present design will permit an investigation of 
whether the psychological characteristics have an independent effect on the prevalence of 
subclinical atherosclerosis in PCOS cases compared to controls. 
  56
4.0  ASSOCIATIONS AMONG DEPRESSIVE SYMPTOMS, ANXIETY, ANGER, 
HOSTILITY, AND SATISFACTION WITH LIFE IN WOMEN WITH POLYCYSTIC 
OVARY DISEASE (PCOS) 
Background:  Polycystic Ovary Syndrome (PCOS) is associated with many physical and 
physiological changes and can affect women’s psychological functioning and satisfaction with 
life.  Previous research has focused mainly on cardiovascular risk factors, with few studies  
investigating the psychological effects of the condition.  The aims of this study were:  (1.) to 
compare the prevalence of depressive symptoms in women with PCOS compared to controls; 
(2.) to determine whether depression and psychological traits (anger, anxiety, hostility/cynicism) 
and satisfaction with life are associated with PCOS; (3.) to examine within PCOS cases factors 
associated with depressive symptoms:  specifically BMI, education, marital and smoking status, 
and parity 
Design:  The subjects examined in this study were selected from those in a previous case-
control study, with observational follow-up over a 12 year period, 1995 to 2006. 
Methods:  A total of 161 cases and controls were matched on age, race, and 
neighborhood and participated in the baseline psychological assessment arm of our original 
study.  They were part of the original Cardiovascular Health and Risk Measurement study 
(CHARM) study by Talbott et al. conducted in 1992-4 to investigate coronary heart disease risk 
factors in women with PCOS.  Psychological characteristics of the women were assessed using 
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the Beck Depression Inventory I (BDI I), the Speilberger Trait Anger and Anxiety Scales, the 
Cook-Medley Scale and the Diener Satisfaction with Life Scale. 
Results:  Women with PCOS had a higher prevalence of depression (BDI scores>9; at 
predominately a mild level of depression):  31% vs. 17% in controls; P=.016: OR 1.9 (CI 1.55-
2.16).  The difference between cases and controls for the BDI scale was statistically significant 
P=.002.  Within cases, results of logistic regression analysis showed that BMI, education, and 
parity were statistically significant predictors of depression p<.05.  The odds of being depressed 
of at least mild severity increased by 6% for each unit increase of BMI, the odds of being 
depressed decreased by 20% for each year of  education and increased by 44% for parity (per 
live birth).  When conditional logistic regression (for the entire sample) was performed, the odds 
of having PCOS increased with each unit of BDI score by 1.06 times, adjusting for marital 
status, BMI,   smoking, and education.  
Conclusions:  Depression is a major psychological concern in PCOS.  Women should be 
screened at regular intervals to detect and treat depression as a risk factor. 
Public Health Significance:  The public health implications of this study center around 
primary and secondary prevention. With secondary prevention, case finding is paramount as 
women are known to have 2 times the prevalence of depression than men even before being 
diagnosed with PCOS.  Finally, implementing a high-risk prevention approach would be a 
strategy to decrease the prevalence of depression in the PCOS population. 
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4.1 INTRODUCTION 
 
Polycystic ovary syndrome is the most common reproductive endocrine condition among 
women.  Estimates in the US reflect a prevalence of 6-10% and in England, the addition of 
ultrasound to the criteria for evidence of polycystic ovaries results in a prevalence rate that is 
higher (1).  PCOS manifests at puberty and is a lifelong condition (2-5).  It is characterized by 
chronic anovulation, obesity, and clinical hyperandrogenism.  Other manifestations include 
infertility, male-pattern balding, ovarian enlargement, and signs of insulin resistance, ie. central 
obesity (5-8).  As this is a lifetime disorder, other medical problems may surface such as 
cardiovascular disease and Type 2 Diabetes (1, 4, 5, 9).  To date, there is no known cure for 
PCOS.  The goal of treatment is to reduce the symptoms and risk factors for complications and 
comorbid conditions.  
Until recently, research and clinical management for PCOS women have been primarily 
focused on the physiological consequences.  However, as a result of the numerous physical and 
metabolic changes, PCOS women may be at high risk for psychological problems, such as 
depression and decreased satisfaction with life (10, 11).  Previous studies have lacked sufficient 
sample sizes, case-control studies, and a complete psychological profile of what mental health 
issues and or personality traits are associated with women with PCOS. 
In general, women are twice as prone to depressive symptoms and disorders when 
compared with men (12) and several studies have reported the total lifetime prevalence of major 
depression in women  to be  approximately 21%  (12-14).  Furthermore, research examining the 
psychological effects of PCOS has been largely lacking. 
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Previous psychological research in women with PCOS has been conducted utilizing small 
sample sizes and case reports  (15-17).  One study (17) reported that depressive symptoms, as 
measured by the Center for Epidemiological Studies Depression Rating Scale (CES-D) (18), was 
associated with greater insulin resistance (p< 0.02) and  with a higher body mass index (p<0.05) 
in a sample of 32 PCOS women.  However, there was no control group. 
In a recent cross-sectional study of women 18 – 50 years of age,  Hollinrake et al. (19)  
studied PCOS women and controls to estimate the prevalence of depressive disorders in women 
with PCOS.  Androgens and other metabolic markers associated with PCOS and depression were 
also studied.  DSM IV (20) diagnostic criteria were used.  Depression was determined based on  
Primary Care Evaluations of Mental Disorders Patient Health Questionnaire (Prime-MD PHQ) 
(21) and the Beck Depression Inventory (BDI) (22).  Women with PCOS were at an increased 
risk of depression (new cases) compared with controls (21% versus 3%, OR 5.11; (95% CI: 1.26-
20.69, p<.03)).  The overall risk of depressive disorders in this sample of PCOS women 
compared to controls was OR; 4.23 (95% CI 1.49-11.98; p<.01), independent of obesity and 
infertility.  When compared with the non-depressed PCOS subjects, the depressed PCOS subjects 
had a higher body mass index (BMI) and evidence of insulin resistance (p<.02).   
Body image was also the focus of psychological research in women with PCOS (23). 
Several studies have supported the existence of increased emotional problems concurrent with 
the physical changes seen in PCOS.  Himelein and Thatcher (23) reported that in comparing 
PCOS women to non-PCOS women with infertility, and to women with neither PCOS nor 
infertility, that PCOS women had higher depression scores and body dissatisfaction (p<.001).  
Further, body image was strongly associated with depression overall, even after controlling for 
body mass index.  The affective self-evaluation measures proved more important in the 
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prediction of depression than other measures of body image.  Some longitudinal studies have 
demonstrated that poor body image in adolescent females is related to later onset of depression 
(24, 25).  Although the association is controversial and inconsistent, obesity in PCOS women has 
been linked to depression (26).  It is  generally accepted that up to two thirds of PCOS women 
are overweight or obese, that three fourths have significant hirsutism (3, 4), and that obesity has 
been associated with depression in women in the general population (27). 
A longitudinal study by Hollinrake et al.(19) further investigated the risk of depression 
and other mental health disorders in women with  PCOS  (28).  A total of 60 women from the 
original sample of 103 were resurveyed within a two year period (mean time was 22 months).  
There were 11 new cases identified in the second survey (19%).  Thirty-four of the 60 subjects 
(56.6%) had mood disorders which also included those with anxiety disorders.  Among these 
depressed subjects, 11.6%  also had an anxiety disorder while 23.3% had binge-eating disorders.  
Other psychological ramifications of PCOS are found in the research on quality of life 
(QOL).  Barnard et al. (29) found that women with PCOS had lower QOL on all seven factors of 
the modified Polycystic Ovary Syndrome Health-related QOL Questionnaire (PCOSQ) (30) (i.e. 
emotional disturbance, weight, infertility, acne, menstrual symptoms, menstrual predictability, 
and hirsutism).  Others have also investigated the quality of life in PCOS women and their 
families (31).  Using the SF-36 to measure quality of life, there was no statistically significant 
difference in PCOS females compared to family members, which may have been reflective of the 
small sample size (20 PCOS cases) compared to 81 family members. 
Acne, hirsutism, and obesity are among the most frequent changes in physical appearance 
among PCOS women.  The major medical changes that frequently occur with PCOS are 
cardiovascular disease, metabolic cardiovascular disease (MCS), Diabetes Type 2, and insulin 
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resistance.  As women attempt to cope and adapt to PCOS, depression may develop.  Anxiety 
and anger have been studied among these women (28, 29, 32).  In a study examining androgens 
and mood dysfunction (32), the state trait anxiety inventory (33) and the state-trait anger 
expression inventory (34) did not demonstrate a group difference or the difference became non-
significant when other mood and symptoms were covaried in the MANCOVA.  The authors (32)  
suggested that the mood states were related to general negative affectivity ( measured by a visual 
analog scale (35) and physical symptomatology). 
In a recent Qol study (29), using the Zung anxiety scale (36), both PCOS groups who 
were on anti-androgens and those without anti-androgens reported almost a threefold higher 
score in anxiety as compared to their controls.  Similarly, findings from a longitudinal study in 
2008 (28) indicated that 11.6% of the 60 had an anxiety disorder.  To date, hostility and cynicism 
have not been studied in persons with PCOS.  Lastly, overall satisfaction with life in relationship 
to PCOS is often compromised (29, 31, 37). 
In the present study, the overall goal is to:  (1.) Determine the prevalence of clinically 
significant depressive symptoms in PCOS cases and controls using the BDI; (2.) To determine if 
depressive symptoms, psychological traits (anxiety, anger, hostility/cynicism), and satisfaction 
with life are associated with PCOS; and (3.) To investigate within cases, factors associated with 
depressive symptoms, controlling for BMI, education, marital and smoking status, and parity. 
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4.2 SUBJECTS AND METHODS 
4.2.1 Case Recruitment 
The study sample is comprised of a subset of  the original “ Cardiovascular Health and 
Risk Measurement” study (CHARM) investigation conducted by Talbott et al. (3).  This study’s 
main aim was to investigate coronary heart disease risk factors in women with PCOS.  A total of 
243 PCOS cases and controls were recruited for the primary study.  Complete data on the 
psychological profile was available on 212 cases and 202 controls, but only 161 cases and 161 
controls had complete psychological data for this analysis.  
Subjects with PCOS were recruited from the Pittsburgh area through the reproductive 
endocrine department/private practices at Magee-Women’s Hospital for the period 1970-1993.  
As a result, a presumptive clinical diagnosis of PCOS was made if there was a history of chronic 
anovulation in association with either clinical evidence of androgen access (hirsutism) and or 
biochemical diagnosis comprising of total testosterone concentration >2nmol/L or the 
LH/follicle-stimulating hormone (FSH) ratio was greater than 2.   
The current group (academic practice group, 1970-93) was comprised of 243 women 
with PCOS.  Details are published elsewhere (3). 
4.2.2 Control Subject Recruitment 
Controls were matched on race, age ± 5 years, and neighborhood.  They were selected by 
using a combination of voters’ registration tapes for 1992 for the greater Pittsburgh area and 
Cole’s Cross Reference Directory of households (38).  The major sources of control candidates 
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were the Allegheny County voters’ registration tapes.  A nonrepeating random selection process 
was used that matched on date of birth, sex, race, and zip code of the case subject.  For each 
PCOS case subject, five control subjects were randomly drawn and contacted by mail.  The letter 
explained the nature of the study and invited the individuals to participate.  A preaddressed, 
stamped postcard was included.  After 2 weeks, a follow-up letter was sent to the same address. 
Those participants living in the greater Pittsburgh area were asked to participate in the 
clinical phase of the study located at Magee-Women’s Hospital.  Subjects were evaluated after a 
12 hour fast.  Another questionnaire was administered on site which included a repeat medical 
history, medication history, current medical practices, and family history of PCOS. 
4.2.3 Psychological Measurement 
The psychological characteristics of the women were assessed using the Beck Depression 
Inventory I (22), the Speilberger Trait Anger (34) and Anxiety Scales (33), the Cook-Medley 
Scale (39), and the Diener Satisfaction with Life Scale (40).  A total of 243 PCOS cases and 
controls were recruited for the primary study.  Data on the psychological profile was available on 
212 cases and 202 controls, but only 161 cases and 161 controls had complete psychological data 
for this analysis. 
4.2.4 Psychological Measures 
Depression Assessment:  The Beck Depression Inventory I (BDI I) (22)  is a self-report 
inventory measuring symptoms of depression.  It contains 21 questions; a cutoff of >9 ( total 
score) was used to identify potential clinically significant symptoms of depression and to define 
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cases in these analyses (22).  In this study, the BDI was used as a screening measure for 
depression.  The psychometric properties of the BDI have been reported as high with internal 
consistency ranging from .73 to .92  with a mean of .86 (41).  The split-half reliability coefficient 
reported was .93.  Concurrent validity was determined by correlations with clinician ratings of 
depression using the revised BDI and ranged from .62 to .66 (42).  The BDI was previously 
tested on the PCOS population in other research studies (10, 23). 
Anxiety and Anger Assessments:  The Spielberger Trait Anger/Anxiety Scales are two of 
six subscales of the  State-Trait Personality Inventory by Spielberger (STPI) (33, 34).  Both 
anger and anxiety scales are comprised of 10 items each.  Responses are rated on a 4-point likert 
scale with response categories ranging from categories “almost never” to “almost always.”  The 
six STPI scales demonstrate good internal consistency as evidenced by alpha coefficients of .80 
to .87 (43).  Reliability testing revealed internal consistency (alpha coefficient = .81-.87)  (33, 
34)  Cronbach alphas were .82-.85 and  .80-.85 for anger and  anxiety, respectively. 
Hostility/Cynicism Assessment:  This 13 item scale derived from the Cook-Medley 
Hostility Scale, measures cynical attitudes and hostile feelings and behaviors rather than overt 
expressions of anger and aggression.  Each item is rated as “probably true” or “probably false.”  
Higher scores indicate greater hostility (range 9-13).  Cronbach’s alpha for the scale was .79, 
indicating good internal consistency (39). 
Diener Satisfaction With Life Scale:  This scale was developed as a measure of the 
judgmental aspect of satisfaction with life.  It measures the cognitive component of subjective 
well-being.  The scale consists of 5 questions each rated on a 7 point likert scale ranging from 
“strongly disagree” to “strongly agree.”  A higher score reflects a greater satisfaction with life.  
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Test retest reliability was .84 (44).  The scale is brief, yet it offers as high or higher predictive 
validity than several longer measures of life satisfaction. 
4.2.4.1 Covariates 
BMI was measured in kg/m2.  Education was measured by each year of education. Parity 
was measured by each live birth.  Marital status was coded yes (married) and no (not married).  
Smoking status was also binary. Current smoking was yes and never or ever smoked was no.  
4.3 STATISTICAL ANALYSES 
All data collected for the original study were entered and verified by using SPSS data-
entry software.  All data were analyzed using SPSS FOR WINDOWS version 15.0 (SPSS Inc., 
Chicago, IL, USA).  
Descriptive statistics, including measures of central tendency and dispersion, were 
computed for all variables of interest for PCOS cases and controls.  Non-normally distributed 
continuous data were logarithmically transformed before performing statistical comparisons.  
Continuous variables of interest were compared using Student’s t test or the Mann-Whitney U 
test.  For categorical data, the χ² test or Fisher’s exact test was used. 
Group differences were assessed using paired and two-sample t-tests.  Spearman 
correlation and logistic regression were used to determine predictors of depression within cases.  
Conditional logistic regression was also performed to determine the association between select 
variables, covariates, and PCOS status. 
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4.4 RESULTS 
4.4.1 Sample characteristics 
One hundred and sixty-one pairs formed the cohort studied.  Pairs were matched on age, 
race, and neighborhood.  The average age of the sample was 35.8 years at baseline (SD = 7.5 
years).  The sample was predominately white (94.7%) and 3.4%  black with a large proportion 
married (65.2%), with most of the PCOS cases being married (72%).  Education was similar 
between cases and controls with each group completing approximately 14 years of schooling.  
Fifty percent of the cases and controls were predominately professionals, while the other 50% 
were either laborers or homemakers in both groups, although the differences between groups 
were not statistically significant.  The mean for parity was higher for the control group at 1.22 ± 
(SD 1.6) compared to the cases at .89 ± (SD 1.6) p< .01.  (Table 4-1) 
There was no significant difference between the proportion of cases and controls on oral 
contraceptives (P=.06) or hormone use.  Of the cases, 15.5% were on hormones as well as 15.5% 
of the controls.  Seventy percent of the cases and 82% of the controls were not on oral 
contraception.  Only 4 categories of psychiatric medications were reported by the total sample as 
being prescribed at baseline:  major tranquilizers, minor tranquilizers, sedatives, and 
antidepressants. One case was on an antidepressant and 2 controls were on a tranquilzer. 
Smoking history did not significantly differ between cases and controls.  Cases reported 23% as 
current smokers and 47.8% for controls.  BMI was statistically significant between cases and 
controls p<.01.  The mean for cases was 30.3 ± 8.2 and 26.3 ± 6.3 for controls.  (Table 4-1) 
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4.4.2 Prevalence of Depression 
Cases scored higher than controls on the BDI, indicating significantly more severe 
depressive symptoms (mean of 7.8 ± SD 7.0) compared to the non-depressed cases (mean of 5.7 
± SD 5) even though they did not fall into the depressive range.  (Table 2)  The mean scores for 
both groups were not in the clinically significant range.  The prevalence for clinically significant 
depressive symptoms (score of > 9) was 31.1% for cases and 17.4% for controls.  
The prevalence of clinically significant mild depression was 24% for cases and 15% for 
controls.  Clinically significant moderate depression was only 5% for cases and 2.5% for 
controls.  Only cases exhibited any significant severe depression (3%).  Within cases (between 
groups), 31% of the sample had a BDI score >9.  As expected, the BDI score differed 
significantly between depressed and non-depressed groups with a mean of  15.7 ± SD 6.6 for 
depressed and a mean 3.9 ± SD 2.7 for non-depressed women.  (Table 4-2) 
4.4.3 Association of Depression and Psychological Traits (anger, anxiety,  
 hostility/cynicism) and Satisfaction with Life  
Cases scored higher on the trait anger scale with a mean of 9.1 ± SD 4.2 compared to 
controls (mean=8.2 ± SD 3.6, p<.02).  For anxiety, the mean for cases was 9.6 ± SD 5.5 
compared to controls (mean of 8.7 ± SD 5.2, p<.01).  Cases scored lower (were less 
hostile/cynical) on the hostility/cynicism measure compared to controls with a mean score of  7.3 
± SD 2.9 and 7.9 ± SD 2.6, respectively (p< .01).  Only satisfaction with life was not statistically 
significant between cases and controls.  Cases also reported a lower mean score satisfaction with 
life compared to controls, 23.9 ± 6.8 and 24.2 ± 6.2  respectively.  (Table 4-2) 
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Conditional logistic regression analysis on the matched-pair data set for psychological 
measures is illustrated below. (Table 4-4)  Candidate variables that were considered for the 
multivariate model were BMI, marital status, parity, education, smoking status, occupation, and 
hormones.  The candidate variables were assessed by univariate analysis using logistic 
regression.  P values were obtained using likelihood ratio tests.  After forward stepwise 
conditional logistic regression, the final model included BMI, marital status, and BDI I score as 
significant predictors.  PCOS status was the dependent variable.  The odds of having PCOS 
increased with each unit of BDI score by 1.12 times when marital status, BMI, smoking status, 
and education were included in the model.  All of the psychological variables were significant in 
univariate models except for satisfaction with life.  When adjusting for BMI, marital status, 
smoking, and education, anger and cynicism/hostility were significant.  BMI remained 
significant (p<.01) in the models with anger and cynicism/hostility.  In the model with 
cynicism/hostility, marital status also remained significant p<.009. 
4.4.4 Comparison of Depressed and Non-depressed PCOS Cases 
Demographics:  The results of the demographics and health variables were similar to the 
total sample.  Both groups were predominately white, 90% in the depressed group, 92.2% in the 
non-depressed group.  Mean age was similar for both groups.  Of the depressed group, 72% were 
married and less educated than the non-depressed group.  More depressed women were identified 
in non-professional occupations (60%).  PCOS cases in the depression group had higher BMI 
scores (mean 32.8, P<.01) than the non-depressed cases (28.9).  Smoking history was higher in 
the depressed versus non depressed group, 58% and 45% respectively.  Twenty-six percent of the 
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group with depression were on hormones compared to 12% of the non-depressed group (Table 
4-3). 
Association of psychological traits (anger, anxiety, hostility/cynicism) and satisfaction 
with life:  Depressed women scored higher trait anxiety and anger scores.  Anxiety means and 
SD were 14.5 ± SD 5.0 for cases and 7.1 5 ± SD 4.0 for controls.  Anger means and SD were 
11.7 ± SD 5.1 for the depressed group and 7.8 ± SD 3.2 for the non-depressed group.  Both 
anxiety and anger compared between the depressed and non-depressed were statistically 
significant p <.01.  Non-depressed women reported significantly greater satisfaction with life 
(mean 26.1 ± SD 5.7) compared to the depressed group mean (mean 19.6 ± SD 7.2, p<.01).  The 
depressed group was less hostile/cynical when compared to the non-depressed group.  Results 
were significant between both groups at <.01 with mean 6.4 ± SD 3.0 for the depressed group 
and 7.8 ± SD 2.8 for the non-depressed.     
Logistic regression (Table 4-5) was performed within cases to determine predictors of 
depressive symptoms.  BMI, education, and parity were statistically significant predictors of 
depression when smoking status and marital status were forced into the model.  The odds of 
being depressed increased by 6% for each unit increase of BMI.  The odds of being depressed 
decreased by 20% for each year of increased education and increased by 44% for parity (per live 
birth).  BMI and education remained consistently significant with the model building.  Parity  
was near statistical significance when marital status was added to the model and when smoking 
was added to the model, parity became significant.  There was no interaction between marital 
status and smoking or between marital status and parity. 
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Table 4-1 Sociodemographic and Health Related Variables in PCOS Case and Matched Control 
               Subjects 
Case Subjects Control Subjects
(n =161)        (n =161)        Total Range p value
Variable
Age   (years)            
        (M ± SD)   35.2   7.3  36.4    7.8 35.8  7.5 18 to 53 0.01
BMI   (M ± SD)       30.3   8.2  26.3     6.3 28.3 7.6 17.6-58.6 0.01
Education (highest level completed)                   
         (M ± SD)  14.2    2.2 14.4   2.0 14.3  2.1 9 to 17 0.42
Parity  (M ± SD)    .89   1.6    1.6   1.5 1.2  1.6 1 to 16 0.01
Race   n        %   n      %   n       % 0.06
    White              148    91.9   157    97.5      305    94.7
    Black                        7     4.3          4      2.5        11     3.4
    Other            6    3.7          6     1.9
Marital Status    n    %    n     %   n     % 0.17
     Married        116   72        94   58.4      210    65.2
     Living alone          29   18        38   23.6        67    20.8
     Living with a partner            5    3.1        13     8.1        18      5.6
     Other            8    5  8     5        16      5
    Missing            3    1.9  8     5        11      3.4
Occupation                                                 n    % n    %     n     % 0.79
    Professional    83   51.6  81   50.3        164   50.9
    Laborer    47   29.2       45   28          92   28.6
    Homemaker    23   14.3       30   18.6          53  16.5
    Other           8     5    5     3.1          13     4
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 Case Subjects Control Subjects                      P 
 (n =161)            (n =161)              Total   Range        
Variable n        %       n        %     n        %     
MEDICATIONS       Self Report     
Oral Contraceptives    1-10+ 
Months on Oral Contraceptives                       .06 
0  124         77.0     13           82.0  256         79.5  
1-4 months    14           8.7      8             5.0    23           6.8  
5-9 months    18         11.2     18           11.2    36         11.2  
10 or more months      2           1.2      3             1.9      7           2.2  
Missing      1           0.6      0                0         1           0.3   
     
HORMONES         Self Report 
(currently taking)                       .58 
Yes    25         15.5    25             15.5     50         15.5    
No  134         83.2 136             84.5  270         83.9  
Unknown      2           1.2     0                  0        2           1.2  
     
OTHER MEDICATIONS             
Psychiatric medications     
Major tranquilizer     0     0       0  
Minor tranquilizer     0     1                 .6       1           .3  
Sedative     2            1.0     1                 .6       3           .9  
Other   Antidepressant     1              .6     0       1           .3  
Steroids     5            3.0     1                 .6       6         1.8  
     
SMOKING HISTORY     
Never         83          51.6    77            47.8   160         49.7                      .66 
Current      37          23.0   44            27.3     81         25.2    
Ever           41          25.5    40            24.8     81         25.2    
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Table 4-2 Psychological Variables in PCOS Case and Matched Control Subjects  
 
 
Case 
Subjects 
  Control 
Subjects   
 (n =161)        (n =161)        Total Range    p value   
Variable                 
BDI  Total Score                                
Beck Depression Inventory *      0-63 
(M ± SD)   7.8          7.0       5.7      5.0    6.8        6.2  
Missing                                              9             14           23                         .02 
Category of Depressive 
sx**Subscale *                    %                         %                 %  
<9  102         63.4    119      73.9   221      68.6   0-9 
>9   50          31.1      28      17.4    78       24.2 10-63          .04 
Missing    9             5.6      14        8.7    23         7.1   
     
Severity of Depressive Sx     
Mild    39          24.2      24      14.9       
 
   63       19.6 10-18 
Moderate      8            5.0        4        2.5    12         3.7 19-29 
Severe     3           1.9          0      3           .9 30-63 
     
Deiner Satisfaction Total*     
(M ± SD)  23.9            6.8     24.2        6.2   24          6.5   5 to 35         .74 
Missing  5       9           14          4.3    
     
Spielberger Trait Anger*       
(M ± SD)   9.1             4.2    8.2            3.6     8.6         4.0                     .02 
missing   9  14   23 10 to 36       
Speilberger Trait Anxiety*     
(M ± SD)   9.6             5.5     8.7           5.2     9.2         5.4                     .01 
missing   10   16   26 10 to 39       
     
Cook-Medley*     
Subscale                      .01 
Cynicism    7.3            2.9     7.9           2.6    7.6          2.8   14 to 26 
(M ± SD)    8   14  14  
missing     
     
*   continuous variables  
** categorical variables     
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Table 4-3 Comparison of Demographic, Health, and Psychological Variables within PCOS Cases Only 
 
    PCOS Cases with                PCOS Cases without 
                              depression                             depression    
                                 BDI>9                                    BDI≤9                                    
          n=50                                n=102* P Value 
 
Age              M±SD     3.0        (7.3)            35.27         (7.2)            .88 
Parity          M±SD       .96      (1.2)         .68          (.91)            .13 
Education   M±SD   13.72      (2.1)      14.66         (1.9)          <.01 
 
Race           %                  %            .82 
White   45            90       94               92.2               
Black      3              6         4                 3.9  
Other*     2              4         4                 3.9  
Marital Status                
Married   36             72        76               74.5          <.01 
Not Married  14              28                  26               25.4  
Occupation           < .04 
Professional  20              40        60               58.8  
Sales  12              24        26               25.5  
Laborer    4                8          3                 2.9  
Homemaker   13             26        10                 9.8  
Other     1               2          3                 2.9  
 
*9 missing 
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 Table 4-3 Continued 
Comparison of Medical Variables within PCOS Cases Only 
 
   PCOS Cases with        PCOS Cases without              P 
                                depression                      depression                    Value    
                                   BDI>9                            BDI≤9 
n=50                              n=102 
 
 
Smoking History  n               %                     n          %            .37 
never   21             42       56         54.9  
current 16             32     20         19.6  
ever 13             26     26         25.5  
            
BMI *          M±SD 32.8 (8.6) 28.9 (7.6)            .01 
 
Months oral 
contraceptives 
  
 n                %             
 
       n           % 
 
           .11 
0 37              74         81         79.4  
1-4 months   2                4         10           9.8  
5-9 months   8              16         10           9.8  
10 or more months   2                4           1           1.0  
Missing   1                2           0              0  
 
Hormones 
  
 n               %              
        
       n             % 
           
          .01 
yes 13              26       12          11.8  
no 36              72       90          88.2  
               missing          1                2        0                0  
 
 
 
*Range 19.26-50.2 for depressed cases 
             18.1-58.7 for cases without depression 
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Table 4-3 Continued 
Comparison of Psychological Variables within PCOS Cases Only 
                                         PCOS Cases with     PCOS Cases without  
                                            depression                     depression      
                                                n=50                             n=102    
           
       Psychological Variable                   M±SD                        M±SD                  P Value    
BDI I  15.7      6.6    3.9    2.7 <.01 
Anger 11.7    5.1 7.8  3.2 <.01 
Anxiety 14.5    5.0 7.1  4.0 <.01 
Cynicism/Hostility 6.4    3.0 7.8  2.8 <.01 
Satisfaction with life 19.6   7.2 26.1 5.7 <.01 
 
 
 
 
 
 
 
 
 
Table 4-4 Terms of Conditional Logistic Regression Model Showing association with PCOS Status on 
the Matched–Pair Data Set (n=161 Pairs) 
Variable                        ß            SE (ß)              OR (CI)              P 
Marital Status 
 
-1.017 .351   .362 (.182-.720) .004 
BMI 
 
.066 .20 1.068 (1.027-1.111) .001 
BDI I  Scale .062 
 
.028 
 
1.068 (1.007-1.125) .028 
Smoking .298 .354 1.347 (.674-2.695) .399 
 
Education .031 .072 1.031 (.896-1.188) .667 
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Table 4-5 Logistic Regression Predictors of Depression within PCOS Cases 
N=50 
        
    β SE OR 95% CI for OR P value  
Education  -.221 .098 .802 .661-.971 .024  
Smoking Status 
Current  -.255 .454 .802 .318-1.888 .775  
Parity  .371 .187 1.449 1.005-2.091 .047  
Marital Status  -.495 .446 .610 .254-1.461 .267  
BMI  .058 .023 1.060 1.013-1.109 .012  
        
 
 
 
4.5 DISCUSSION 
The Cardiovascular Health and Risk Measurement Study (Charm) is the largest case 
control study examining the prevalence of depressive symptoms and psychological traits in 
women with PCOS.  One of the major findings from the psychological arm of this study was that 
the point prevalence of clinically significant high depressive symptoms on a screening 
instrument (BDI I) >9 was 31.1% compared to 17% in controls (OR = 1.75).  Within cases, 
results of logistic regression analysis showed that BMI, education, and parity were statistically 
significant predictors of depression p<.05.  The odds of being depressed of at least mild severity 
increased by 6% for each unit increase of BMI.  The odds of being depressed decreased by 20% 
for each year of education and increased by 44% for parity (per live birth).  Other studies have 
supported the high prevalence of depression in the PCOS population (16, 17, 32, 45).  The 
prevalence rates have been higher, 35% independent of obesity and fertility, as reported by  
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Hollinrake  et al. (10) in a matched control study of  PCOS cases and controls and  similarly a 
40% prevalence rate in another longitudinal study (28). 
The depressive symptoms on the BDI scale were also examined within cases.  Mean 
scores for the BDI were significantly higher in the cases.  Almost 80% of cases scored within the 
moderate and severe categories.  As expected, the cases had a higher BMI compared to controls.  
This finding is supported by  the literature on obesity and depression in the general 
population (27).  Large community studies have evaluated the relationship between obesity and 
depression.  The second largest community study on obesity and mood disorders reported that 
obesity (BMI ≥ 30) was associated with major depression in women (OR 1.82, 95% CI = 1.01 to 
3.3).  More importantly, the severely obese patient is at even greater risk for depression.(46).  In 
this study, 25% of cases with BMI ≥ 40 had increased depressive symptoms. 
In addition to BMI, education, marital and smoking status, and parity were factors 
examined to determine whether there was a relationship to depressive symptoms within cases.  In 
this study, education was protective against having increased depressive symptoms. 
Studies in the literature reach different conclusions about the association between 
education and depression.  For example, in a recent community study (47) results indicated that 
the highest rates of depression were reported by those “with other post-secondary” education, 
which is contrary to the current findings that the odds of being depressed decreased by 20% for 
each year of education within cases. 
Parity was found to be positively associated with depression in the full model. This 
finding is unexpected in the PCOS population as infertility is often a result of the condition.  In 
the general population, however, studies have reported increased depression during the 
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childbearing years (48).  It is unclear whether this findings regarding parity could be a result of a 
combination of age and the stress of caretaking. 
Marital status was not associated with depression in the logistic analyses.  Typically, it 
has been found that  unmarried persons were approximately 1.5 to 2.5 times more likely than 
married individuals to have had a recent episode of depression.(49).  Others have reported that 
there are lower rates of depression among people living with their marriage partners when 
compared to divorced individuals (47).  Another important aspect of marital status is measuring 
the quality of the marital relationship, which was not ascertained.  This may have contributed to 
the results. 
Likewise, smoking status was not associated with depression.  The research has shown 
that smoking does have an association with depression and has been found in early studies to be 
related to major depression (50).  The analyses only included smoking status and may have 
changed if more precise data regarding smoking habits were included. Yet, it was left in the 
model as parity was no longer significant when smoking status was removed. 
Findings from the adjusted conditional logistic regression concluded that BMI, marital 
status, and BDI score were independently associated with PCOS.  This highlights the importance 
of focusing on depressive symptoms concurrently with BMI when attempting to identify PCOS 
women who may be at risk for depression.  It also substantiates the complexity of the disorder, in 
that weight along with depressive symptoms and other demographic characteristics should be 
considered when screening for depression. 
It was notable that all the psychological variables, depressive symptoms and trait anger, 
anxiety, and cynicism on univariate analysis were associated with PCOS case status.  However, 
satisfaction with life was not.  In retrospect, other measures investigating quality of life that have 
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been tested on the PCOS population may have been more appropriate, i.e. the Health-Related 
Quality- of- Life Questionnaire (30). 
There were strengths to this study.  The matched pair design allowed for more robust 
results. The sample size of 161 matched pairs was the largest case control study that reported 
psychological manifestations of PCOS.  It also provided a model to predict PCOS women who 
may have increased depressive symptoms and require treatment.  The psychological measures 
were well known, reliable, and valid measures. 
The limitations to the study included its cross-sectional perspective and lack of diagnosis 
of depression.  The BDI I was useful as a screening tool for identifying individuals at risk for 
depression but did not have the ability to make a clinical diagnosis of depression. 
In conclusion, this study has highlighted the high risk and prevalence of depression that is 
associated with PCOS.  The mortality of women with PCOS is concerning not only from a 
medical standpoint but also from a psychological one.  These analyses have also shed light on 
factors such as BMI, education, and parity that are associated with increased depressive 
symptoms and which can provide useful clinical information with which to screen and identify 
women at risk for depression.  Additionally, the findings indicate that depression was associated 
with PCOS status independent of BMI. 
Further study is needed to examine the many confounding variables that mediate and 
moderate depressive symptoms in women with PCOS.  Identifying women with increased 
depressive symptoms, which often can lead to a clinical diagnosis, is implicit not only to provide 
early treatment for depression but to mitigate the probability of recurrent depression as this is a 
chronic disorder.  With appropriate psychological intervention, women with this condition can 
improve their quality of life and psychological functioning. 
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The public health implications of this study center around primary and secondary 
prevention. With secondary prevention, case finding is paramount as women are known to have 
2 times the prevalence of depression than men even before the having the diagnosis of PCOS.  
Finally, implementing a high-risk prevention approach would be a strategy to decrease the 
prevalence of depression in the PCOS population. 
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5.0  PCOS, PSYCHOLGICAL MANIFESTATIONS, AND THE METABOLIC 
SYNDROME.  WHAT IS THE RELATIONSHIP? 
Objective:  The aims of this study were:  1) to determine the prevalence of Metabolic 
Syndrome (MS) in PCOS cases and controls and 2) to determine if psychological factors 
(depression, anger, anxiety, hostility/cynicism, and satisfaction with life) are risk factors for 
Metabolic Syndrome independent of age, marital status, education, and  parity. 
 Methods:  A cross sectional study consisting of 148 PCOS cases and 151 controls with a 
mean age of 35.4 years was conducted to determine the prevalence of Metabolic Syndrome (MS) 
at baseline. A total of 40 (27%) PCOS cases and 15 (9.9%) controls met the criteria for MS 
according to the Adult Treatment Panel III (ATPIII).  In addition, psychological characteristics 
of the women were collected at baseline using the Beck Depression Inventory I (BDI I), the 
Spielberger Trait Anger and Anxiety Scales, the Cook-Medley Scale, and the Diener Satisfaction 
with Life Scale. 
Results:  In the sample, 27.0% (n=40) of the cases and 9.9% (n=15) of the controls had 
MS; p<.05; OR 3.4 (CI 1.726-6.400).  Differences between cases with and without MS for age 
was statistically significant, p<.001 and <.04, for cases and controls respectively.  Differences 
between controls with and without MS for education was also statistically significant, p<.04.  
In univariate analyses, BDI was borderline when associated with MS (p=.053).  Only 
PCOS and age were significant predictors for MS when BDI was forced into the model. The 
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odds of having MS increased by 10% for each year of age and three fold for PCOS cases.  
Within the subjects who had a BMI>30, the odds of having MS increased by 3% for each year of 
age.  
Conclusions:  Metabolic syndrome has been related to premature coronary heart disease.  
PCOS women have three times the prevalence of MS and should be monitored for a reduction in 
CHD risk factors as well as for lifestyle modification. The prevalence of depressive symptoms, 
although greater in cases than controls, is not significantly related to MS after adjusted for age 
and PCOS status. 
Public Health Significance:  The presence of MS and depressive symptoms in PCOS has 
clinical implications in screening for depression and also for evaluating women at intervals as 
they age so as to prevent the progression of MS.  Early identification and treatment of depression 
in PCOS women could possibly reduce the prevalence of MS as well as other features of MS, 
such as obesity and diabetes. 
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6.0  INTRODUCTION 
Polycystic ovary syndrome is the most common reproductive endocrine condition with a 
prevalence rate between 6-10%.  Features of PCOS, a heterogeneous disorder, include chronic 
anovulation, hyperandrogenism, and insulin resistance (1, 2).  Metabolic  abnormalities often 
occur in PCOS women and have been identified as Metabolic Syndrome (MS) or Metabolic 
Cardiovascular Syndrome (3, 4).  They include central adiposity, increased triglycerides, low 
levels of high density lipoproteins (HDLc), hypertension, impaired glucose tolerance, and 
Diabetes 2 (3, 5, 6).  Consensus on the definition and components of the Metabolic Syndrome 
varies (7, 8). 
The literature describing the Metabolic Syndrome (MS) in PCOS and the relationship 
with psychological characteristics are limited.  The association between MS and PCOS has been 
primarily on the medical features.  It is clear that there is a high prevalence of MS in women with 
PCOS (9, 10).  Previous research by Talbott et al. 2004 (10) concluded that women with PCOS 
are at increased risk for developing MS.  In this prospective study of 61 PCOS white women and 
85 similarly aged controls, they reported that PCOS cases were 4.4 times more likely to meet the 
criteria for MS.  
Psychological factors may be an important component of MS.   In a recent cross-sectional 
study by Hollinrake et al.(11), 103 women between the ages of 18-50 years with PCOS and 
controls were studied to estimate the prevalence of depressive disorders in women with PCOS.  
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They reported the comparison of biochemical variables between cases and controls with and 
without depression but did not examine those with metabolic syndrome. 
Depressive symptoms, stressful life events, and anxiety have been studied in relationship 
to MS in premenopausal middle-aged women (12).  Gender dependent associations (13) were 
also investigated finding that depression among women was associated with a 1.94-fold risk of 
having the MS with an elevated risk of having two of its five components:  elevated waist 
circumference (OR=2.23) and elevated glucose levels (OR=2.44) (14).  Further, a positive trend 
was observed toward an association with low high-density lipoprotein, hypertension, and 
elevated triglycerides suggesting that depression and cardiovascular diseases might be linked via 
the metabolic processes (14). Findings from a review by Goldbacher and Matthews 2007 (15) 
suggested that psychological characteristics, predominately depression, hostility, and anger may 
increase risk for the metabolic syndrome.     
Other areas of interest in association with MS are quality of marital status (16) and parity 
(17).  Women in high-quality marriages are at a lower risk of developing MS (16). The presence 
of MS is significantly higher in women with increasing numbers of children demonstrating a 
dose-response relationship (p<0.0001) (18).  After controlling for age, race/ethnicity, income, 
education, and other sociodemographic and behavioral risk factors, the odds of metabolic 
syndrome increased 13% (95% CI, 6%-20%) with each additional child (18). 
Numerous cross sectional studies have reported on the relationship between 
psychological variables and MS (13, 14, 19).  Likewise, research studies have reported on the 
association of MS and cardiovascular disease (3, 20) and the association with depression, MS 
and cardiovascular disease (21). 
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In longitudinal study investigating antecedents to MS, cynicism and hostility were  
characteristics identified as predictors of Metabolic Syndrome in older men and women.(22).  
Similarly, studies have substantiated that baseline anger scores in middle age women predicted 
increased risk for developing MS (12, 23).  However, the association of anxiety and MS is 
equivocal (23). 
Others have reported on the prospective relationship of metabolic syndrome and 
psychological characteristics in various populations but not with PCOS (12, 23).  Research by 
Raikkonen et al. (23) investigated the reciprocal relationship between psychological risk 
attributes and Metabolic Syndrome in healthy women.  Women who had high levels of 
depression and anger at baseline and increased anger during the follow-up had an elevated risk of 
developing MS during the follow-up, P<.04.  Conversely, MS syndrome at baseline predicted 
increasing anger and anxiety 7.4 years later, P<.001.  It was thus concluded that psychological 
risk factors affect the development of the MS and that the association between anger and the MS 
is indeed reciprocal. 
In another study by Raikkonen and colleagues (2007) (12), women enrolled in the 
population-based prospective cohort Healthy Women Study were followed for an average of 15 
years after baseline.  Premenopausal women (n=523) participated with a 3 year follow-up.  When 
women did not have MS at baseline, the risk for developing MS was 1.21 to 2.12 fold (P<.05) 
for more severe depressive symptoms or for very stressful events.  This was true even though 
MS was defined in various ways.  Those who at the baseline reported feeling frequently angry 
measured by the Spielberger Trait Anger Scale had an increased risk for developing the MS at 
least by one definition (relative risk 1.19-1.166 [1.00-2.39]. 
  90
A recent study examining the temporal relationship of depression and MS (24) found that 
non-depressed women with MS at baseline were twice as likely to have depressive symptoms at 
follow-up (OR 2.2, 95% CI=1.1 to 4.5) as compared to the non-depressed cohort members 
without Metabolic Syndrome at baseline.  This finding underscores the possibility that MS may 
be an important risk factor for depression in other populations, such as PCOS.  Moreover, 
effective identification and prevention of the MS could aid in the prevention of depression and 
other psychological symptoms. 
In a large matched pair study by Cipkala-Gaffin and colleagues (25) investigating the 
psychological ramifications of PCOS, the prevalence of depression was 31% for cases as  
compared to 17% for controls (OR 1.9, CI 1.55-2.16).  In continuation of that study, further 
research was conducted to determine the psychological characteristics related to MS in women 
with PCOS as there is a paucity of research in this area. 
The present study was designed to:  1) determine the prevalence of Metabolic Syndrome 
(MS) in PCOS cases and controls and 2) to determine if psychological factors (depression, anger, 
anxiety, hostility/cynicism, and satisfaction with life) are risk factors for Metabolic Syndrome 
independent of age, marital status, education, and parity.  
6.1 SUBJECTS AND METHODS 
Case and Control Recruitment:  The study population is comprised of a subset of the 
original Cardiovascular Health and Risk Measurement study (CHARM) investigation conducted 
by Talbott et al. (l995) (26) .  This study’s main aim was to investigate coronary heart disease 
risk factors in women with PCOS.  At baseline, psychological characteristics of the women were 
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collected using the Beck Depression Inventory I, the Spielberger Trait Anger and Anxiety 
Scales, the Cook-Medley Scale, and the Diener Satisfaction with Life Scale.  A total of 243 
PCOS cases and controls were to be recruited for the primary study.  Approximately 200 cases 
and controls participated in answering the psychological measures.  However, complete data on 
the psychological profile was available for only 160 cases and controls and forms the basis for 
this analysis.  Details and further information about the participants have been published 
elsewhere (26).  Controls were matched to cases by age ± 5 years, race, and neighborhood.  
Those participants living in the greater Pittsburgh area were asked to participate in the 
clinical phase of the study located at Magee-Women’s Hospital.  Subjects were evaluated after a 
12 hour fast.  Another questionnaire was administered on site which included a repeat medical 
history, medication history, current medical practices, and family history of PCOS.      
6.2 MEASURES 
Metabolic Syndrome (MS) was defined according to the Adult Treatment Panel III 
(ATPIII) Criteria.  Criteria for MS are listed in Table 6-1. 
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Table 6-1 Metabolic Syndrome 
      (3 or more of the following)  
 
                        DIMENSION                                              CRITERIA 
 
1.Waist 
 
>88cm  
 
 
2.Elevated fasting glucose /or 
Type 2 Diabetes (MD diagnosed)/ 
or receiving treatment for Type 2 Diabetes 
 
 
>110mg/dl 
 
Dyslipidemia  
 3.↑tryglcerides 
                        4.↓ (HDLc) 
 
 
 
≥150mg/dl 
≤50mg/dl 
 
5.Hypertension* ↑ SBP /or 
↑DBP/ 
or receiving treatment for hypertension 
 
 
≥ 135mmHg and 
≥ 85mmHg 
 
 
Systolic Blood Pressure=SBP 
Diastolic Blood Pressure=DDP 
*ATP criteria (2001) includes any three of the components 
 
 
 
 
Lipid and Lipoprotein Measurement 
Serum concentrations of total cholesterol, total HDL cholesterol (HDLc), subfractions 
HDL2, HDL3, triglycerides, LDL and VLDL were measured at the University of Pittsburgh, 
Heinz Lipid Laboratory.  Total cholesterol was determined by the enzymatic method of Allain et 
al.(27).  Duplicate samples with standards, control sera, and serum calibrators were included in 
each run.  The coefficient of variation (CV) runs was 1.3%. 
HDL-C was determined after selective precipitation by heparin/manganese chloride and 
the removal by centrifugation of VLDL and LDL (28).  The cholesterol was measured as 
  93
described above for total cholesterol.  Duplicate samples, standards, and control sera were 
included in each run.  The CV between runs was 2.1%.  After precipitation and removal of VLDL 
and LDL by heparin/manganese chloride as described above, the supernatant was mixed with 
dextran sulfate (29).  The HDL2 precipitates and the HDL3 in the supernatant were then measured 
using the methods described above for cholesterol measurement.  The HDL2 content was 
estimated by subtracting the HDL3 level from the total HDL content.  Duplicate samples, 
standards, and control sera were included in each run.  The CV between runs was 6.0%.  LDL 
concentration was estimated by using the Friedewald formula (30).  Triglycerides were 
determined by using the enzymatic procedure of Bucolo and David (31).  The CV between runs 
was 1.7%.  Blood for glucose and insulin determinations was obtained when the subjects were 
fasting.  Plasma glucose was analyzed by using an enzymatic assay (Yellow Springs Glucose 
Analyzer, Yellow Springs Instruments) and plasma insulin by radioimmunoassay. 
6.2.1 Standardized Psychological Measures 
Depression Assessment:  The Beck Depression Inventory I (BDI I) (32) is a self-report 
inventory measuring characteristic attitudes and symptoms of depression.  It contains 21 
questions with a cutoff of >9 (total score) to identify potential clinically significant symptoms of 
depression.  The psychometric properties of the BDI have been reported as high with internal 
consistency ranging from .73 to .92 with a mean of .86.  The split-half reliability coefficient 
reported was .93.  Concurrent validity was determined by correlations with clinician ratings of 
depression using the revised BDI and ranged from .62 to .66 (32).  The BDI was previously 
tested on the PCOS population (33, 34) and in other research studies on women with obesity that 
may be applicable to the PCOS population as obesity is a central feature of  this disorder.  
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Anxiety and Anger Assessments:  The Spielberger Trait Anger/Anxiety Scales are 
components of the State-Trait Personality Inventory by Spielberger (35, 36) (2 of 6 subscales).  
For reliability testing, alpha coefficients ranged from .80 to .87 and provide evidence for internal 
consistency of the six STPI scales (37).   Reliability testing was done to determine internal 
consistency, alpha coefficient = .81-.87 (Spielberger manual reports).  Cronbach alphas were .82-
.85 and .80-.85 for anger and anxiety (35, 36). 
Hostility/Cynicism Assessment:  This 13 item scale derived from the Cook-Medley 
Hostility Scale (38) measures cynical attitudes and hostile feelings and behaviors rather than 
overt expressions of anger and aggression.  Higher scores indicate greater hostility (range 9-13).  
Cronbach’s alpha for the scale was .79 indicating good internal consistency (38). 
Diener Satisfaction With Life Scale:  This scale (39) measures judgmental components of 
subjective well-being.  It is comprised of 2 major components, the emotional or affective 
component and the judgmental or cognitive component.  The scale consist of 5 questions with a 
7 point likert scale ranging from strongly disagree to strongly agree.  A higher score reflects a 
greater satisfaction with life.  Test retest reliability was .84 (39).  While brief, this instrument 
offers as high or higher predictive validity than several longer measures of life satisfaction. 
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7.0  STATISTICAL ANALYSES 
All data collected for the original study were entered and verified by using SPSS data-
entry software.  All data were analyzed using SPSS FOR WINDOWS version 15.0 (SPSS Inc., 
Chicago, IL, USA).  Univariate and multivariable analyses were performed. 
Descriptive statistics, including measures of central tendency and dispersion, were 
computed for all variables of interest for PCOS cases and controls.  Due to it’s non-normally 
distribution, triglyceride levels were logarithmically transformed before performing statistical 
comparisons.  Variables of interest were compared using the Student’s t test or the nonparametric 
Mann-Whitney U test for continuous data.  For categorical data, x² or Fisher’s exact test was 
used. 
The group differences were determined by using independent t-tests.  Spearman 
correlation and logistic regression were utilized.  The logistic regression models examined the 
relationship between the metabolic syndrome (dependent variable), covariates (PCOS, age, 
marital status, education, and parity), and depressive symptoms. 
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7.1 RESULTS 
7.1.1 Demographics 
One hundred and sixty-one pairs formed the cohort studied.  Pairs were initially matched 
on age, race, and neighborhood.  Fifty five subjects met criteria for Metabolic Syndrome.  
Because of the small number of subjects with MS, it was not possible to retain the matched pairs 
for all of the analyses without losing sample size. 
From the total sample, PCOS cases (n=148) and controls (n=151), 40 cases and 15 
controls met criteria for MS, OR 3.4.  (Figure 7-1)  Of those with MS (n=55), 27.0% of the 
cases and 9.9% of the controls had MS, OR 2.7.  (Table 7-2)  The average age of the initial 
CHARM matched pair sample (CHARM I) was 35.8 ± 7.5.  The average age of the total sample 
with MS was 39.2 ± SD 5.2.  (Table 7-1)  Cases and controls with MS were similar in age, 39.2 
± 5.2 and 39.7 ± 5.7 respectively.  However, the cases and controls without MS were younger in 
comparison.  For the cases, the mean age was 33.9 ± 7.5 and for controls, 36.2 ± 8.0.  The age 
between cases with and without MS was statistically significant, p<.001.  Those with MS were 
older, 39.2 ± 5.2, compared to cases without MS, 33.9 ± 7.5 years.  The same was true between 
controls.  The controls with MS were older, 39.9 ± 5.7 years, compared to those without MS, 
36.2 ± 5.7years (P<.04). 
The sample was predominately White in both the cases and controls with MS (97.5%, 
93.3% respectively) with only 1 case and 1 control with MS being Black. Seventy-five to 80% of 
the MS cases and controls were married, which was higher in comparison to the original cohort 
(65.2%) in which cases exhibited the greater percentage (72%).  PCOS cases with MS had a 
mean of 1 child compared to controls with MS who had 2.  Education within controls, with and 
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without MS, was statistically significant at p<.04 (13.2 ± 2.2 and 14.5± 2.0 years respectively) 
but not for cases.  No statistically significant differences were found between groups for marital 
status and hormone use and smoking status.  BMI was statistically different between those with 
MS within cases and controls separately, p<.001 (not shown in table, but relevant for analyses).  
Table 7-2 presents the distribution of components of MS among PCOS cases (n=40, 27%) and 
controls (n=15, 9.9%).  At baseline, a total of nine PCOS cases (15.3%) versus three control 
women (3.5%) had MS defined by the presence of 3 or more critical components (10). 
7.2 PSYCHOLOGICAL VARIABLES 
The mean BDI score for cases with MS was 9.1 ± 7.4 compared to 6.6 ± 4.3 for controls 
with MS.  (Table 7-3)  Differences in BDI scores between cases with and without MS and 
controls with and without MS as well as in the total samples of cases and controls, were not 
statistically significant.  However, differences between BDI scores for the total cases and 
controls, 8.0 ± 7.2 and 5.8 ± 5.1, was statistically significant, p <.003. Mean scores for anger, 
anxiety, hostility/cynicism, and satisfaction with life were similar between cases and controls 
with and without MS and for the total sample, with the exception of hostility/cynicism in regard 
to the total sample.  Hostility/cynicism was borderline significant between cases and controls for 
the total sample.  
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7.3 LOGISTIC REGRESSION ANALYSES 
To adjust for the matching of the subjects, case status and age were variables kept in the 
model.  (Table 7-4)  On univariate logistic regression, BDI was borderline significant in 
predicting MS (p=.053) and no other psychological factor was significant.  PCOS status was 
significant in univariate analysis (P<.001) and in all of the other modeling (P<.001 to P<.002).  
Age, also, remained significant in all of the models at P<.001.  None of the other 
sociodemographic variables, marital status, parity, or education were significant. 
The final model chosen was with PCOS, age, and BDI forced into the model. The sample 
was also stratified by BMI >30 (Table 7-5) in order to examine the relationship between the 
psychological and sociodemographic on MS.  Age was the only significant predictor in the 
models, most notably with BDI, PCOS, Age, and Education. In this model, age was significant at 
P<.003.  Analyses were not performed on the BMI sample < 30 due to small sample size. 
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Figure 7-1 Frequency of Metabolic Syndrome in Cases and Controls 
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Table 7-1 Selected Sociodemographic Variables in PCOS Cases and Controls at Baseline (1993-1994) 
     PCOS Cases                          Controls 
       MS*          Y   n=40 N    n=108 Y    n=15 N   n =136          P**            P*** 
      
Variable M ±SD M ±SD M ±SD M ±SD    Cases          Controls 
Age 39.2   (5.2) 33.9  (7.5) 39.7   (5.7) 36.2  (8.0)      <.001           < .04 
Race a       white 39     97.5 109    90.1 14      93.3 143    97.9          .33               .27   
                (other)  1        2.5 11       9.1 1          6.7    3       2.1   
Education 14.4    1.9 14.3    2.0 13.2      2.2 14.5     2.0          .74             <.04 
Marital Status bY 30        75 86     71.1 12         80 82    56.2          .80               .12 
Parity .9        1.0 .78      1.0 1.9       1.3 1.43     1.3  .69                .20 
Hormones        Y 5       12.5 20    16.5 0            0 25     17.1          .60               .08 
Smoking            Y 11     27.5 26    21.5 3          20 48     28.1          .43               .50 
Values are the mean (SD) or number (percentage) 
*MS= Metabolic Syndrome 
**between cases with and without MS 
***between controls with and without MS 
Missing: 
              a=1 
              b=10 
 
 
 
 
Table 7-1 Continued 
PCOS Cases               Controls 
 
MS n= 148         n=151    p value 
Deleted/missing 13          10  
 Variable M ±SD M ±SD  
Age    35.2         7.2 36.5       7.9     .163 
Race  a        white    136        91.9     146      97.4   <.029 
                  (other)   11            7.9     4            2.6  
Education    14.3         2.0     14.4       2.1     .608 
Marital Status Y  b     113        71.5     93        58.1   <.030 
Parity   .8             1.0     1.5         1.4   <.001 
Hormones  Y   c          25         15.5      25       16.6     .190 
Smoking      Y   34          23.0      40       26.5     .483 
Values are the mean (SD) or number (percentage) 
 *MS= Metabolic Syndrome 
 **between cases with and without MS 
 ***between controls with and without MS 
  Missing: a=1 
                     b=10 
                   c=2 
  101
Table 7-2 Distribution of MS Components among PCOS Cases and Controls 
________________________________________________________________________ 
 
MS risk factors                                         PCOS                              Controls 
 
      (n=148)                              (n=151) 
 
MS absent (≤ 2 risk factors) †                 108  73.0%                     136     90.1.0% 
None                                                          42                                     72 
One                                                            35                                     40 
Two                                                           31                                     24 
MS present (3+ risk factors)                    40  27.0%                        15*** 9.9% 
Three                                                         17                                     10 
Four                                                           14                                       5 
Five                                                             9                                       0 
________________________________________________________________________ 
 
*3 cases deleted with 1 missing risk factor that could have changed MS status to present 
** 1 control deleted with missing risk factor that could have changed MS status to 
present 
*** 1 control had risk factors =3 even with 1 missing risk factor, added to sample 
† if subject had missing risk factor or factors but remained <3, left in sample 
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Table 7-3 Psychological Variables in PCOS Cases and Controls at Baseline by MS Status (1993-1994) 
 
         Cases                                     Controls 
Mean and SD  
MS Y  n=40  N   n=108 Y    n=15    N   n=136    P***         P**** 
      
Variable M±SD M ±SD M ±SD M ±SD  
BDI a 9.1    7.4 7.5   7.1 6.6    4.3 5.6     5.2 .254           .501 
Anger b 9.3    4.4 9.1   4.2 9.1    4.4 8.2     3.6     .744           .379 
Anxiety c 9.5    5.4 9.3   4.4 9.0    5.4 8.9     5.3 .653           .926 
Host/cyn* d 6.8    2.9   7.5   3.0 8.0    2.9 8.0     2.6     .176           .873 
Sat. w/l** e 23.0  6.6 24.2  7.1    26.5   5.7 24.0   6.3     .351           .134 
*Hostility/Cynicism 
**Satisfaction with life 
***between cases with and without MS 
****between controls with and without MS 
Missing: 
     a=21 
     b=22 
     c=25 
     d=20 
     e=13 
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Table 7-3 Continued Psychological Variables in Total PCOS Cases and Controls at Baseline  
(1993-1994)             
 
        Total Cases      Total Controls 
 
       n=188       n=136        P*** 
    
Variable M ±SD M ±SD  
BDI  a      8.0    7.2       5.8    5.1 <.003 
Anger b      9.1    4.2       8.2    3.7  .103 
Anxiety c  9.6    5.5       8.8    5.3 .249 
Host/cyn*d      7.3    2.9       8.0    2.6  .056 
Sat. w/l**e    23.8    7.0      24.2   6.3 .606 
    
 
 
 
 
 
Mean and SD  
*Hostility/Cynicism 
**Satisfaction with life 
***between cases with and without MS 
****between controls with and without MS 
Missing: 
     a=21 
     b=22 
     c=25 
     d=20 
     e=13 
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Table 7-4 Logistic Regression Models of MS (yes/no) and Selected Sociodemographic and  
Psychological Risk Factors for  Cases and Controls with MS  
 
             n              β            SE         OR           95% CI  for OR     p value   
 BDI 278 .043 .022 1.044 (.999,1.090) .053 
       
PCOS 299 1.211    .329 3.358 (1.762,6.400) <.001 
       
BDI 
PCOS 
278 .030 
1.068 
.023 
.338 
1.030 
2.910 
(.986,1.077) 
(1.501,5.640) 
.187 
<.002 
       
BDI  * 
PCOS 
Age 
278 .035 
1.252 
.096 
.024 
.355 
.025 
1.036 
3.496 
1.101 
(.989,1.084) 
(1.743,7.014) 
(1.049,1.156) 
.139        
<.001 
<.001 
       
BDI 
PCOS 
Age 
MARS** 
278 .036 
1.231 
.094 
-.154 
.024 
.359 
.026 
.396 
1.037 
3.425 
1.099 
.857 
(.990,1.087) 
(1.695,6.922) 
(1.045,1.155) 
(.394,1.864) 
.128 
<.001 
<.001 
.697 
       
BDI 
PCOS 
Age 
Parity 
278 .037 
1.175 
.101 
-.099 
.024 
.372 
.026 
.152 
1.037 
3.238 
1.106 
.905 
(.990,1.087) 
(1.562,6.712) 
(1.051,1.163) 
(.672,1.220) 
.120 
<.002 
<.001 
.514 
       
BDI 
PCOS 
Age 
Education 
278 .031 
1.266 
.096 
-.069 
.024 
.357 
.025 
.081 
1.032 
3.547 
1.101 
.933 
(.984,1.081) 
(1.762,7.141) 
(1.048,1.156) 
(.796,1.094) 
.195 
<.001 
<.001 
.393 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Final Model 
** MARS= Marital Status 
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Table 7-5 Logistic Regression Models of MS (yes/no) and Selected Sociodemographic and  
Psychological Risk Factors for  >30 BMI 
 
      n              β            SE          OR          CI for OR             p value 
 
 BDI 101 -.009 .026 .991 (.941,1.044) .742 
       
PCOS 108 .640 .429 1.896 (.817,4.398) .136 
       
BDI 
PCOS 
101 -.018 
.720 
.027 
.449 
.982 
2.055 
(931,1.036) 
(.852,4.958) 
.505 
.109 
       
BDI 
PCOS 
Age 
101 -.007 
.841 
.098 
.029 
.475 
.034 
.993 
2.319 
1.103 
(.938,1.051) 
(.915,5.881) 
(1.031,1.180) 
.812 
.076 
<.004 
       
BDI 
PCOS 
Age 
MARS* 
101 -.003 
.797 
.094 
-.778 
.030 
.483 
.035 
.473 
.997 
2.219 
1.099 
.459 
(.941,1.057) 
(.862,5.714) 
(1.025,1.178) 
(.182,1.160) 
.920 
.099 
<.008 
.100 
       
BDI 
PCOS 
Age 
Parity 
101 -.006 
.784 
.101 
-.087 
.029 
.492 
.035 
.201 
.994 
2.190 
1.106 
.916 
(.939,1.052) 
(.834,5.750) 
(1.032,1.185) 
(.618,1.359) 
.838 
.111 
<.004 
.664 
       
BDI 
PCOS 
Age 
Education 
101 -.012 
.873 
.106 
-.102 
.030 
.479 
.036 
.106 
.988 
2.393 
1.112 
.903 
(.932,1.048) 
(.937,6.116) 
(1.036,1.193) 
(.734, 1.110) 
.697 
.068 
<.003 
.332 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 *MARS= Marital Status 
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8.0  DISCUSSION 
The present investigation evaluated the prevalence of Metabolic Syndrome among 
women with PCOS and controls of similar age and the association between MS and certain 
psychological factors. 
Previous studies have reported on the prevalence of MS in PCOS (10, 40-42).   Studies 
have reported that the prevalence of the Metabolic Syndrome in premenopausal women with 
PCOS ranges from 33% to 47% (42).  In our study, 27% of the PCOS cases had MS according to 
the ATP III criteria.  As can be seen, the prevalence in PCOS women is concerning.  In a 
previous study by Talbott and colleagues (10), 15.3% met the same ATP IIII criteria for MS even 
when subjects were limited to those with a BMI of  <35.  The literature supports the fact that MS 
is common in PCOS and notably in women with the highest BMI and insulin and androgen 
levels (43).  
No studies have reported specifically on the MS syndrome in PCOS and its relationship 
to psychological factors.  Only one investigation, related to MS (44), did a pilot study which 
investigated the rate of depression among women with PCOS and with clinical and biochemical 
markers of  PCOS.  Others have found that there is a significant relationship between depression 
and anger and the number of risk factors comprising the Metabolic Syndrome (23).  Similarly, 
others have supported the finding of increased depressive symptoms in studies with MS in other 
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populations (14, 23, 24).  In this study, we also found that women  exhibited high levels of 
depression at baseline as in a previous study by Cipkala-Gaffin et al. 2009 (45).  
In our study, we found that increased depressive symptoms were borderline significant in 
its association with MS on univariate analyses.  However, it did not remain at this level of 
significance when other factors entered the models.   
Age was a significant predictor of MS in PCOS and this finding has been consistent in 
the investigation of age and MS in PCOS.  In a case control study, it was found that patients with 
a BMI>25 and who were 30 years of age or older had a higher prevalence of  MS (46).  Age, 
PCOS, and MS have been proven to have associations overall.  The prevalence of  MS increases 
with age (47) and likewise the prevalence of PCOS increases with age(48). 
There are limitations to our study.  The sample consisted mostly of Caucasians, limiting 
the generalization of the findings for other ethnic groups.  Also, the matching was not retained 
throughout the analyses as the sample size would have been greatly reduced.  Further, this study 
was cross-sectional which limited the ability to identify the depressive symptoms in subjects.  
The BDI, although reliable and valid, is a screening measure for increased depressive symptoms 
and does not provide diagnostic information. 
In conclusion, there is a high prevalence of MS in PCOS women compared to controls, a 
threefold increase.  Depressive symptoms and age are associated with MS in PCOS women and 
as the number of MS risk factors increase, so does age and the severity of depressive symptoms.  
Moreover, parity, marital status, and education all appeared to have no significant impact on 
these risk estimates.  The presence of MS and depressive symptoms in PCOS has clinical 
implications in screening for depression and also for evaluating women at intervals as they age 
so as to prevent the progression of MS.  Early identification and treatment of depression in 
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PCOS women could possibly reduce the prevalence of MS as well as other features of MS, such 
as obesity and diabetes. 
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9.0  POLYCYSTIC OVARY DISEASE, (PCOS),                                 
PSYCHOLOGICAL FACTORS,                                                                         
AND INTIMA-MEDIA THICKNESS (IMT) 
Objective:  Earlier work has shown that women with PCOS have increased subclinical 
atherosclerosis as measured by IMT in addition to increased depression. The aim of this study is 
to investigate whether psychological factors, independent of baseline cardiovascular risk factors, 
are a risk factor for IMT in women with PCOS 
 Methods:  A longitudinal study was done.  The sample originated from 161 cases and 
controls matched on age, race, and neighborhood that participated in the baseline psychological 
assessment arm of our original study.  In turn, these subjects were part of the original 
Cardiovascular Health and Risk Measurement (CHARM) study by Talbott et al. conducted in 
1993-4 to investigate coronary heart disease risk factors in women with PCOS.  Psychological 
characteristics of the women were collected at baseline using the Beck Depression Inventory I 
(BDI I), the Spielberger Trait Anger and Anxiety Scales, the Cook-Medley Scale 
(Hostility/Cynicism), and the Diener Satisfaction with Life Scale.  Cardiovascular risk factors 
were also measured at baseline.  Four years later (l997-1998), subjects aged 30 years and older 
returned for follow-up and underwent B-mode ultrasonography of the carotid arteries for the 
evaluation of carotid intima-media thickness (IMT).  There were 196 subjects that had both 
psychological and IMT data which formed the basis for these analyses.     
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Results:  Overall, PCOS remained a significant risk factor for carotid IMT independent 
of age, BMI, and systolic blood pressure in cases compared to controls (for the total group).  In 
the group < 45 years of age, systolic blood pressure was a significant predictor of IMT.  There 
were no significant effects from any of the psychological factors (depression, state anger and 
anxiety, hostility/cynicism, and satisfaction with life), independent of baseline cardiovascular 
risk factors, on IMT.   
Conclusions:  There was no independent relationship between the psychological 
variables and IMT measurements (either for the total group or when the groups were divided by 
age at follow-up after adjusting for age and selected risk factors). Psychological variables do not 
appear to be independently related to IMT.  Further research to explore the association between 
psychological traits and IMT, independent of cardiovascular risk factors, is indicated. 
Public Health Significance:  It is well known that there is an association between 
subclinical cardiovascular disease and negative emotional states (depression, state anger and 
anxiety, and hostility/cynicism) which warrants psychological evaluations in PCOS women in 
order to prevent the incidence of psychiatric disorders in this population.  
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10.0  INTRODUCTION 
Polycystic ovary syndrome (PCOS) is the most common reproductive endocrine 
condition, manifesting in puberty, with a prevalence rate between 6-10% among women of 
reproductive age (1).  Features of PCOS, a heterogeneous disorder, include chronic anovulation, 
hyperandrogenism, obesity, and insulin resistance (2-6).  There is concern that PCOS women 
may be at risk for cardiovascular disease (CVD) given the characteristics of PCOS which include 
dyslipidemia, hypertension, obesity, metabolic cardiovascular syndrome (MCS) (7), 
abnormalities in coagulation, and fibrinolytic pathways.  Other studies have supported these 
findings in younger women with PCOS (8-10).  Orio et al. (8) studied women with a mean age of 
22.2 years and Carmina and colleagues (10) investigated women with a mean age of 25.2 years.  
These studies concluded that the diagnosis of PCOS was associated with carotid intima-medial 
wall thickness (IMT) independent of insulin resistance or visceral fat distribution.  In a large 
study by Talbott (3), women ≥45 years of age had significantly greater IMT readings than 
controls.  Intima-media wall thickness (IMT) has been highlighted and researched as a marker of 
subclinical CVD particularly because of its association with an adverse cardiovascular risk 
profile such as elevated LDLc and triglycerides, higher systolic blood pressure, increased 
abdominal adiposity, and hyperinsulinemia (3, 11).  Research has substantiated that this risk 
profile is equivalent to the risk factors in PCOS (12, 13).  Carotid IMT determined by B-mode 
ultrasound has been shown to be directly associated with an increased risk of myocardial 
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infarction and stroke in older adults without a previous history of cardiovascular disease (14).  
Similarly, B-mode ultrasonography has been proven to be a reliable measure of generalized 
atherosclerosis (15) and has been associated with adverse cardiac events (16, 17). 
Evidence for the association between PCOS and premature carotid atherosclerosis was 
reported in middle-aged women (ages ranged from 30-44 and ≥ 45 years of age) by measuring 
carotid IMT (3).  In a follow-up study by Talbott et al. (3), 125 white PCOS cases and 142 
controls ≥ 30 years of age, matched on age, were investigated by B-mode ultrasound.  In the total 
group (30-60 years of age), no difference was found.  However, when the group was stratified 
between 30-44 years and ≥ 45 years, the PCOS women ≥ 45 years had significantly greater mean 
IMT than controls (0.78 vs  0.70 mm, p= 0.005).  This was independent of age and BMI.  The 
results suggests that lifelong exposure to an adverse cardiovascular profile in women with PCOS 
may lead to premature atherosclerosis (3).  The difference between the 2 groups remained 
significant even after controlling for BMI (p<.005).  The results suggest that the association 
between PCOS and IMT was mediated by central adiposity (7).   
In addition to the medical consequences of PCOS, often there are also psychological 
difficulties such as depression, anxiety, anger, hostility, and dissatisfaction with life (16).  These 
psychological complications may increase the risk of cardiovascular disease in this population.  
Cipkala–Gaffin et al. 2009 (18) noted that compared to a control group, women with PCOS had a 
higher prevalence of depression (BDI scores > 9):  31% vs. 17% in controls, P<.016: OR 1.9 (CI 
1.55-2.16).  The literature has focused on depression as the most evident psychological insult 
(19-22).  Hollinrake and colleagues (2007) found that women with PCOS were at an increased 
risk for depressive disorders (new cases) compared with controls (21% vs 3%; odds ratio 5.11 
[95% (CI) 1.26-20.69]; P<.03)  (22).  Additionally, the overall risk of depressive disorders in 
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women with PCOS was 4.23 (95% CI 1.49-11.98; P<.01) independent of obesity and infertility.  
Compared with the nondepressed PCOS subjects, the depressed PCOS subjects had a higher 
body mass index (BMI) and evidence of insulin resistance (P<.02). 
Over the past 20 years, the literature is replete on the relationship of CVD and negative 
emotional states such as depression, anxiety, anger, and hostility (23).  Agista et al. 2005 
reported on the association of coronary and aortic calcification in women with a history of major 
depression in the Study of Women’s Health Across the Nation (SWAN).  After adjusting for 
cardiovascular risk factors and sociodemographic characteristics in a sample of 58 African 
American and 152 healthy white women, it was found that when comparing a history of 
recurrent major depression with a single episode or no history that the Odds Ratio (OR)  was 
2.46 for any coronary calcification, 2.71 for high coronary calcification, and 3.39 for high aortic 
calcification (24).  Depression and coronary heart disease have been associated in many studies 
independent of standard cardiovascular risk factors (24-26).  Rozanski et al. (25), reported that 
patients with coronary heart disease compared to the 1 month prevalence of major depressive 
episodes in community samples (approximately 5%) yielded results that were nearly 3 fold 
greater among patients with coronary heart disease.  The Pittsburgh Healthy Heart Project (26), 
an ongoing prospective cohort study of healthy, older men and women from the general 
community, examined depressive symptoms, anxiety symptoms, and hostility/anger in predicting 
subclinical atherosclerotic progression over a 3 year period by measuring IMT.  Regression 
analyses indicated that higher depressive symptoms at baseline were associated with greater 3 
year change in carotid IMT (ΔR²=0.026, P=.002) even when accounting for demographic 
factors, cardiovascular risk factors, medication use, medical conditions, and other correlated 
negative emotions.  Anxiety, hostility, and anger were unrelated to IMT.  Stewart et al. (27) have 
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measured IMT to determine the relationship between hostility and carotid atherosclerosis and 
found that there was a significant relationship between hostility and greater subclinical 
atherosclerosis not explained by traditional risk factors in middle-aged women.  Evenson-Rose et 
al. (28) also reported on the relationship between cynical hostility and carotid atherosclerosis in 
American, white women from the SWAN Heart Study. They found that hostility is related to 
small but significantly greater subclinical athersoclersosis in middle-age women. Even after 
adjusting for race, education, body mass index, resting systolic blood pressure, and smoking, the 
association remained significant at a P≤.01.  Others studies support that men and women who 
were high on hostile attitudes had increased IMT readings (29, 30).  Matthews et al. in 1998 (29) 
reported that women who held their anger in as opposed to expressing it in an outward fashion 
were more likely to have increased IMT and carotid plaque.  Lastly, Paterniti et al. (31) reported 
that men and women who had persistent anxiety with elevated anxiety scores had a greater 
increase in IMT across 4 years. 
Thus far, there has been little attention paid to investigating the psychological risk factors 
as predictors of cardiovascular disease (measuring IMT) in women with PCOS. This study seeks 
to examine psychological factors as predictors of IMT over a 5 year follow-up.  The aim of this 
study is to examine whether the psychological factors (depression, state anger and anxiety, 
hostility/cynicism, and satisfaction with life) act as a risk factor for IMT independent of baseline 
cardiovascular risk factors. 
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11.0  METHODS 
11.1.1 Subjects 
Women with PCOS were originally identified from the practice records of physicians in 
the Division of Reproductive Endocrinology at Magee-Women’s Hospital between 1970 and 
1990.  A clinical diagnosis of PCOS was made if there was:   (1) a history of chronic anovulation 
in association with (2) clinical evidence of androgen excess (hirsutism) or biochemical evidence 
of an elevated total testosterone concentration (>2.0 nmol/L), or with (3) a ratio of luteinizing 
hormone to follicle-stimulating hormone of > 2.0.  A total of 244 cases and 244 controls from the 
Cardiovascular Health and Risk Measurement (CHARM I) study by Talbott et al. (32) agreed to 
a clinical assessment of their hormonal and cardiovascular status.  Voter registration tapes and 
household directories were used to identify the 244 age-matched control women.  Detailed data 
collection and laboratory methodologies have been previously published (32).  In the second 
phase of the CHARM study, Talbott et al. investigated whether the increase in cardiovascular 
risk factors noted four years earlier would now manifest in increased subclinical carotid 
atherosclerosis measures in carotid IMT (CHARM II).  PCOS cases and controls who were ≥30 
years were eligible for CHARM II.  A total of 335 subjects,, cases (n=175) and controls (n=160), 
participated (75% of eligible).  Of the 335, a total of 196 had both baseline data (including 
psychological data) and subsequent IMT measurement on follow-up (1996-1999) (3). 
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11.1.2 Covariates 
Covariates considered included age and race.  These variables were used for matching in 
the original study. Body composition variables were BMI and average waist measurements.  
BMI was chosen to represent weight.  History of hormone use and smoking history were 
included.  Systolic blood pressure and the following lab values were evaluated:  LDL, Hdl, 
Insulin, Testosterone, Triglycerides, Cholesterol, and Glucose.  Details of the blood analyte, 
blood pressure, and anthropometrics have been published elsewhere (3).  Psychological variables 
were depression, anger, anxiety, hostility, and satisfaction with life 
11.1.3 Carotid Ultrasound Protocol 
A detailed description of the carotid ultrasound protocol for measuring intima–media 
thickness has been published (2000).  A Toshiba SSA-270A scanner equipped with a 5-MHz 
linear array imaging probe was used.  Sonographers scanned the right and left common carotid 
artery, carotid bulb, and the first 1.5 cm of the internal and external carotid arteries. For each 
location, the sonographer imaged the vessel in multiple planes and then focused on the interfaces 
required to measure IMT and also on any areas of focal plaque.  The best images were digitized 
for later scoring.  Trained readers measured the thickness of the intima and medial layers of the 
vessel wall across 1-cm segments of the near and far walls of the distal common carotid artery 
and the far wall of the carotid bulb and the internal carotid artery on both right and left sides.  
Measures from each location were then averaged to produce an overall measure of carotid IMT.  
A computerized reading program developed for the Cardiovascular Health Study and modified in 
Pittsburgh was used.  Sonographers also scored the ultrasound images for plaque in the common 
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carotid, carotid bulb, internal carotid, and external carotid.  Plaque was defined as a distinct area 
protruding into the vessel lumen with at least 50% greater thickness than the surrounding areas.  
Reproducibility of carotid IMT was assessed in 5 women who underwent 2 ultrasound 
examinations within 1 week.  Two separate sonographers scanned these women; 2 readers also 
scored each scan.  When accounting for sonographer and reader variation, the intraclass 
correlation was 0.86 for IMT. 
11.1.4 Standardized Psychological Measures 
Depression Assessment:  The Beck Depression Inventory I (BDI I) (33) is a self-report 
inventory measuring characteristic attitudes and symptoms of depression.  It contains 21 
questions with a cutoff of >9 (total score) to identify potential clinically significant symptoms of 
depression.  The psychometric properties of the BDI have been reported as high with internal 
consistency ranging from .73 to .92 with a mean of .86.  The split-half reliability coefficient 
reported was .93.  Concurrent validity was determined by correlations with clinician ratings of 
depression using the revised BDI and ranged from .62 to .66.(34).  The BDI was previously 
tested on the PCOS population (35, 36) and in other research studies on women with obesity that 
may be applicable to the PCOS population, being that obesity is a central feature of PCOS.  
Anxiety and Anger Assessments:  The Spielberger Trait Anger/Anxiety Scales are 
components of the State-Trait Personality Inventory by Spielberger (37) (2 of 6 subscales).  For 
reliability testing, alpha coefficients ranged from .80 to .87 and provide evidence for internal 
consistency of the six STPI scales (38).   Overall reliability testing was also done to  determine 
an internal consistency (alpha coefficient = .81-.87) (39).  Cronbach alphas were .82-.85 and..80-
.85 for anger and anxiety. 
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Hostility/Cynicism Assessment:  This 13 item scale derived from the Cook-Medley 
Hostility Scale (40) and measures cynical attitudes and hostile feelings and behaviors rather than 
overt expressions of anger and aggression.  Higher scores indicate greater hostility (range 9-13).  
Cronbach’s alpha for the scale was .79 indicating good internal consistency. 
Diener Satisfaction With Life Scale:   This scale(41) measures the judgmental component 
of subjective well-being. It is comprised of 2 major components:  the emotional or affective 
component and the judgmental or cognitive component.  The scale consist of 5 questions with a 
7 point likert scale ranging from strongly disagree to strongly agree. 
A higher score reflects a greater satisfaction with life.  Test-retest reliability was .84 (41). 
While brief, this instrument offers as high or higher predictive validity than several longer 
measures of life satisfaction. 
11.1.5 Statistical Analysis 
Statistical analyses were performed by using SPSS (version 15.0).  The baseline risk 
factors were collected during the 1993 to 1994 clinic visit to represent CVD risk status at that 
time point.  Demographic, hormonal, and all laboratory and psychological data were available 
for analysis from the original sample previously described (32). 
Results are presented for 196 women with IMT measurements and psychological data. 
Descriptive statistics inclusive of measurement of central tendency and dispersion were 
computed for PCOS cases and controls.  The t test for independent samples (for continuous data) 
or chi square tests (for categorical data) were used to detect differences in means (± SD) or 
proportions, respectively, between cases and controls. 
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Linear regression modeling was used to identify the independent baseline psychological 
factors that predicted IMT, the dependent continuous variable.  Baseline cardiovascular risk 
variables were used as covariates to represent cardiovascular disease. They included age, race, 
BMI, Hdl, systolic blood pressure, triglycerides, glucose, and insulin.  Carotid IMT levels were 
stratified by age and BMI to better assess the confounding effects of age and BMI on IMT.  
Psychological predictors of IMT in these analyses included depression, anger, anxiety, 
hostility/cynicism, and satisfaction with life and were assessed with individual linear regression 
models.  All regression analyses were conducted by the linear regression module in SPSS.  BDI 
was forced into the model as it was the main psychological predictor of interest.  The regression 
models were constructed for the total population and for subgroups stratified by age, <45 and 
≥45 years. 
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12.0  RESULTS 
A total of 196 subjects, 93 PCOS cases and 103 controls, underwent carotid ultrasound 
scanning.  The baseline sociodemographic factors in PCOS cases and controls obtained during 
the initial clinic visit (1992-1994) are presented in Table 12-1.  Cases and controls were similar 
in most characteristics, except for age, parity, and marital status.  Controls were slightly older 
than cases (38.5 versus 36.4 years, respectively), which may have been a result of the 
unmatching of the groups from the initial study.  As well, not all of the original cases and 
controls had IMT measurements. Cases had fewer pregnancies as often seen in PCOS cases due 
to infertility issues. No difference was found in menopausal status, as a result of the small 
numbers of women who experienced natural or surgical menopause. 
Baseline psychological characteristics are shown in Table 12-2.  Consistent with recent  
findings (Cipkala-Gaffin et al. 2009) (18) by earlier analyses on 161 cases and 161 controls from 
the same population, BDI ratings differed between groups, P<.014.  When comparing the 
categories for symptoms of depression, PCOS cases rated higher in all categories than controls:  
Mild, 26% versus 11.7%; Moderate, 5.4% versus 2.9%; Severe, 1.1% versus 0, respectively, 
P<.038.  The remaining psychological characteristics were similar between cases and controls.      
Selected cardiovascular risk factors are seen in Table 12-3.  Similar to previous findings, 
significant differences (P<.001) were noted in several baseline characteristics including BMI, 
waist measurement, HDLt, Insulin, triglycerides, and total testosterone.  Systolic blood pressure 
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and glucose was marginally significant (P<.081 and P<.071, respectively).  Diastolic blood 
pressure, cholesterol, and LDLc were not significant.  Results were similar for the original cohort 
study of 244 cases and controls (Talbott et al., 1995) (32) and for the subsequent study of 125 
PCOS cases and 142 controls ≥ 30 years of age (Talbott et al., 2000) (3). 
To control for possible confounding, age and BMI adjusted analyses were performed. 
The mean adjusted values for each of the biochemical parameters are reported. Again, the results 
were similar, except that waist measurement was no longer significantly different between the 
cases and controls. 
Overall, no significant differences in carotid IMT were noted between cases and controls 
for the total group (P=.261).  (Table 12-4)  However, subgroup analyses by age revealed 
different results.  The mean BMI for PCOS cases and controls was significantly different, 
P<.001, with cases having higher BMI (30.3±8.7 versus 26.8±6.4 respectively). Among cases, 
those ≥ 45 years of age had a BMI of  32.9±9.6 versus 29.0±8.0 in the <45 group, P <.044.  
Therefore, IMT was adjusted for age and BMI.  Adjusted IMT means for cases and controls < 45 
years of age were not significantly different for BMI <26 (P=.629) and BMI ≥ 26 (P=.694).  In 
the age group <45, no significant differences were noted.  However, in the older women ≥45 
years, PCOS cases had significantly greater IMT readings than did controls (.790±.196 
versus.708±.084mm, respectively, P <.042).  These findings were consistent with the overall 
study of 335 cases and controls and reflects the overall reasonable representation of this smaller 
subgroup of 196.     
For the older age group, ≥ 45 years of age, again there were no differences between cases 
and controls for those with BMI <26 (P=.996).  However, for the women ≥ 45 with a BMI ≥ 26, 
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there was a borderline significant difference between cases and controls, P=0.54.  This may be 
explained in part due to the greater BMI within cases, as is usually seen in PCOS women. 
Univariate analyses were performed in order to select significant variables.  (Tables 12-5, 
12-6)  Multiple linear regression models (Table 12-7) were carried out to assess the independent 
effect of the psychological variables on IMT, adjusted for age, BMI, and cardiovascular risk 
factors found to be associated with IMT in the univariate analyses (HDL, systolic blood pressure, 
triglycerides, glucose, and insulin).  BDI was forced into the model as it was significantly 
different between cases and controls.                
The cardiovascular risk factors, age, BMI, and systolic blood pressure showed themselves 
to also be consistent significant predictors of IMT in most models for the total sample.  However, 
when the sample was stratified by age groups, age and systolic remained consistently significant, 
but BMI did not for the group <45. For the ≥ group age was the only consistent predictor. 
             In the final model for the total sample, PCOS, age, and BMI were both 
significant in predicting IMT, (P<..005; P<.001; P< .023 respectively).  Systolic blood pressure 
was borderline significant p=.073 whereas BDI was not significant.  There was an interaction 
between PCOS and age, P< .003.  
   In the final model for the age group < 45 years of age, only age and systolic blood 
pressure were  significant predictors for IMT, P<.002 and P<.042 respectively.  In the final 
model for the age group ≥ 45, only age was a significant predictor of IMT, P<.004. 
Even though PCOS and BDI were not significant in the final models for the total group 
and for the 2 stratified age groups, age was consistently a significant predictor of IMT.  Further, 
the cardiovascular risk factors, BMI, and systolic blood pressure showed themselves to also be 
significant predictors of IMT in the three different models. 
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Table 12-1 Baseline Sociodemographic Factors in PCOS Cases and Controls 
________________________________________________________________________          
   Variables                                           PCOS                             Controls 
                                                            (n= 93)                              (n=103)                P 
Age                                                     36.4 ± 6.4                      38.5 ± 6.9             < .018 
 
Race 
    White                                               94.6%                              99.0%                  .776 
    Other                                                  5.4%                                1.0% 
 
Education                                           14.3 ± 1.9                      14.6 ± 2.0                .441 
 
Married  y                                            82.8%                              65.0%                  <.006 
 
Current Smoking %  y                         23.7%                             17.5%                   .284 
 
OC %  y                                               21.5%                             22.3%                   .776 
 
Hormones %  y                                    14.0%                             14.6%                   .907 
 
Parity                                                   1.0 ± 1.1                        1.6 ± 1.3                <.000 
 
Reported no periods % y                  (10)10.8%                       (11)10.7%               .987        
    Age when stopped periods              32.0 ± 8.8                      37.4 ± 8.4              .177 
                    
Menopausal status 
                           Natural                    1 (1.1%)                          1(1.0%)                  .303 
                           Surgical*                 6 (6.5%)                         9 (8.7%)    
________________________________________________________________________ 
Values are means and ± SD or percentages 
OC = Oral Contraceptive 
Menopausal status, y = still having periods 
** surgical menopause = total hysterectomy and bilateral oophorectomy (questionnaire states surgical, uterus and/or 
ovaries removed) 
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 Table 12-2 Baseline Psychological Characteristics in PCOS Cases and Controls 
________________________________________________________________________          
   Variables                                           PCOS                             Controls                P 
                                                            (n= 93)                              (n=103)                 
BDI Ratings                                         7.6 ± 6.8                           5.4 ± 5.0           <.014 
Missing                                                     4.3%                                  4.9% 
     Normal                                              62.4%                                 80.6%          <.038 
      Mild                                                  26.9%                                 11.7% 
      Moderate                                           5.4%                                     2.9% 
      Severe                                                1.1%                                       0 
Anger *                                               8.5 ± 4.0                              8.1 ± 3.5               .468 
Anxiety *                                            9.6 ± 5.8                               8.5 ± 5.1               .167 
Hostility/Cynicism **                        7.9 ± 2.9                                8.5 ± 2.5               .167 
Satisfaction with Life †                      24.2 ± 6.7                             24.3 ± 6.3              .875 
Values are means and ± SD or percentages 
* missing = 10 
** missing =11 
† missing = 4 
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Table 12-3 Selected Risk Factors in PCOS Cases and Controls of Similar Age 1992-1994 Adjusted for 
Age and BMI 
____________________________________________________________________ 
                                  Cases (n= 93)                                 Controls (n=103) 
                                                   Adjusted                                     Adjusted        Unadjusted 
Variables          Mean ± SD       Mean ± SD           Mean ± SD     Mean ± SD            P 
BMI                    30.3±8.7               NA                   26.8±6.4              NA **          <.001 
Waist cm            91.7±20.0         88.4±1.3               81.8±18.9         85.0±1.2          <.001 
SBP,mm Hg      114.6±14.9        113.2±1.2            111.0±13.0        112.3±1.7          .081 
DBP,mm Hg       72.8±11.2         71.8±0.9                70.8±8.4          71.7±0.9           .162 
CHOL, mg/dl     192.5±26.8       191.9±3.4            186.3±35.9        186.8±3.2          .184 
LDLc, mg/dl       117.5±27.8      116.5±3.2            113.8±32.7         114.4±3.1         .399 
HDLt,mg/dl        49.85±14.65      51.0±1.5            56.58±14.14         55.7±1.4 †     <.001 
Insulin,µU/ml     25.5 ± 23.6        23.2±1.8              14.2±10.0           16.3±1.7*      <.001 
TRI. Mg/dl         125.5± 80.1       122.3±6.3            79.7±39.1            83.3±6.0 **   <.001 
Total T, nmol/dl    1.7±1.2            1.7±0.1               1.1±.5              1.1±0.1**      <.001 
Glucose               97.1±27.3          96.0±3.0             89.7±29.4             90.9±2.8       <.071 
_______________________________________________________________________ 
Adjusted for age and BMI 
**Adjusted P<0.001;* P<.05;† P<.026; 
Missing 
1= CHOL; LDLc; HDLt; TRI; Glucose 
2=BMI; Total T;  
3= SBP; DBP; 
7=Waist cm 
21=Insulin 
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Table 12-4 IMT Results in PCOS Cases and Controls 
________________________________________________________________________          
   Variables                                           PCOS                             Controls 
                                       n                    (n= 93)                              (n=103)                P 
IMT total                     196                .697 ± .142                    .678 ± .088                .261         
                                                                                                                          
                                                              (n= 63)                              (n=62) 
<45*                           125                  .655 ± .083                     .659 ± .006              .779 
                                                  
                                                               (n=29)                               (n=41) 
 
≥45y                               70                 .790 ±.196                       .708 ± .084            <.042 
_______________________________________________________________________ 
Values are means and ± SD  
* 1 case missing 
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Table 12-5 Univariate Linear Regression Results of IMT and Baseline CHD Risk Factors 
Total                                 Age<45                             Age≥45 
 n β SE P n β SE P n β SE P 
PCOS 196 -.019 .016 .247 125 .004 .013 .779 70 -.082 .034 .020 
Age 196 .007 .001 .000 125 .006 .001 .000 70 .007 .005 .132 
Race 196 -.012 .030 .684 125 -.010 .023 .659 70 .009 .074 .901 
BMI 194 .005 .001 .000 123 .003 .001 .002 70 .006 .002 .003 
Hormone 196 .006 .023 .793 125 .016 .018 .381 70 -.061 .058 .293 
Smoking 196 .003 .010 .723 125 -.004 .008 .580 70 .013 .020 .530 
LDL 195 .000 .000 .091 125 .000 .000 .135 69 .001 .001 .256 
HDL 196 -.003 .001 .035 119 -.001 .001 .238 66 -.004 .002 .127 
SBP 193 .003 .001 .000 122 .002 .000 .000 70 .003 .001 .005 
DBP 193 .003 .001 .000 122 .002 .001 .001 70 .003 .002 .060 
Insulin 175 .001 .000 .035 110 .001 .000 .087 64 .002 .001 .081 
Waist 189 .002 .000 .000 120 .001 .000 .000 68 .002 .001 .015 
Testosterone 194 -.002 .009 .818 123 .006 .007 .377 70 -.007 .018 .725 
Trig 195 .000 .000 .002 125 .000 .000 .255 69 .001 .000 .016 
Chol 195 .001 .000 .030 125 .000 .000 .192 69 .001 .001 .114 
Glu 195 .001 .000 .018 125 -3.50 .000 .892 69 .001 .001 .152 
IMT was measured in 1995-1997 and baseline risk factors were measured in 1992-1994 
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Table 12-6 Univariate Linear Regression Results of IMT and Baseline Psychological Variables 
 
      Total                                 Age<45                             Age≥45 
Depression 187 .002 .001 .148 121 .001 .001 .174 65 .003 .003 .331 
Anger 186 .002 .002 .363 119 .003 .002 .106 66 .003 .006 .617 
Anxiety 186 .002 .002 .259 118 .001 .001 .305 67 .003 .003 .416 
Hostility 185 -.001 .003 .744 117 .001 .003 .783 67 -.002 .006 .793 
Satis w life 192 -.002 .001 .054 123 -.002 .001 .025 68 -.002 .003 .572 
IMT was measured in 1995-1997 and baseline risk factors were measured in 1992-1994 
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Table 12-7 Multiple Linear Regression Models of Effect of PCOS on IMT Adjusted for Age and Selected 
Risk Factors                                       
TOTAL <45y ≥ 45y
n β SE P n β SE P n β SE P
PCOS 187 0.001 0.017 0.516 121 -0.010 0.013 0.432 65 0.076 0.038    .052*
BDI  0.002 0.001 0.193 0.002 0.001 0.146 0.001 0.003 0.467
PCOS 195 0.030 0.015 0.041 125 -0.003 0.013 0.828 70 0.098 0.034 0.005
Age 0.007 0.001 0.001 0.005 0.001 0.001 0.012 0.005 0.014
PCOS 193 0.016 0.014 0.281 123 -0.009 0.012 0.473 70 0.063 0.034 0.072
Age 0.007 0.001 0.001 0.006 0.001 0.001 0.014 0.005 0.004
BMI 0.004 0.001 0.001 0.003 0.001 0.001 0.006 0.002 0.007
PCOS 192 0.014 0.014 0.321 122 -0.011 0.012 0.378 70 0.062 0.035 0.079
Age 0.007 0.001 0.001 0.005 0.001 0.001 0.013 0.005 0.010
BMI 0.003 0.001 0.015 0.001 0.001 0.164 0.005 0.003 0.062
SYS BP 0.001 0.001 0.020 0.001 0.001 0.008 0.001 0.001 0.430
PCOS 173 0.017 0.016 0.278 109 -0.008 0.013 0.535 64 0.057 0.039 0.152
Age 0.007 0.001 0.001 0.006 0.001 0.001 0.013 0.005 0.015
BMI 0.003 0.001 0.037 0.001 0.001 0.338 0.005 0.003 0.113
SYS BP 0.002 0.001 0.018 0.002 0.001 0.001 0.001 0.002 0.351
Insulin 0.001 0.001 0.777 4.98 0.001 0.9 -9.58 0.001 0.943
PCOS 191 0.014 0.015 0.332 122 -0.011 0.012 0.376 69 0.006 0.037 0.078
Age 0.007 0.001 0.001 0.005 0.001 0.001 0.014 0.005 0.008
BMI 0.003 0.001 0.037 0.001 0.001 0.209 0.004 0.003 0.150
SYS BP 0.002 0.001 0.017 0.001 0.001 0.008 0.001 0.001 0.332
HDl 0.001 0.001 0.782 -5.87 0.001 0.903 0.001 0.001 0.724
PCOS 191 0.011 0.015 0.459 109 -0.010 0.013 0.446 69 0.058 0.039 0.141
Age 0.007 0.001 0.001 0.005 0.001 0.001 0.013 0.005 0.010
BMI 0.002 0.001 0.034 0.156 0.001 0.001 0.004 0.003 0.155
SYS BP 0.001 0.001 0.026 0.002 0.001 0.008 0.001 0.001 0.360
TRI     9.49E 0.001 0.434 -3.53 0.001 0.749 0.001 0.001 0.504
PCOS 183 0.001 0.015 0.454 118 -0.015 0.012 0.212 65 0.065 0.038 0.090
Age 0.007 0.001 0.001 0.005 0.001 0.001 0.013 0.005 0.016
BMI 0.003 0.001 0.026 0.001 0.001 0.263 0.005 0.003    .058*
SYS BP 0.001 0.001 0.056 * 0.001 0.001 0.034 0.001 0.001 0.497
BDI 0.001 0.001 0.388 0.001 0.001 0.248 0.001 0.003 0.964
PCOS 183 -0.254 0.090 0.005 118 -0.047 0.098 0.635 65 -0.771 0.496 0.125
Age 0.010 0.002 0.001 0.005 0.002 0.002 0.022 0.007 0.004
BMI 0.003 0.001 0.023 0.001 0.001 0.250 0.005 0.003   .064*
SYS BP 0.001 0.001 0.073 * 0.001 0.001 0.042 0.001 0.001 0.462
PCOS*Age -0.006 0.002 0.003 0.001 0.003 0.747 -0.017 0.010 0.096
BDI 0.001 0.001 0.424 0.001 0.001 0.253 0.001 0.003 0.886
*borderline
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13.0  DISCUSSION 
This study was the first reported to examine whether psychological factors, independent 
of cardiovascular risk factors, predict IMT in women with PCOS. Although in this sample of 
women with PCOS, none of the psychological variables measured (depression, anger, anxiety, 
hostility/cynicism, and satisfaction with life) predicted IMT independent of traditional CVD risk 
factors, there were some noteworthy findings.  First, depression at baseline for PCOS cases was 
significantly different compared to controls (P<.014).  In particular, for the group ≥45 years of 
age (P<.039) with PCOS, cases scored higher on this dimension.  The findings are consistent 
with previous studies (18, 21, 22, 36, 42) that were done reporting that PCOS women have an 
increased risk of depressive disorders.  Hollinrake in 2007 (22) found that women with PCOS 
were at an increased rate for newly diagnosed depression compared with controls (OR 5.11).  A 
longitudinal study by Kerchner 2008 (42) investigating the risk of depression over time found 
that over 1-2 years the prevalence rate for depression increased from 40% to 56% in PCOS 
cases. 
An explanation for the lack of relationship between baseline depression scores and IMT 
can be due to the possibility that the PCOS cases may have adapted over time to their diagnosis 
of PCOS or could have been treated for depression with medications or psychotherapy.  
Additionally, IMT was only measured once on follow-up several years later and was represented 
at baseline by cardiovascular risk factors.  Finally, depression was not measured at the follow-up 
time with IMT. 
Depression has been associated with subclinical atherosclerosis in various studies (24, 43, 
44).  Post hoc analyses (44) investigating negative emotions in the 3 year progression of 
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subclinical atherosclerosis reported that the somatic-vegetative symptoms of depression (P<.002) 
were positively associated with intima-media thickness.  In another study (44)  measuring 
lifetime history of major depression, subclinical atherosclerosis, and IMT in middle-aged 
women, it was found that women with recurrent major depressive episodes were more than twice 
as likely to have plaque on carotid ultrasonography than women with no history of major 
depression.  Moreover, a single major depressive episode or current depressive symptoms were 
not associated with an increased risk of plaque.  These findings are relative to the null findings in 
the present study, as depression was only measured (screened with the BDI) at baseline, and it 
was not determined whether patients had recurrent depressive episodes or how severe the clinical 
depression was. 
Other negative emotions, state anger and anxiety and hostility/cynicism, were explored 
and found not to be predictive of IMT readings independent of the cardiovascular factors.  These 
results are similar to what was reported by Stewart et. al (44) in women ages 50-70 years of age.  
Except for depression, anxiety, anger and hostility were not predictors of atherosclerotic 
progression over a 3 year period.  Yet, over the past 20 years, the literature supports the fact that 
hostility is an independent risk factor for CHD and all-cause mortality (45).  Others investigated 
hostility scores and high trait anger associated with subclinical atherosclerosis.  In a 10 year 
follow up study  by Matthews in 1998 (46), with a sample of 200 postmenopausal women, high 
hostility scores and high trait anger and anger-in were associated with the extent and severity of 
carotid atherosclerosis.  In this same study, baseline levels of trait anxiety were not related to 
mean levels of carotid IMT.  More recently, in the Study of Women’s Health Across the Nation 
(SWAN) Heart Study, Everson-Rose and colleagues (28) found that in age and site adjusted 
models that each 1 point increment in  hostility score predicted a significant 0.0057-mm higher 
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mean IMT (P<.0001) and 0.0081-mm higher maximum IMT (P<.0001), effects that were 
identical in magnitude to each 1 year increment in age.  In this study, the one time measurement 
of state anxiety and anger may not have been an adequate representation of the psychosocial 
variables and certainly over the follow-up time period of approximately 4 years these 2 
characteristics could have changed, thus affecting their  association with IMT.  Similarly, the 
hostility/cynicism ratings could have been biased by when the subjects were diagnosed with 
PCOS, as they may have gone through various coping stages and adapted to their disease 
process. 
The null findings for satisfaction with life as a predictor of IMT are not surprising given 
the nature of the measure.  The Diener Scale is a global measurement of satisfaction with life.  
Further, this instrument was not tested on the PCOS population.  Since the development of this 
tool, other measures that are specific to the measurement of quality of life for the PCOS 
population have been reported, such as The Polycystic Ovary Syndrome Health-Related Quality 
of Life (PCOSQ) (47).  Using population tested measures would most likely yield more accurate 
results.  Further, it was surprising that there were no differences exhibited by the other 
psychological variables. This could be explained by the fact that the original study was not 
designed to measure the relationship between psychological variables and IMT. 
The regression analyses, intended to explain whether the psychological variables, 
independent of cardiovascular risk factors, predicted IMT, resulted in all negative findings.  
Depression, measured by the BDI, was the major focus given the baseline findings showing 
significant differences between cases and controls (P<.014), with cases having higher depression 
ratings.  In all of the models, BDI did not show to be a significant predictor of IMT, independent 
of the selected cardiovascular risk factors. 
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In the final model including PCOS, age (at IMT reading), BMI, systolic blood pressure, 
PCOS*age and BDI forced into the model, the variables, age, BMI, systolic blood pressure and 
the interaction between PCOS and age  were significant predictors of IMT for the total sample.  
In previous studies (14, 250), BMI has been associated with increased subclinical 
atherosclerosis.  In a study by Talbott et al. 2000 (14), IMT was greater in thin and heavy women 
with PCOS compared with controls of similar size.  
     In the group aged < 45 years, age and systolic blood pressure were significant 
predictors of IMT in the final model, whereas BMI was not. Because age and blood pressure 
were significant, there are clinical implications for the younger group.  PCOS women at a 
younger age and with elevated blood pressure readings may be at higher risk for subclinical 
cardiovascular disease as previously supported by Talbott et al. (14).  
     The older aged group, ≥ 45 years, consistently showed age as a predictor for IMT in 
all models, which would be expected as IMT would increase over time.  For the final model, 
only age was significant whereas BMI was borderline significant as a predictor of IMT.  The 
findings for BMI are surprising as one would think that BMI would increase with age in this 
population. On the other hand, the mean age for cases and controls were 36.4 ± 6.4 and 38.5 ± 
6.9, respectively, indicating that they were early in the menopausal transition and thus may not 
have had weight increases.    
There are many strengths to this study despite the null findings.  The original sample 
from which this cohort was obtained was from random digit dialing chosen and matched on age, 
race, and neighborhood.  A reliable technique for assessing subclinical cardiovascular disease, B- 
mode ultrasonography was utilized.  All of the psychological measures were reliable and valid 
and the BDI was previously used in other studies with PCOS women (18, 19).    
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Limitations of the study included the need to unpair the PCOS cases and controls in order 
to preserve the greatest number of subjects who had IMT ratings and psychological data.  
Because the original study was not intended to measure the relationship between the 
psychological variables as predictors of IMT, follow up (repeated measures of the psychological 
characteristics) was not included in the design.  Lastly, a baseline measurement of IMT would 
have been useful instead of utilizing the cardiovascular risk factors in its place. 
There are significant research and clinical implications from this study.  First, it is evident 
that PCOS women are at risk for a multitude of reasons ranging from infertility to obesity, 
diabetes, changes in body image, metabolic syndrome, hormone disturbances, diabetes, and 
cardiovascular disease.  These comorbid factors tend to aggravate depression.  Further research 
to identify women who are depressed is essential, beginning at diagnosis and through repeated 
measures during their course of treatment.  Diagnostic research tools such as the  Primary Care 
Evaluation of Mental Disorders (PRIME-MD) (49) and the Patient Health Questionnaire  
(PRIME-MD PHQ), which is a four-page self administered version of the PRIME-MD, was 
validated for use in gynecology outpatients (49).  The PRIME-MD PHQ and other screening 
measures such as the BDI are time efficient and useful in identification and the prevention of 
depression.  Utilizing these assessment measures could decrease the progression of depressive 
symptoms into a clinical depression.  In all, additional research is needed, incorporating the 
psychological variables, depression, anxiety, anger, hostility/cynicism, and satisfaction with life, 
to further determine whether there is an association to subclincial cardiovascular disease in this 
vulnerable PCOS population.  
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14.0  GENERAL DISCUSSION 
                                        14.1    SUMMARY OF FINDINGS 
The objective of this dissertation was to evaluate the psychosocial and socio-
demographic factors associated with Metabolic Syndrome and cardiovascular risk in Polycystic 
Ovary Syndrome cases and controls (women without PCOS). 
     Research Paper 1:  Women with PCOS had a higher prevalence of depression, 31% 
versus 17%, than controls at a mild level of depression.  The difference between cases and 
controls for the BDI scale was statistically significant.  Within cases, BMI, education, and parity 
were statistically significant predictors of depression (p<.05).  The odds of being depressed, of at 
least a mild severity, increased by 6% for each unit increase of BMI, the odds of being depressed 
decreased by 20% for each year of  education and increased by 44% for parity (per live birth).  
The odds of having PCOS (for the entire sample) increased with each unit of BDI score by 1.06 
times, when adjusting for marital status, BMI, smoking, and education.  These results have 
clinical implications in the comprehensive treatment of PCOS patients.  Psychological 
evaluations of patients at diagnosis and repeated throughout their lifetime are indicated to 
prevent, identify, and provide treatment for those women who present with depressive 
symptoms. 
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     Research Paper 2:  Twenty-seven percent of the cases and 9.9% of the controls had 
MS.  Age was statistically significant between cases and controls.  Additionally, differences 
between controls, with and without MS, for education were statistically significant.  
     Although on univariate analyses, BDI was borderline associated with MS, only PCOS 
and age were significant predictors for MS when BDI was forced into the model.  The odds of 
having MS increased by 10% for each year increment of age and threefold for PCOS cases. 
Within the subjects who had a BMI>30, the odds of having MS increased by 3% for each year 
increment of age.  These results highlight the need to target individuals with PCOS, increased 
BMI > 30, and MS to receive psychological evaluations to screen for possible mental health 
problems. 
     Research Paper 3:  Research Paper 3:  there was no significant effect of any of the 
psychological factors (depression, state anger and anxiety, hostility/cynicism, and satisfaction 
with life), independent of baseline cardiovascular risk factors, on IMT.  Age was a consistent 
predictor of IMT in regression analyses.  For the total group PCOS, age, BMI, and PCOS* age 
were predictors of IMT.  Systolic blood pressure was a borderline significant predictor. For the 
group ≥ 45, age and BMI (borderline) were predictors of IMT.  Age and systolic blood pressure 
were significant predictors in women <45 of IMT.  Even though there were null findings from 
this study, clinical implications are still apparent.  It is well known that there is an association 
between subclinical cardiovascular disease and negative emotional states (depression, state anger 
and anxiety, and hostility/cynicism) which warrants psychological evaluations in PCOS women 
in order to prevent the incidence of psychiatric disorders in this population. 
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 PSYCHOLOGICAL FACTORS AND PCOS 
 
 It is clear that the psychological ramifications of PCOS are problematic for the 
women who are diagnosed with the condition and throughout their life.  There is a myriad of 
stressors with PCOS that can lead to possible mental health problems including chronic 
anovulation, hursutism, acne, obesity, infertility, baldness, DiabetesII, and cardiovascular 
disease.  Only recently, are the psychological issues in PCOS being addressed.  The area of 
depression seems to be the most reported consequence of the stress of PCOS.  It is implicit 
that the plan of medical care for women with PCOS include a psychological component to 
ensure that excellent comprehensive care is available to women with PCOS. 
 
         PUBLIC HEALTH SIGNIFICANCE 
 
Women are twice as likely than men in the general population to be diagnosed with 
depression.  Thus, women with PCOS become even more susceptible to depression.  Women 
with PCOS should be screened on diagnosis and monitored closely for depression, a major 
public health problem, which can affect their level of functioning and increase their overall 
burden of disease. 
Metabolic syndrome has been related to premature coronary heart disease.  PCOS women 
have three times the prevalence of MS and should be monitored for a reduction in CHD risk 
factors as well as for lifestyle modification.  Early identification of depressive symptoms could 
possibly decrease the prevalence of characteristics of MS such as obesity, which is epidemic.  
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PCOS women should be monitored for weight and encouraged to make lifestyle changes i.e. 
nutrition and exercise. 
This research has shown that women with PCOS, aged ≥ 45 years, had significantly 
greater mean IMT than did controls.  Prevention and screening for subclinical cardiovascular 
disease is important to decrease the risk of cardiovascular disease in all PCOS women. 
 
FUTURE RESEARCH 
 
Further research to identify women with PCOS who are depressed is essential, beginning 
at diagnosis and through repeated measures during their course of treatment.  Appropriate   
diagnostic research tools such as the Primary Care Evaluation of Mental Disorders (PRIME-MD) 
and the Patient Health Questionnaire (PRIME-MD PHQ) should be considered when screening 
for mental health disorders.  The PRIME-MD PHQ and other screening measures such as the 
BDI are time efficient and useful in identification and the prevention of depression in PCOS 
women as has been shown in previous research studies..  Utilizing these assessment measures 
could possibly decrease the progression of depressive symptoms into a clinical depression.  In 
all, additional research is needed, incorporating the psychological variables, depression, anxiety, 
anger, hostility/cynicism, and satisfaction with life, to further determine whether there is an 
association to metabolic syndrome and subclinical cardiovascular disease in this vulnerable 
PCOS population.  
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